Deregulated notch and CD40 signaling in murine B lymphocytes by Draeseke, Anne
 
 
 
Deregulated Notch and CD40 signaling  
in murine B lymphocytes  
 
Dissertation der Fakultät für Biologie der 
Ludwig‐Maximilians‐Universität München 
 
 
 
 
 
Anne Draeseke 
 
München 2013 
  
 ii 
 
Erklärung 
 
Diese Dissertation wurde von Januar 2009 bis Dezember 2012 am Institut für Klinische 
Molekularbiologie und Tumorgenetik des Helmholtz Zentrums München (später Abteilung für 
Genvektoren) in der Arbeitsgruppe von PD Dr. Ursula Zimber-Strobl erstellt und von Prof. Dr. Dirk 
Eick betreut. 
 
 
 
 
Eidesstattliche Erklärung 
 
Hiermit erkläre ich, Anne Draeseke, geboren am 07. Januar 1983 in Bonn, an Eides statt, dass ich 
die vorliegende Arbeit selbständig und nur unter Verwendung der angegebenen Hilfsmittel und 
Quellen angefertigt habe.  
Diese Dissertation hat weder in gleicher oder ähnlicher Form einem anderen Prüfungsverfahren 
vorgelegen. Ich habe weder bereits früher Doktorgrade erworben noch versucht zu erwerben. 
 
 
 
München, den 10.06.2013       Anne Draeseke 
 
 
 
 
 
 
Erstgutachter: Prof. Dr. Dirk Eick  
 
 
Zweitgutachterin: Prof. Dr. Elisabeth Weiß  
 
 
Tag der Abgabe: 11.06.2013 
 
Tag der mündlichen Prüfung: 09.12.2013  
 iii 
 
TABLE OF CONTENTS 
LIST OF TABLES .............................................................................................................................. vii 
LIST OF FIGURES ............................................................................................................................viii 
LIST OF ABBREVIATIONS .................................................................................................................. x 
1. INTRODUCTION ................................................................................................................ 1 
1.1 CD40 and Notch ............................................................................................................... 1 
1.2 Notch signaling ................................................................................................................. 1 
1.3 T-cell development .......................................................................................................... 3 
1.3.1 Notch in T-cell development ..................................................................................... 5 
1.4 B-cell development .......................................................................................................... 5 
1.4.1 Notch in B-cell development ..................................................................................... 8 
1.5 The CD40 receptor ........................................................................................................... 8 
1.6 T-cell dependent and T-cell independent immune response ........................................ 10 
1.7 CD40 and Notch signal deregulation in human malignancies ....................................... 11 
1.7.1 Notch signaling in cancer ........................................................................................ 11 
1.7.2 CD40 signaling in cancer.......................................................................................... 12 
1.8 B-cell lymphoma ............................................................................................................. 13 
1.8.1 Innate immune cells ................................................................................................ 14 
1.9 Rationale for studying deregulated CD40- and deregulated Notch2IC signaling .......... 15 
1.10 The LMP1/CD40 and Notch2IC transgenic mouse strains ............................................. 16 
1.10.1 The LMP1/CD40flSTOP mouse strain (Homig-Holzel et al., 2008) ............................. 16 
1.10.2 The Notch2ICflSTOP mouse strain (Hampel et al., 2011) ........................................... 17 
1.10.3 The CD19-cre mouse strain (Rickert et al., 1997) ................................................... 18 
2. AIM ................................................................................................................................. 19 
3. RESULTS ......................................................................................................................... 20 
3.1 Concomitant expression of constitutive Notch2IC and LMP1/CD40 in B cells has 
synergistic effects on increase in spleen size and weight ............................................. 20 
3.2 Expression of the transgenes Notch2IC and LMP1/CD40 is a B-cell specific event ....... 21 
3.3 In Notch2IC//LMP1/CD40//CD19-cre mice total splenic cell numbers and B-cell 
numbers are significantly higher than in control and Notch2IC//CD19-cre mice but 
B-cell numbers are significantly lower than in LMP1/CD40//CD19-cre mice ............... 23 
3.4 Notch2IC//LMP1/CD40//CD19-cre mice display an increased number of splenic 
accessory cells ................................................................................................................ 24 
3.4.1 Notch2IC//LMP1/CD40//CD19-cre mice display an increased number of 
granulocytes and macrophages .............................................................................. 25 
3.4.2 Notch2IC//LMP1/CD40//CD19-cre mice display an increased number of 
activated dendritic cells .......................................................................................... 27 
 iv 
 
3.5 Notch2IC//LMP1/CD40//CD19-cre mice display significantly increased numbers of 
splenic T cells ................................................................................................................. 28 
3.5.1 Notch2IC//LMP1/CD40//CD19-cre mice display a shift from CD4pos towards 
CD8pos splenic T cells ............................................................................................... 29 
3.5.2 Notch2IC//LMP1/CD40//CD19-cre mice display activation of splenic T cells ........ 30 
3.5.3 In Notch2IC//LMP1/CD40//CD19-cre mice splenic T cells display a Th1 
activation pattern with and without PMA/Ionomycin stimulation ........................ 34 
3.5.4 Splenic Treg are increased in splenic preparations of 
Notch2IC//LMP1/CD40//CD19-cre mice ................................................................ 36 
3.6 Early concomitant expression of constitutive Notch2IC and CD40 partially blocks 
early B-cell development between pre- and immature B cells in the bone marrow .... 37 
3.6.1 Total and B-cell numbers are normal in bone marrow preparations of 
Notch2IC//LMP1/CD40//CD19-cre mice, but exhibit significantly increased T-
cell numbers ............................................................................................................ 38 
3.6.2 Early concomitant expression of constitutive Notch2IC and CD40 leads to a 
reduction in the pre- and immature B-cell populations in the bone marrow ........ 39 
3.6.3 Recirculation of mature B cells into the bone marrow is restricted in 
Notch2IC//LMP1/CD40//CD19-cre mice ................................................................ 42 
3.7 AA4.1pos transitional B cells are not reduced in the spleens of 
Notch2IC//LMP1/CD40//CD19-cre mice ....................................................................... 43 
3.8 Marginal zone B cells are expanded in Notch2IC//LMP1//CD40//CD19-cre mice 
while the follicular B-cell population is decreased ........................................................ 45 
3.9 Splenic B cells of Notch2IC//LMP1/CD40//CD19-cre mice display an activated 
phenotype ...................................................................................................................... 48 
3.10 B-cell numbers are reduced and B-cell subsets are altered in inguinal lymph nodes 
of Notch2IC//LMP1/CD40//CD19-cre mice ................................................................... 49 
3.10.1 T-cell numbers are normal but B-cell numbers are significantly reduced in 
inguinal lymph nodes of Notch2IC//LMP1/CD40//CD19-cre mice compared to 
CD19-cre and LMP1/CD40-cre mice ....................................................................... 49 
3.10.2 B cells in inguinal lymph nodes of Notch2IC//LMP1/CD40//CD19-cre mice 
display a shift towards a MZ B-cell phenotype ....................................................... 50 
3.11 Splenic architecture is grossly disrupted in Notch2IC//LMP1/CD40//CD19-cre mice .. 52 
3.11.1 Splenic B cells of Notch2IC//LMP1/CD40//CD19-cre mice are intermediate in 
their CXCR4 expression ........................................................................................... 54 
3.12 Notch2IC//LMP1/CD40//CD19-cre mice show distinct changes in the expression of 
cyto- and chemokines .................................................................................................... 55 
3.12.1 CXCR3 and IL13ra1, IL2Rγ, LTβ and TGFβ mRNA levels in splenic B cells of 
Notch2IC//LMP1/CD40//CD19-cre mice are differentially up-regulated by 
Notch2IC and LMP1/CD40 ...................................................................................... 56 
3.12.2 Notch2IC//LMP1/CD40//CD19-cre mice show an upregulation of CXCL9 and 
CXCL10 in serum ..................................................................................................... 58 
 v 
 
3.13 Notch2IC//LMP1/CD40-expressing splenic B cells show an increased proliferation 
in in vitro culture regardless of the supply of stimuli .................................................... 59 
3.13.1 Unstimulated Notch2IC//LMP1/CD40-expressing splenic B cells survive better 
in culture than Notch2IC-, but not than LMP1/CD40-expressing splenic B cells ... 62 
3.14 Notch2IC//LMP1/CD40‐expressing splenic B cells are highly and actively cycling 
cells ................................................................................................................................ 65 
3.15 Aged Notch2IC//LMP1/CD40//CD19-cre mice are prone to develop B-cell 
lymphomas ..................................................................................................................... 68 
3.15.1 Aged Notch2IC//LMP1/CD4//CD19-cre mice display increased numbers of 
splenic Mac1pos cells ............................................................................................... 69 
3.15.2 Aged Notch2IC//LMP1/CD40-expressing B cells display distinctly altered 
surface marker expression in the spleen ................................................................ 70 
3.15.3 Aged Notch2IC//LMP1/CD40-expressing splenic B cells display differential up-
regulation of activation markers ............................................................................ 72 
3.15.4 Aged Notch2IC//LMP1/CD40//CD19-cre mice maintain shift towards effector 
T-cell compartment................................................................................................. 74 
3.15.5 Aged Notch2IC//LMP1/CD40//CD19-cre mice develop monoclonal B-cell 
lymphoma ............................................................................................................... 76 
3.16 Aged Notch2IC//LMP1/CD40//CD19-cre mice develop salivary gland carcinomas ...... 77 
Southern blot analysis of SGTs shows a partial deletion of stop cassette ............................ 81 
4. DISCUSSION .................................................................................................................... 83 
4.1 Notch2IC//LMP1/CD40//CD19-cre mice display an increase in reactive accessory 
cells in their spleens ....................................................................................................... 83 
4.2 Notch2IC//LMP1/CD40//CD19-cre mice display an increase of activated T cells and 
increase in the percentage of both central memory as well as effector memory T 
cells in their spleens ....................................................................................................... 86 
4.2.1 Tregs are increased in splenic preparations of Notch2IC//LMP1/CD40//CD19-
cre mice ................................................................................................................... 87 
4.3 Concomitant expression of constitutively active Notch2IC and CD40 has synergistic 
effects on spleen size and activation status of the splenocytes ................................... 89 
4.4 Marginal zone B cells are expanded in Notch2IC//LMP1//CD40//CD19-cre mice at 
the expense of the follicular B-cell population .............................................................. 89 
4.5 Splenic architecture is grossly disrupted in Notch2IC//LMP1/CD40//CD19-cre mice .. 90 
4.6 Notch2IC//LMP1/CD40//CD19-cre mice show distinct changes in the expression 
level of cyto- and chemokines in serum and splenic B cells .......................................... 92 
4.7 Notch2IC//LMP1/CD40-expressing splenic B cells show an increased proliferation 
in in vitro culture regardless of the supply of stimuli .................................................... 95 
4.8 Aged Notch2IC//LMP1/CD40//CD19-cre mice are prone to develop B-cell 
lymphomas ..................................................................................................................... 96 
4.9 Aged Notch2IC//LMP1/CD40//CD19-cre mice develop salivary gland carcinomas ...... 98 
5. SUMMARY .................................................................................................................... 101 
 vi 
 
6. ZUSAMMENFASSUNG .................................................................................................. 103 
7. MATERIAL ..................................................................................................................... 105 
8. METHODS ..................................................................................................................... 107 
REFERENCES ................................................................................................................................ 116 
SUPPLEMENTARY DATA .............................................................................................................. 132 
 vii 
 
LIST OF TABLES 
Tab. 3.1 Early concomitant expression of constitutive Notch2IC and LMP1/CD40 affects 
early B-cell development in the bone marrow leading to an equal reduction in pre - and 
immature B-cell population. .................................................................................................. 42 
Tab. 3.2 Overview of 13-16 month-old Notch2IC//LMP1//CD19-cre mice that developed 
hyperplasia of the spleen or the lower neck region. ............................................................. 69 
Tab. 3.3 Aged Notch2IC//LMP1/CD40//CD19-cre mice display distinctly altered surface 
marker expression with regard to CD5 and B220 expression................................................ 74 
Tab. 3.4 Splenic T cells of aged Notch2IC//LMP1/CD40//CD19-cre mice show an increase in 
the percentage of both central memory as well as effector memory T cells. ....................... 75 
Tab. 3.5 Overview over LMP1/CD40//CD19-cre mice age in months with SGTs and B-cell 
lymphoma. ............................................................................................................................. 79 
Tab. S.1 Overview over cell numbers of splenic T cell populations of CD19-cre, 
Notch2IC//CD19-cre, LMP1/CD40//CD19-cre and Notch2IC//LMP1/CD40//CD19-cre 
mice. ..................................................................................................................................... 132 
 viii 
 
LIST OF FIGURES 
Fig. 1.1 Notch maturation and signaling cascade. .......................................................................... 3 
Fig. 1.2 Overview of CD40 activation and impact on signaling pathways. ..................................... 9 
Fig. 3.1 Notch2IC//LMP1/CD40//CD19-cre mice display a splenomegaly and heavier spleens 
than all control mice. ............................................................................................................. 21 
Fig. 3.2 Transgene expression is a B-cell-specific event. ............................................................... 22 
Fig. 3.3 Notch2IC//LMP1/CD40//CD19-cre mice display higher splenic cell numbers and 
increased B‐cell numbers compared to control CD19-cre and Notch2IC//CD19-cre mice, 
but lower B‐cell numbers than LMP1/CD40//CD19-cre mice. .............................................. 23 
Fig. 3.4 Spleens of Notch2IC//LMP1/CD40//CD19-cre display an increase in the myeloid cell 
population. ............................................................................................................................. 25 
Fig. 3.5 Notch2IC//LMP1/CD40//CD19-cre mice display an increased number of 
granulocytes and macrophages. ............................................................................................ 26 
Fig. 3.6 Notch2IC//LMP1/CD40//CD19-cre mice display an increased number of activated 
dendritic cells. ........................................................................................................................ 27 
Fig. 3.7 Notch2IC//LMP1/CD40//CD19-cre mice display higher splenic T‐cell numbers 
compared to control CD19-cre, Notch2IC//CD19-cre and LMP1/CD40//CD19-cre mice. .... 28 
Fig. 3.8 Notch2IC//LMP1/CD40//CD19-cre mice display higher CD4pos and CD8pos splenic T‐
cell numbers compared to CD19-cre, Notch2IC//CD19-cre and LMP1/CD40//CD19-cre 
mice. ....................................................................................................................................... 30 
Fig. 3.9 Splenic T cells of Notch2IC//LMP1/CD40//CD19-cre show an enhanced expression 
of the T-cell activation markers CD25 and CD69. .................................................................. 31 
Fig. 3.10 Splenic T cells of Notch2IC//LMP1/CD40//CD19-cre mice show an increase in the 
percentage of both central memory as well as effector T cells. ............................................ 33 
Fig. 3.11 T cells of Notch2IC//LMP1/CD40//CD19-cre and Notch2IC//CD19-cre mice display 
a Th1 and not a Th2 cytokine profile both with and without stimulation. ............................ 35 
Fig. 3.12 Notch2IC//LMP1/CD40//CD19-cre mice display a substantial increase in Tregs. ............ 37 
Fig. 3.13 Total and B-cell numbers are normal in bone marrow preparations of 
Notch2IC//LMP1/CD40//CD19-cre mice, but exhibit significantly increased T-cell 
numbers. ................................................................................................................................ 38 
Fig. 3.14 Early concomitant expression of constitutive Notch2IC and LMP1/CD40 affects 
early B-cell development in the bone marrow leading to a reduction in pre- and 
immature B cells. .................................................................................................................... 40 
Fig. 3.15 Recirculation of mature B cells into the bone marrow is restricted in 
Notch2IC//LMP1/CD40//CD19-cre mice................................................................................ 43 
Fig. 3.16 AA4.1pos transitional B-cell numbers are not reduced in spleens of 
Notch2IC//LMP1/CD40//CD19-cre mice................................................................................ 44 
Fig. 3.17 Marginal zone B cells are expanded in Notch2IC//LMP1/CD40//CD19-cre mice 
while the follicular B-cell population is decreased. ............................................................... 46 
Fig. 3.18 Notch2IC//LMP1/CD40-expressing splenic B cells show an increase in cell size and 
enhanced expression of cell surface activation markers. ...................................................... 49 
Fig. 3.19 T-cell numbers are normal but B-cell numbers are reduced in inguinal lymph 
nodes of Notch2IC//LMP1/CD40//CD19-cre mice ................................................................. 50 
Fig. 3.20 B-cell subsets are altered in the inguinal lymph nodes of 
Notch2IC//LMP1/CD40//CD19-cre mice................................................................................ 51 
 ix 
 
Fig. 3.21 Splenic architecture is grossly disrupted in Notch2IC//LMP1/CD40//CD19-cre 
mice. ....................................................................................................................................... 53 
Fig. 3.22 B cells of Notch2IC//LMP1/CD40//CD19-cre mice display intermediate level in 
their CXCR4 expression. ......................................................................................................... 55 
Fig. 3.23 CXCR3 and IL13ra1, IL2Rγ, LTβ and TGFβ mRNA levels in B cells of 
Notch2IC//LMP1/CD40//CD19-cre mice are differentially up-regulated by Notch2IC 
and LMP1/CD40. .................................................................................................................... 57 
Fig. 3.24 Notch2IC//LMP1/CD40//CD19-cre mice show an up-regulation of CXCL9 and 
CXCL10 and a down-regulation of CXCL12 in serum. ............................................................. 59 
Fig. 3.25 Notch2IC//LMP1/CD40-expressing splenic B cells show an increased proliferation 
in in vitro culture. ................................................................................................................... 61 
Fig. 3.26 Unstimulated Notch2IC//LMP1/CD40‐expressing B cells survive better in culture 
than Notch2IC-, but not than LMP1/CD40-expressing B cells. .............................................. 64 
Fig. 3.27 Notch2IC//LMP1/CD40‐expressing splenic B cells are highly and actively cycling 
cells. ........................................................................................................................................ 67 
Fig. 3.28 Aged Notch2IC//LMP1/CD4//CD19-cre mice display increased numbers of splenic 
Mac1pos cells. .......................................................................................................................... 70 
Fig. 3.29 Aged Notch2IC//LMP1/CD40-expressing splenic B cells display distinctly altered 
surface marker expression in the spleen. .............................................................................. 71 
Fig. 3.30 Aged Notch2IC//LMP1/CD40-expressing splenic B cells display up-regulation of 
activation marker. .................................................................................................................. 73 
Fig. 3.31 Aged Notch2IC//LMP1/CD40//CD19-cre mice display distinctly altered surface 
marker expression with regard to CD5 and B220 expression................................................ 73 
Fig. 3.32 Aged Notch2IC//LMP1/CD4//CD19-cre mice display increased numbers of T cells. ..... 74 
Fig. 3.33 Gating scheme for T-cell activation after CD4pos or CD8pos pre-gating of T cells. .......... 75 
Fig. 3.34 Aged Notch2IC//LMP1/CD40//CD19-cre mice develop monoclonal B-cell 
lymphoma. ............................................................................................................................. 77 
Fig. 3.35 SGT localization in mouse. .............................................................................................. 78 
Fig. 3.36 Histological evaluation of lymphocytic infiltrates and surface marker expression in 
the SGTs of Notch2IC//LMP1/CD40//CD19-cre mice. ........................................................... 80 
Fig. 3.37 Southern blot analysis of SGTs shows a partial deletion of stop cassette. .................... 82 
Fig. S.1 Notch2IC//LMP1/CD40-expressing B cells show an increased proliferation in in vitro 
culture. ................................................................................................................................. 133 
 
 x 
 
LIST OF ABBREVIATIONS 
APC   antigen-presenting cell 
B-CLL   B-cell chronic lymphocytic leukemia  
BCR  B-cell receptor 
BM   bone marrow 
bp   base pairs 
BrdU   Bromodesoxyuridin 
BSA   bovine serum albumin 
CD   cluster of differentiation 
cDNA   complemetary DNA 
CFSE   Carboxyfluorescein succinimidyl ester  
Cre   protein recombinase of the phage P1 (“Causes Recombination”) 
CXCR   cysteine-X-cysteine chemokine receptor 
DLBCL   Diffuse Large B-cell lymphoma  
DC   dendritic cell 
Dll   Delta-like 
DNA   deoxyribonucleic acid  
EBNA   EBV nuclear antigen 
EBV   Epstein-Barr Virus  
FCS  fetal calf serum 
FACS   fluorescence-activated cell scanning/sorting 
FL   Follicular lymphoma 
Fo   follicular 
Foxp3   Forkhead box P3, transcription factor 
FSC   forward scatter 
g   gram 
GC  germinal center 
(c)HL   (classical) Hodgkin Lymphoma 
hi  high 
HIV  human immunodeficiency virus  
HRS cells  Hodgkin-Reed-Sternberg cells 
hrs   hours 
IHC   immunohistochemistry 
IFN   interferon 
Ig   immunoglobulin 
IL  interleukin 
int  intermediate 
kb   kilobase 
LMP   latent membrane protein 
LN   lymph node 
LPS   lipopolysaccharide 
LT   lymphotoxin 
MACS   magnetic cell separation 
MALT   mucosal-associated lymphoid tissue 
MDSC  myeloid-derived suppressor cell  
mRNA   messenger RNA 
 xi 
 
MZ   marginal zone 
neg  negative 
NF-κB   nuclear factor κ B 
NotchIC  intracellular part of the Notch receptor 
o/n  overnight 
PCR   polymerase chain reaction 
pos  positive 
qPCR   quantitative real-time polymerase chain reaction 
RBP-Jκ   recombination signal binding protein for immunoglobulin κ J region 
RNA   ribonucleic acid 
SCID   Severe Combined Immunodeficiency 
SMZL   splenic marginal zone lymphoma 
SP   spleen 
S1PR3  sphingosine 1-phosphate receptor 3 
SSC  side scatter 
TD   T-cell dependent 
TCR   T-cell receptor 
TGFβ  transforming growth factor-β  
TI   T-cell independent 
TNFR   tumor necrosis factor receptor 
TRAF   TNF receptor associated factor 
Tregs   T regulatory cells 
 
 
INTRODUCTION 1 
 
1. INTRODUCTION 
1.1 CD40 and Notch 
CD40 and Notch represent two signaling transmembrane receptors that are expressed in a 
multitude of different cells and influence various signaling contexts initiated through cell-cell 
contact during cellular proliferation and differentiation processes. Both have numerous 
intersection points with other signaling pathways and consequently their activation or 
inactivation can have significant impact on health or disease states of the individual. 
Since the work at hand is at the crossroads of immunology and oncology the molecules as such 
will be introduced, B- and T-cell development will be laid out and the impact the respective 
molecule has on the lymphocyte compartment as well as their roles in malignancies will be 
pointed out. 
1.2 Notch signaling 
The family of Notch receptors is found on a large number of different cell types and is involved in 
a multitude of different cellular processes. Notch signaling was originally discovered in Drosophila 
melanogaster, but has been shown to be conserved throughout evolution (Artavanis-Tsakonas et 
al., 1999). 
This family of receptors consists of four members in mammals (Notch1-4) sharing structural and 
sequence homologies (Radtke et al., 2010). The Notch protein belongs to the family of LNG 
proteins (LIN12 and GLP1 in Caenorhabditis elegans; Notch in Drosophila melanogaster). In the 
extracellular part Notch presents three LNG and 10–36 copies of EGF (epidermal growth factor)- 
like repeats, where ligand-binding is mediated by the latter (Rebay et al., 1991). The intracellular 
region of Notch contains a PEST sequence (proline-, glutamate-, serine-, threonine- rich) 
important for the degradation of the protein, a RAM domain (RBPJκ-associated molecule) and six 
to seven ankyrin repeats, both sequence of which are crucial for nuclear interaction with other 
proteins. Notch1 and Notch2 additionally feature a TAD domain (transcriptional activator 
domain). 
Notch receptors have five different membrane-bound ligands in mammals that can be subdivided 
into two groups, according to the homology with the Drosophila genes serrate or delta; the first 
mentioned comprises Jagged 1 and 2, the latter Delta-like-1, -3 and -4 (Dll-1, -3 and -4). Delta and 
Serrate form part of the family of DSL (Delta/Serrate/Lag2) proteins. They consist of a small 
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intracellular part, and in the extracellular space they have varying number of EGF-like repeats and 
a DSL domain in the N-terminus. This DSL domain was also identified to be responsible for the 
interaction with Notch (Fitzgerald et al., 1995).  
Notch receptors -like their ligands- are type I single pass transmembrane proteins. From their 
maturation until activation the Notch receptor undergoes three distinct proteolytic cleavage 
events (Fig. 1.1). The first cleavage (S1 cleavage) is mediated by a furin-like protease in the trans-
Golgi network during synthesis (Logeat et al., 1998). Loss of S1 cleavage leads to loss of function 
of the Notch receptor (Lake et al., 2009). S1 cleavage results in a bipartite protein, composed of a 
small transmembrane and intracellular part linked to the larger extracellular part. After 
localization in the membrane the receptor can interact with its respective ligand. Crosslinking of 
the extracellular part then leads to a cascade of proteolytic cleavage events: first a 
metalloproteinase such as ADAM 10 or ADAM 17/TACE (a disintegrin And 
metalloproteinase/tumor necrosis factor-α-converting enzyme) (Gibb et al., 2010; Murthy et al., 
2012) leads to membrane shedding of the extracellular portion of the protein (NotchEC; S2 
cleavage). Subsequently, a presenilin-dependent γ-secretase (De Strooper et al., 1999) cuts 
within the membrane spanning domain of the receptor (S3 cleavage) so that the intracellular part 
(NotchIC) is released and can translocate to the nucleus. 
In the absence of NotchIC in the nucleus its nuclear binding partner CSL (C promoter binding 
factor1/Suppressor of Hairless/Lag1) in humans and RBP-J in mice (recombination-signal-binding 
protein-J) (Matsunami et al., 1989) is bound to DNA with co-repressors including SMRT (silencing 
mediator of retinoid and thyroid receptors), HDAC1 and HDAC2 (histone deacetylase) which leads 
to suppression of Notch-target genes. Once NotchIC enters the nucleus, it binds to RBPJ via its 
ankyrin repeats and RAM domain (Kurooka et al., 1998). Subsequently, co-repressors are 
released from the complex and co-activators such as PCAF (P300/CBP-associated factor), p300 
itself, and MAML1-3 (mastermind-like 1-3) are recruited which turn the complex into an activator 
complex. This eventually results in the expression of Notch-responsive genes such as hes1 (hairy 
and enhancer of split 1) and deltex1. Via direct and indirect effectors expression of Notch-
responsive genes influences diverse processes such as cell-fate decisions, cell migration (CCR4, 
CCR6, CCR7; CC chemokine receptors), angiogenesis (VEGF; vascular endothelial growth factor) 
and cell proliferation (c-myc, p21, p27, Cyclin D1). Ubiquitination of the PEST domain of NotchIC 
by E3 ligases terminates signaling and Notch is subsequently degraded in the proteasome 
(Hubbard et al., 1997; Fostier et al., 1998; Cornell et al., 1999; Oberg et al., 2001; Wu et al., 
2001). 
The largest body of research with regard to Notch signaling has probably been compiled in 
developmental studies (e.g. in embryonic pattern formation such as during somitogenesis) and 
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outside the lymphocyte compartment. Nonetheless, Notch signaling is also of key importance in 
the development of T cells as well as in the development of marginal zone (MZ) B cells (Tanigaki 
et al., 2002). 
 
Fig. 1.1 Notch maturation and signaling cascade. 
In its lifetime Notch undergoes three cleavage events: cleavage at S1 during transit to the cell surface in 
the Golgi apparatus by a furin-like protease after which it functions as a transmembrane receptor. Upon 
engagement with its membrane-bound ligands of the family of DSL proteins Notch undergoes cleavage at 
S2 extracellularly by a metalloprotease and S3 within the membrane by a presenilin-dependent γ 
secretase. NotchIC then translocates to the nucleus transforming the transcriptional repressor CSL into a 
transcriptional activator by recruiting MAML1 and possibly other co-activators leading to expression of 
Notch-responsive genes. CSL, human C protein binding factor1/Suppressor of Hairless/Lag1; DSL, 
Delta/Serrate/Lag2 proteins; MAML1, mastermind-like 1; MP, metalloprotease; NotchEC, Notch 
extracellular portion; NotchIC, Notch intracellular portion; S, site. (adapted from (Nam et al., 2002; von 
Boehmer, 2005) 
1.3 T-cell development 
Like all cells of the adaptive immune system T cells are derived from the common lymphoid 
progenitor (CLP) in the bone marrow, but they undergo their final developmental stages in the 
thymus. Each compartment gives important developmental cues: for example both B and T cells 
in the bone marrow depend on interleukin7 receptor (IL7R) signaling. Mice deficient for this non-
redundant cytokine or its receptor display lymphopenia of both the B- and T- cell lineage 
(Peschon et al., 1994; von Freeden-Jeffry et al., 1995; Rich, 1997). Afterwards, the lobules of the 
thymus with their different compartments (i.e. the cortex and the medulla) provide the 
appropriate environment for the T-cell progenitors to develop into mature T cells.  
T-cell progenitors still do not bear any of the distinct lineage markers of T cells, namely the T-cell 
receptor (TCR) complex, with the co-receptors CD4 and CD8. With reference to the CD4/CD8 
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status the progenitors are termed double negative (DN). They develop through distinct DN 
phases (DN 1-4), characterized by consecutive rearrangement of the Variable (V), Diverse (D), and 
Joining (J) gene segments of the TCR and change in surface marker expression of CD25 and CD44 
(D'Acquisto et al., 2011) to finally becoming double-positive (DP) for CD4 as well as CD8. At this 
stage T-cell precursors stop proliferating and finally an α:β TCR-CD3 complex is presented at the 
cell surface and the cells are able to undergo positive selection (in the medullary areas of the 
thymus) and subsequently negative selection (in the cortical areas of the thymus). Only 2-4 % of T 
cells will successfully accomplish the process of selection and then migrate into the periphery as 
naïve single-positive T cells (CD4pos or CD8pos), i.e. functional T helper or cytotoxic T cells, 
respectively, that can further develop into effector T cells upon antigen encounter. CD4pos T cells 
can further differentiate into Th(helper)1 and Th2 cells. These distinct cell types are characterized 
e.g. the type of cytokines the respective cell produces and whether it rather promotes humoral 
or cellular immune responses. 
There are two other distinct groups of DN cells that already acquire their effector potential in the 
thymus before their emigration to the periphery: natural killer (NK) T cells and T cells that belong 
to the γ:δ lineage (as opposed to the α:β lineage).  
NK T cells are a small group of T cells (0.01 %–1 % of CD3pos lymphocytes in humans) expressing 
the surface marker NK1.1 and in contrast to conventional T cells they respond to CD1d-restricted 
lipid ligands (Juno et al., 2012). The various functions of NK T cells are mediated mainly by a rapid 
release of large amounts of cytokines, including IL4 and IFNγ (Oki et al., 2004).  
γ:δ T cells, like NK T cells, are a quite small group of T cells. They diverge from α:β T cells at the 
DN2/DN3 stage (D'Acquisto et al., 2011). In humans and mice, the vast majority of T cells (>90 %) 
in peripheral blood and conventional lymphoid organs express the α:β-TCR and only a minority 
(<10 %) express the γ:δ- TCR (Haas et al., 1993).  
Interestingly, another T-cell population called T regulatory cells (Tregs) is able to prohibit the 
developmental step from naïve CD8pos T cells into effector T cells in the periphery (McNally et al., 
2011). Tregs themselves develop from the late DP stage (i.e. from α:β TCR-positive cells) (Fontenot 
et al., 2005) in the thymus and are characterized by the expression of transcription factor Foxp3 
(Forkhead box P3), and the surface markers CD4 and CD25. The expression and activity of Foxp3 
is essential to the development of this cell population which in some instances can also be 
induced in the periphery upon antigenic stimulation in the presence of transforming growth 
factor-β (TGFβ) (Chen et al., 2003; Apostolou et al., 2004; Coombes et al., 2007), IL2 (Laurence et 
al., 2007) and retinoic acid (Benson et al., 2007; Mucida et al., 2007; Sun et al., 2007). However, it 
is still a topic of debate whether these so-called induced Tregs (iTregs) are functionally stable in vivo 
(Floess et al., 2007).  
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Natural Treg from the thymus play a role critical for the maintenance of peripheral immunological 
tolerance (Dejaco et al., 2006), thereby suppressing autoimmunity, inflammatory bowel disease 
and allergies. Treg are of quintessential importance to keep self-reactive cells under control. 
However, this property seems to be mostly detrimental with regard to the role of Treg in cancer, 
where they are suspected to dampen adaptive and innate immune responses leading to anti-
tumor cytotoxicity (Wang et al., 2011). Nonetheless, it is not yet clarified whether their presence 
in tumors is really causal or rather correlative and it is now thought that the role of Treg might be 
much more versatile and strongly context-dependent (deLeeuw et al., 2012; Savage et al., 2012). 
1.3.1 Notch in T-cell development 
With regard to hematopoiesis Notch signaling is best studied in T-cell lymphopoiesis. It is 
instructive for T-cell development as such and it remains important throughout T-cell 
development and differentiation. Notch1 expression in early lymphopoiesis influences B- versus 
T-cell lineage determination and constitutive Notch signaling in the very early pro-B-cell stage 
leads to formation of an aberrant T-cell population in the bone marrow while blocking B2 B-cell 
development (Pui et al., 1999; Hampel et al., 2011). In the thymus, T cells express the Notch1 
receptor and cells of the thymic stroma express the Notch-ligand Dll4. Genetic inactivation of 
notch1 (Radtke et al., 1999; Wilson et al., 2001) or of dll4 on thymic stroma cells (Koch et al., 
2008) leads to a complete block in T-cell development. Moreover, interference with Notch 
signaling such as through a dominant negative form of MAML1 results in a similar phenotype 
(Maillard et al., 2004). 
In later developmental stages Notch signaling is thought to play a role in the α:β versus γ:δ T-cell 
lineage choice (Wolfer et al., 2002) and seems to be important for the development of IL17-
producing γ:δ T cells (Shibata et al., 2011). Expression of active Notch3 in T cells and transgenic 
expression of Jagged1 by B lymphocytes significantly increases the pool of Treg (Vigouroux et al., 
2003; Anastasi et al., 2003). Notch has also repeatedly been discussed to be involved in 
differentiation of Th1 cells, Th2 cells, or both. However, to date the issue remains unresolved. 
(Minter et al., 2005; Tu et al., 2005; Sun et al., 2008; Ong et al., 2008; Amsen et al., 2009). 
1.4 B-cell development 
Under many aspects B-cell development parallels T-cell development. B cells also rely on the 
surrounding stroma in the bone marrow for developmental cues, both through cell-cell contact 
as well as through secreted growth factors (Nagasawa, 2006). The developmental process of B 
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cells resembles that of T cells with regard to successively rearranging V(D)J-gene segments in a 
gradual and coordinated fashion, testing whether the rearrangement was successful, which 
finally results in the formation of a heterodimeric, disulfide bridge-linked antigen-receptor. Also, 
like in T cells, these stages are marked by characteristic expression of certain surface molecules 
and intracellular proteins. Striking differences in development are however that B cells are 
continually produced over the lifetime of the individual in the bone marrow (Nunez et al., 1996), 
whereas development of T cells occurs in the thymus and slows down with the thymus eventually 
undergoing involution during puberty. 
One of the very first decisive factors for the commitment of an uncommitted progenitor cell 
towards the B-cell as opposed to T-cell lineage and further maturation of the B cell is the 
transcription factor Pax5 (paired box 5). Pax5 encodes the B-cell lineage specific activator protein 
(BSAP) (Rolink et al., 1999; Nutt et al., 1999). From the early pro-B-cell phase the germline 
conformation of the heavy chain IgH-locus with its V(D)J segments is rearranged, through action 
of RAG-1 and RAG-2 (Recombination Activating proteins) (Oettinger, 1996) resulting in a pre-B-
cell-receptor at the large pre-B-cell stage. Only if the rearrangement of the heavy chain was 
successful subsequent rearrangement first of the light κ- and then λ-chain gene locus in the now 
committed B cell is initiated. Upon successful completion of this process IgM is expressed on the 
surface of the immature B cell. Only B cells expressing a non-self-reacting B-cell receptor (BCR) 
can further differentiate. B cells expressing a self-reactive BCR have been observed to re-induce 
RAG expression and to subsequently undergo additional Ig-gene rearrangements. These usually 
occur at the light chain locus in response to encountering self-antigens in the bone marrow (Gay 
et al., 1993; Tiegs et al., 1993). This mechanism has been termed receptor editing and if cells fail 
to undergo it successfully development of the respective cell is arrested and the cell dies by 
apoptosis, which has been termed clonal deletion (Nemazee et al., 1989; Hartley et al., 1993). 
Therefore, at the end of the development in the murine bone marrow only 10-20 % of the 
∼2×107 IgMpos immature B cells that are produced daily leave the bone marrow as transitional B 
cells (Osmond, 1991), enter the blood stream and initially home to the spleen (Osmond, 1986; 
Allman et al., 1993; Rolink et al., 1998). 
Via different transitional stages (termed T1-3) these B cells mature into naïve follicular B cells (Fo 
B cells) and into MZ B cells in the spleen (Loder et al., 1999; Su et al., 2002; Chung et al., 2003; 
Pillai et al., 2009). With 75 % of all mature B cells Fo B cells represent the largest group. They 
express high levels of surface IgD and CD23. As their name suggests, they are rather found in the 
follicular areas in the white pulp of the spleen and lymph nodes, but they have the ability to 
recirculate, entering and exiting follicular niches in secondary lymphoid organs until they 
encounter antigen (Hardy et al., 1983; Waldschmidt et al., 1988). With only 5 % of total splenic B 
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cells MZ B cells represent the smaller group of mature B cells. In mice they are exclusively found 
and defined by their anatomical niche in the marginal zone at the rim of splenic follicles, 
separating the red from the white pulp in the spleen. Unlike Fo B cells they are sessile in this 
location adjacent to MZ macrophages, reticular fibroblasts and metallophilic macrophages that 
reside at the inner border of the marginal sinus through which the blood enters the organ. This 
architectural setup accounts for the fact that the spleen is the largest filter of blood in the body. 
The MZ therefore presents a highly effective line of defense against blood-borne bacteria 
(Tanigaki et al., 2002): the macrophages are extremely potent phagocytic and apt for the uptake 
and clearance of even large foreign particles, such as bacteria and also effete red blood cells. 
Thereby produced antigenic fragments are taken up by dendritic cells which relay them to the T 
cells in the PALS (periarteriolar lymphoid sheath). The MZ B cells 
(CD1dposCD9posCD21hiCD23low/IgDlowIgMhiB220lowS1P1hiS1PR3hi; sphingosine 1-phosphate receptor 
3) are in a pre-activated state (indicated also by higher levels of CD80 and CD86) which allows 
them to rapidly respond to antigen contact. Not only do they become potent antigen-presenting 
cells (APCs) after brief antigenic stimulation but they have been shown to be superior activators 
of naïve CD4pos T cells over Fo B cells both in vivo and in vitro (Oliver et al., 1999; Attanavanich et 
al., 2004). Moreover, they differentiate quicker into plasma cells upon T-cell-independent (TI) 
stimuli such as bacterial lipolysaccharide (LPS) (Oliver et al., 1999). Furthermore, our group could 
demonstrate that they display enhanced proliferation after stimulation, and have an inherent 
increased basal signaling activity of Akt, extracellular signal-regulated kinase (ERK) and c-Jun N-
terminal kinase (JNK) (Hampel et al., 2011).  
Localization of the MZ B cells is thought to be managed majorly by expression of S1PR1, but not 
S1PR3 (Cinamon et al., 2004). However, S1PR3 expression by the endothelial cells lining the MZ is 
vital for proper establishment of the zone (Girkontaite et al., 2004). For Fo B cells expression of 
the chemokine receptor CXCR5 is key to access the lymphoid follicles (Forster et al., 1996), as the 
chemokine ligand CXCL13 is expressed along the dense follicular dendritic cell (Fo DC) network.  
In mice there is another subset of mature B cells beside the B2 cell populations (Fo and MZ B 
cells). These are so called B1 B cells. This self-renewing B cell subset is found mainly in peritoneal 
and pleural cavities and unlike B2 cells they are not derived postnatally from the bone marrow, 
but the fetal liver. They share certain characteristics with MZ B cells with regard to their longevity 
and pre-activated status and high expression of CD9, which is not found on unstimulated Fo B 
cells (Miller et al., 1975; Won et al., 2002). Furthermore, they respond similarly to common 
bacterial antigens through their intrinsic ability to differentiate into antibody secreting cells if 
their Toll-like receptors (TLR) are stimulated by appropriate ligands (Genestier et al., 2007). 
Therefore, both MZ B cells and B1 B cells have been referred to as “innate B cells”.  
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1.4.1 Notch in B-cell development 
Lineage decision between a Fo and MZ B-cell fate is affected by several factors: e.g. BCR-signaling 
strength (Martin et al., 2000; Girkontaite et al., 2001; Cariappa et al., 2001) and also Notch 
signaling (Tanigaki et al., 2002; Kuroda et al., 2003). While there is strong evidence that strong 
BCR signaling rather drives the B cells into adopting a Fo B-cell fate, strong Notch signaling is 
instructive for B cells to adopt a MZ B-cell fate.  
While Dll4, but not Dll1 is quintessential for T-cell development (Koch et al., 2008), Dll1-Notch2 
interaction in fact is crucial for proper MZ B-cell development as was evidenced by studies in 
mice deficient for either one of the interaction partners (Saito et al., 2003; Hozumi et al., 2004). 
These findings are further supported by studies showing that MZ B-cell generation is similarly 
affected if a player of the Notch-signaling pathway is affected; such as MAML1 (Oyama et al., 
2007; Wu et al., 2007). Dosage of Notch pathway players such as MAML1 in fact correlates with 
MZ B-cell number (Wu et al., 2007). Furthermore, deletion of negative regulators of Notch and 
constitutive action of Notch2 led to an increase in the MZ B-cell compartment in the analyzed 
mice (Kuroda et al., 2003; Hampel et al., 2011).  
1.5 The CD40 receptor 
The CD40 receptor is involved in T-cell-dependent (TD) activation of B cells. It is like Notch and its 
ligands a type I single pass transmembrane glycoprotein and belongs to the superfamily of tumor 
necrosis factor receptors (TNFRs). CD40 is mainly expressed on B cells, DCs and macrophages. 
Additionally, various levels of CD40 were described on a multitude of different cells such as 
epithelial cells, monocytes, basophils, eosinophils, T cells and neurons (Banchereau et al., 1994). 
The natural ligand of CD40 is CD154 (CD40L), a type II transmembrane molecule that also belongs 
to the TNF family. Expression has like its receptor CD40 been noted on a variety of different cell 
types, but is majorly found on activated T cells. Ligand-receptor interaction leads to the clustering 
of CD40 from monomers into trimeric complexes and subsequent relocation into lipid rafts 
initiating CD40 signal transduction. Since the CD40 molecule itself lacks enzymatic activity it relies 
on signaling via its intracellular carboxy-terminal domain via the assembly of adaptor proteins, 
i.e. TNFR-associated factors (TRAFs) along the cytoplasmatic tail of the receptor. These TRAFs, 
namely TRAF1, -2, -3, -5 and -6 mediate all downstream effects of active CD40 (Fig. 1.2), resulting 
in the activation of a variety of kinases including p38, ERK and JNK, PI3K and PLCγ2 
(phosphoinositol-3-kinase; phospholipase C-γ2) and the Src family kinases Syk, Lyn and Fyn. 
CD40-signaling leads to the activation of numerous transcription factors such as members of the 
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canonical as well as non-canonical NF-κB (nuclear factor κB) family and STAT3 (signal transducer 
and activator of transcription) (Hanissian et al., 1997). Engagement of the CD40 receptor in in 
vitro experiments showed that B cells display better survival and proliferation and that they up-
regulate numerous activation markers, including CD23, CD80, CD86, CD95 (Fas) and ICAM1 
(intercellular adhesion molecule 1). Notably, CD40 activation also triggers production and release 
of various cyto- and chemokines, including IL1, IL2, IL7, IL10, IL12, IL15, IL17, LTα, which play a 
role in regulating CD40 function in immunity since these are involved in regulating processes such 
as Ig-isotype switching and antigen presentation. Its role in immunity has also been highlighted in 
male individuals carrying CD154-mutations leading to the immunodeficiency X-linked Hyper IgM 
(HIGM) syndrome, which is characterized by normal to elevated IgM levels, a deficiency in IgG, 
IgE and IgA antibodies and a reduction of memory B cells, while overall B-cell numbers remain 
normal. This is recapitulated in CD40- (Kawabe et al., 1994) and CD154-KO mice (Renshaw et al., 
1994). As observed for HIGM patients no IgG, IgA, and IgE responses to TD antigens could be 
mounted by the B cells in these mice and germinal center (GC) formation is severely affected, 
while the TI response was largely unaffected. 
Hence, proper CD40 signaling is of utmost importance in many different processes most notably 
in B-cell signaling notably in TD-immune responses leading to formation of B-cell memory 
through the GC-reaction. 
 
Fig. 1.2 Overview of CD40 activation and impact on signaling pathways. 
Upon engagement of CD40 with CD40L and trimerization of the receptor (not shown) signaling is 
mediated via CD40’s intracellular carboxy-terminal domain and the assembly of TRAF adaptor proteins 
along the cytoplasmatic tail of the receptor. TRAF1, 2, 3, 5 and 6 mediate all downstream effects of active 
CD40. CD40L: CD154; ERK, extracellular signal-regulated kinase; IKK, IκB kinase; JNK, c-Jun N-terminal 
kinase; MKK, Mitogen-activated protein kinase kinase; NF-κB, nuclear factor κB family; NIK, NF-κB-
inducing kinase;STAT, signal transducer and activator of transcription; TAK1, transforming growth factor-b 
(TGF-b)-activated kinase 1; TRAF, Tumor necrosis factor receptor (TNFR)-associated factor  
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1.6 T-cell dependent and T-cell independent immune response 
While T cells recognize their cognate antigen mainly in processed form presented on MHCs, B 
cells are able to directly bind soluble antigen in blood and lymph. Depending on the type of 
antigen presented the naïve B cell elicits a TD- or TI immune response. 
TI antigens can activate B cells without help from a T helper cell (TI response). The TI immune 
response is fast and yields B-cell antibodies that have low affinity and are often polyreactive. The 
TI immune response does not lead to generating immunological memory.   
TD antigens however, can elicit a much more refined immune response in B cells. When 
crosslinking the BCR, the TD-antigen is internalized by receptor-mediated endocytosis, 
intracellularly processed and loaded onto MHCII molecules which are brought to the cell surface. 
The production of MHCII is up-regulated simultaneously along with other activation molecules, 
i.e. ICAM and co-stimulatory molecules B7.1 and B7.2 (CD80 and CD86, respectively). In contrast 
to macrophages and DCs, this process is initiated already at very low antigen concentrations in B 
cells. These TD antigens are thereby presented to T helper (i.e. CD4pos) cells. In case the T helper 
cell is specific for the same antigen it is activated by engagement of its TCR binding to the 
MHCII/peptide-complex and CD28 to the B cell’s B7 surface molecules and thereby activate the 
peptide-presenting B cell.  
This T-cell mediated B-cell activation is further based on two components: secreted cytokines and 
cell-cell contact mediated signals, such as IL4-stimulation and CD40L-CD40-ligation, respectively. 
Receiving the aforementioned signals the B cell then enters mitosis and can initiate isotype 
switching to IgG, IgA and IgE. Proliferating B cells are able to form either extra-follicular foci or to 
migrate to primary lymphoid follicles ultimately forming a GC. In extra-follicular foci, mainly 
short-lived plasma cells producing low-affinity antibodies are found and the foci quickly involute 
after some days (Ho et al., 1986; Smith et al., 1996). On the other hand GCs represent sites in 
secondary lymphoid organs where activated B cells commence to highly proliferate at first. 
Afterwards they undergo a number of further, crucial genetic modifications in the Ig genes 
leading to diversification and the refinement of the BCR, while migrating through distinct 
compartments (dark and light zones) of the GC. These modifications include somatic 
hypermutation, which alters the V regions of BCR, affinity maturation, which selects for survival 
of B cells with high affinity for the antigen, and isotype switching. Eventually the positively 
selected B cells differentiate either into long-lived plasma or memory B cells (McHeyzer-Williams 
et al., 1999). The latter can be rapidly reactivated upon contact with the same antigen, conferring 
quick and highly effective protection against previously encountered pathogens. 
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1.7 CD40 and Notch signal deregulation in human malignancies 
Both CD40 and Notch signaling molecules have been implicated in the development of many 
human malignancies, both within and apart from the lymphocyte context. Given that CD40 as 
well as Notch can induce a variety of signaling cascades in the cell it is not surprising that the 
results of deregulated signaling can be quite disparate.  
1.7.1 Notch signaling in cancer 
At multiple stages during development Notch signaling is involved in maintaining the balance 
between cell proliferation, differentiation and apoptosis. Therefore it is plausible that disrupting 
this balance by Notch deregulation can have both tumorigenic as well as anti-proliferative effects 
and the ultimate outcome is context-dependent. Anti-tumorigenic effects of Notch signaling have 
been observed in human hepatocellular and small lung carcinoma for example. In in vitro cultures 
of human esophageal cells a Notch3-mediated program has been shown to induce squamous 
differentiation and to counter-regulate invasive growth (Ohashi et al., 2011). Suppressing Notch1 
signaling in murine keratinocytes undercuts the Notch-induced expression of p21 that usually 
leads to cell cycle withdrawal and terminal differentiation (Rangarajan et al., 2001). Moreover, it 
abrogates Notch activation of caspase3 which as well leads to the terminal differentiation of the 
cells (Okuyama et al., 2004). Epidermal deletion of the notch1 gene leads to extensive epidermal 
hyperplasia and the notch1 conditional knock-out mice spontaneously develop cutaneous basal 
cell carcinoma (Nicolas et al., 2003). These experiments showed a role for Notch1 in the murine 
skin as a tumor suppressor.  
Nonetheless, most studies were able to show the tumor promoting effects of aberrant Notch 
signaling due to up-regulation of the receptor and/or its ligands, such as in colon, head and neck 
carcinoma and renal carcinoma and pancreatic cancer. High expression levels of Notch1 and 
Jagged1 in patients with breast, bladder and prostate cancer are correlated with a poor prognosis 
(Santagata et al., 2004; Reedijk et al., 2005; Reedijk et al., 2008; Shi et al., 2008). This underscores 
the effect Notch has by activating expression of its responder genes as well as its cross-talk with 
other pathways, such as sonic hedgehog (SHH) and Wnt signaling, EGF- and platelet-derived 
growth factor- (PDGF) signaling. Cross-talk with other pathways such as TGFβ and SMAD signaling 
is important during epithelial mesenchymal transition (EMT) - a central process in carcinoma 
progression in which Notch was found to be an inducing key player (Zavadil et al., 2004; Wang et 
al., 2010; Matsuno et al., 2012). 
The first connection between Notch dysregulation and cancer was made in 1991 by Ellisen and 
colleagues showing that the human homologue TAN1 of the Drosophila’s Notch gene was 
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disrupted in patients suffering from T-cell lymphoblastic leukemia (Ellisen et al., 1991). Since then 
the extensive involvement of Notch especially with regard to the development of T-cell 
malignancies has been progressively elucidated. However, considering direct effects on B-cell 
tumorigenesis the role of Notch is somewhat unclear. Like for other cell types the up-regulation 
of the receptor and/or its ligands was also found in the B-lymphocyte compartment, such as in 
Hodgkin Lymphoma (HL). It is under discussion whether HL could be distinguished from Non-HL 
on the basis of a Notch-associated gene expression profile (Kochert et al., 2011). In B-cell chronic 
lymphocytic leukemia (B-CLL) the oncogenic effects of Notch were found to be due to its capacity 
to up-regulate CD23 expression (Hubmann et al., 2002), while Lee and colleagues could identify 
gain of function mutations in the PEST domain – usually ubiquitinated before Notch degradation 
in the proteasome- in Diffuse Large B-cell lymphoma (DLBCL) samples (Lee et al., 2009). 
Consistent with the role of Notch in developmental decision of the B-cell lineage in the periphery 
(i.e. its capacity to push B cells towards a MZ B-cell fate) Notch2 and other molecules involved in 
the Notch signaling pathway were recently found to be the most frequent lesions in splenic 
marginal zone lymphoma (SMZL) as determined by whole-exome and –genome sequencing and 
copy-number analysis (Rossi et al., 2012; Kiel et al., 2012). The concomitant presence of viruses 
within the B cells such as Kaposi’s sarcoma herpes virus (KSHV) and Epstein-Barr Virus (EBV) 
(Hsieh et al., 1997) also seems to support the oncogenic capacities of Notch in the B cell (He et 
al., 2009) as shown in primary effusion lymphoma (PEL) (Lan et al., 2009; Lan et al., 2007) and 
Burkitt lymphoma (BL) (He et al., 2009).  
Nonetheless, the role of Notch in B cells remains controversial: while on the one hand synergistic 
effects of Notch with BCR and CD40 signaling have been shown in the promotion of proliferation 
(Thomas et al., 2007; He et al., 2009), Notch has also demonstrated to induce apoptosis and cell 
cycle arrest at both immature and mature developmental stages (Morimura et al., 2000; Romer 
et al., 2003; Kohlhof et al., 2009) as well as in B-cell malignancies (Zweidler-McKay et al., 2005). 
1.7.2 CD40 signaling in cancer  
CD40 signaling has been shown to play a role in multiple myeloma, both B-CLL and B-ALL (B-cell 
acute lymphocytic leukemia), MALT (low-grade mucosal-associated lymphoid tissue) lymphoma, 
BL and HL. The background for this effect becomes evident when looking at the effects that 
active CD40 signaling has on the cell. CD40 can promote cell growth and inhibit the induction of 
apoptosis, since it increases the level of anti-apoptotic proteins of the Bcl-family of proteins, 
protecting the cell from TRAIL- (TNF-related apoptosis-inducing ligand) and Fas-induced 
apoptosis (Benson et al., 2006; Travert et al., 2008). The ability of CD40 to induce IL6 production 
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for example has a stimulatory effect on tumor cell types such as multiple myeloma, in which IL6 is 
a key feature (Urashima et al., 1995). In melanoma, CD40 leads to self-stimulation through the 
up-regulation of its ligand CD154 (van den Oord et al., 1996). On the other hand down-regulation 
of CD154 on T cells results in decreased activation of the T lymphocytes in colon and pancreatic 
carcinoma cell lines and growth of the tumor cells (Batrla et al., 2002). Indirectly, CD40 can have 
a positive effect on tumor growth by inducing and supporting neo-vascularization of the tumor by 
relaying strong angiogenic signals (Melter et al., 2000; Chiodoni et al., 2006). 
On the other hand CD40 also supplies anti-tumorigenic signals, this has been shown primarily in 
solid tumors but it also holds true for some lymphomas. For example, anti-CD40 treatment in B-
cell lymphomas can have growth inhibiting effects in vitro and in vivo after transfer into SCID 
(Severe Combined Immunodeficiency) mice (Funakoshi et al., 1994). Moreover, CD40 on B cells 
promotes the stimulation of other APCs, in fact turns the tumor cells themselves into potent 
APCs leading to the attraction of cytotoxic T cells in turn leading to eradication of the tumor cell.  
Therefore, whether engagement of CD40 has tumorigenic or anti-tumorigenic effects depends 
largely on cell type, experimental conditions (in vitro, in or ex vivo) and type of stimulus used 
(soluble versus membrane-bound CD154). 
1.8 B-cell lymphoma 
As described in the previous sections both CD40 and Notch play a role in diseases of the 
lymphatic system and therefore also in the B-cell compartment. B-cell lymphomas comprise both 
HL and non-HL, the latter of which represent the majority of cases. HL can then be differentiated 
into two larger groups: classical HL (cHL; 95 % of cases) and nodular lymphocyte predominant HL 
(NLPHL; 5 % of cases). Of the non-HL, DLBCL, MALT and Follicular lymphoma (FL) are the most 
common types, while primary effusion lymphoma (PEL) and Burkitt lymphoma (BL) are more rare 
(however with endemic differences).  
Most B-cell lymphoma develop upon recombination processes in B cells. This can happen during 
the maturation of a B cell and its BCR at two distinct time points: A) during development in the 
bone marrow and B) during the GC reaction, i.e. somatic hypermutation and class switch 
recombination. HL, like FL, marginal zone B-cell lymphoma (MZBL) and DLBL display a clear post-
GC phenotype, as indicated by the Ig-configuration of the B cell that has undergone somatic 
hypermutation (Kanzler et al., 1996; Lossos et al., 2003). These mutations are usually unfavorable 
and would force the B cells to undergo apoptosis, but due to simultaneously occurring genetic 
lesions in genes such as p53, c-myc etc. these cells rather receive growth promoting cues (Lossos 
et al., 2003). 
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As with most GC lymphomas the neoplastic follicles do not only comprise the malignant cells 
themselves but also increased numbers of non-neoplastic, but highly reactive cells such as 
myeloid cells, DCs, macrophages and T cells. This is probably most pronounced in cHL. This type 
of lymphoma can be particularly characterized by the fact that the actual tumor cells, the so-
called Hodgkin-Reed-Sternberg (HRS) cells, only constitute roughly 0.1 - 10 % of the tumor mass 
(Kuppers, 2009). The rest of the cells in the mass consists of infiltrates of reactive cells with 
varying composition according to which the type of HL can be further classified. Members of the 
innate immune system are key constituents of the HL tumor microenvironment. Their abundant 
cytokine production adds significantly to maintaining the inflammatory background in cHL 
(Aldinucci et al., 2010). However, of course, these cellular infiltrates cannot only be found in HL 
but in various tumors not only of the lymphatic system. Therefore, a short excursus will be made 
at this point to illustrate the physiological role of these innate immune cells. 
1.8.1 Innate immune cells 
The innate immune system is in its cellular part represented by granulocytes, monocytes and 
macrophages. These are myeloid cells derived from common myeloid progenitor cells (CMPs) in 
the bone marrow.  
The first cell type a pathogen is likely to encounter in solid tissues is macrophages. While for long 
having been regarded to be inflammation mediators and phagocytes only, their role seems to be 
more refined with regard to the effect they have on T cells and the extracellular matrix (Mosser, 
2003). Therefore, macrophages are now usually divided into type 1- and type 2-activated 
macrophages, which refers to the way in which the macrophage ultimately serves as an effector 
cell in type 1 or type 2 T helper cell immune responses elicited by IFN-γ or IL4 (Ding et al., 1988; 
Stein et al., 1992; Mantovani et al., 2004). Activated macrophages secrete a range of cytokines 
having both local and systemic effects; such as IL8 for example which leads to the recruitment of 
neutrophil granulocytes to the site of infection (Mosser et al., 2008; Cailhier et al., 2006). 
Neutrophils are then the first cells to arrive in large numbers at the site of inflammation. They 
limit the expansion and spread of pathogens directly at the site by phagocytosis, release of anti-
microbial peptides and pro-inflammatory cytokines (Cassatella, 1999; Denkers et al., 2003). 
Neutrophils further attract and activate other effector cells such as monocytes and DCs by the 
secretion of chemokines, which ultimately aids in mounting an adaptive immune response. DCs 
are further cellular representatives of the innate immune system. They are the most potent and 
therefore major APCs. The DCs key role is T-cell activation, providing a highly critical link to the 
adaptive immune system (Clark et al., 2000).  
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Furthermore, there are cells derived from the CLP, which unlike B- and T-lymphocytes, lack 
antigen specificity and form part of the innate immunity such as NK cells. NK cells develop in the 
bone marrow and are activated in response to cytokines and interferons secreted by 
macrophages and like cytotoxic T cells they release granules onto the surface of the respective 
target cell leading to its demise (Gapin et al., 2001). 
Looking only at these few cell types one can already fathom that cytokines and chemokines play 
a key role both in the initiation and amplification of the inflammatory response, as well as in the 
orchestration of the different cell types involved and finally in the initiation of the adaptive 
immune response. And this gives an impression that deregulation of these mechanisms can have 
quite detrimental effects for the individual such as seen not only in allergies but of course also in 
cancer. 
1.9 Rationale for studying deregulated CD40- and deregulated Notch2IC 
signaling 
In a number of lymphomas (i.e. HRS cells in cHL) the tumorigenic cells display an up-regulation of 
both CD40 and Notch. In fact Notch1 is thought to be one of the key players during malignant re-
programming of the cells (Jundt et al., 2008). CD40 has been shown to be strongly expressed in 
the cytoplasmatic and membrane sections in samples of HL patients and is now accepted as a 
hallmark of the disease (Aldinucci et al., 2010). Moreover, T cells in the neoplastic follicles 
express high amounts of CD40L (Carbone et al., 1995).  
Furthermore, HRS-cells in 40 % of all cHL cases are positive for EBV-infection. Interestingly, in 
EBV-infection the virus hijacks the cellular machinery to express viral genes that are functional 
mimics of cellular proteins. Latent membrane protein 1 (LMP1), is a functional homologue of 
CD40, whereas EBV nuclear antigen 2 (EBNA2) mimics a Notch receptor and LMP2A a BCR signal. 
All of these viral proteins target the same pathways as their cellular counterparts yet with the key 
difference that they are constitutively active forms. LMP1 is critical for B-cell transformation, a 
quality that has first been discovered in rodent fibroblasts. With regard to EBNA2 and Notch Hella 
Kohlhof from our group was able to show that although EBNA2 and Notch interact with RBP-J 
resulting in the activation of target genes their respective function has still differential outcomes 
(Kohlhof et al., 2009). While Notch-IC like EBNA2 is able to bring quiescent B cells to actively cycle 
again, an mRNA-screen revealed that it also up-regulates genes related to apoptosis. EBNA2 
mimics this physiological function, yet simultaneously leads to the up-regulation of anti-apoptotic 
genes. In case Notch signaling is active, LMP1- or constitutively active CD40-signaling could 
provide anti-apoptotic signals leading to onset of tumorigenesis. And indeed, Thomas and 
INTRODUCTION 16 
 
colleagues were able to show that Notch and CD40 together with BCR-signaling in vivo lead to an 
enhancement of B-cell activation, also leading to an increase in proliferation of the B cells 
(Thomas et al., 2007), which is a necessary prerequisite for lymphoma. To study the immediate 
effects of deregulated CD40- and Notch2IC- signaling in an in vivo situation also with regard to 
lymphomagenesis was the aim of this project at hand. 
1.10 The LMP1/CD40 and Notch2IC transgenic mouse strains 
In order to examine deregulated signaling of the Notch receptor as well as the CD40-receptor 
two conditional mouse strains were generated in our lab that allow for tissue- and 
developmental stage-specific deregulation of the two molecules; the Notch2ICflSTOP and the 
LMP1/CD40flSTOPP mouse (Homig-Holzel et al., 2008; Hampel et al., 2011). 
1.10.1 The LMP1/CD40flSTOP mouse strain (Homig-Holzel et al., 2008) 
The LMP1/CD40 molecule represents a fusion protein, consisting of the membrane spanning 
domain of the viral protein LMP1 and the intracellular part of the cellular CD40 molecule. 
Thereby, we are able to exploit the ability of the six membrane spanning domain of LMP1 to 
signal ligand-independently via self-oligomerization. This N-terminal domain that tethers the 
fusion protein to the cell membrane and leads to its self-aggregation was fused to the C-terminal 
signaling domains of CD40. Thus, this construct conveys constitutively active CD40 signals to the 
respective cell in which it is expressed.  
The targeting construct was inserted into the Rosa26 locus and is under the control of the 
endogenous Rosa26 promoter. This locus is ubiquitously expressed and even a complete knock-
out of the locus has no deleterious effects on the cell (Zambrowicz et al., 1997; Casola, 2010).  
The construct is preceded by a loxP site flanked STOP cassette, which is removed upon Cre-
expression leading to the expression of the fusion protein. Hence, crossing the LMP1/CD40flSTOP 
mice to mice expressing Cre recombinase in a developmental stage- and tissue-specific manner 
allows for cell type and differentiation stage-specific expression of the transgene.  
Overall, in the LMP1/CD40 mouse strain the CD40 signaling is deregulated in the sense of it being 
constitutively active, yet the signaling pathways that are involved are still physiological CD40 
targets. This is important because even though LMP1 is the viral homologue for CD40, there are 
subtle differences in the regulation of those targets and the effect the expression of LMP1, 
respectively CD40, has on the cell (Lam et al., 2003; Rastelli et al., 2008). 
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Crossing these mice to CD19-cre mice leads to expression of the transgene in the CD19-
expressing B cells of those mice. Already at 8 weeks these mice display splenomegalies due to 
increased B- and also T-cell numbers in the spleen (eight and three times, respectively). 
Moreover the numbers of lymphocytes are as well as thrice as high in the inguinal lymph nodes 
compared to controls. In line with the effects of CD40 signaling LMP1/CD40-expressing B cells 
display an activated phenotype with regard to both surface expressed activation markers as well 
as the activation of intracellular signaling pathways, such as MAP kinase signaling (ERK, JNK). TD-
immunization of the LMP1/CD40flSTOP//CD19-cre mice does neither lead to the formation of GCs 
in those mice, nor to the subsequent production of high-affinity antibodies by plasma cells. B 
cells of the LMP1/CD40flSTOP//CD19-cre mice do not only show increased survival and diminished 
apoptosis in vitro but develop lymphomas with a very high incidence from the age of 12 months 
onward compared to controls. These lymphomas are very diverse with regard to the activation of 
their signaling pathways. Interestingly, we further found that these aged mice also develop 
tumors in the lower neck region.  
1.10.2 The Notch2ICflSTOP mouse strain (Hampel et al., 2011) 
The Notch2IC mouse was also generated in our lab in a similar manner as was the LMP1/CD40 
mouse. The murine cDNA coding for the intracellular portion of the Notch receptor was inserted 
into the Rosa26 locus and also contains a loxP flanked STOP cassette like the LMP1/CD40 mouse 
strain. Unlike the LMP1/CD40 transgene however, the Notch2IC sequence was moreover 
preceded by an endogenous ATG-Kozak site (serving as a translational start site) as well as a 
sequence coding for the CAGGS promoter (Cytomegalovirus early enhancer/chicken β-
actin/rabbit globin promoter). This promoter was chosen in order to ensure strong and 
consistent expression, as has been shown in various cellular systems (Niwa et al., 1991; Daly et 
al., 1999a; Daly et al., 1999b). Another crucial point of distinction between the Notch2IC and 
LMP1/CD40 mouse strain is that in the Notch2IC mouse an IRES-hCD2 (internal ribosomal entry 
site-human CD2) cassette is inserted downstream of the sequence coding for Notch2IC. Thereby, 
Notch2IC expression in any given cell can be monitored via concomitant surface expression of a 
truncated form of human CD2.  
Crossing the Notch2IC mice to CD19Cre mice led to a shift towards MZ B cells at the expense of 
Fo B cells in the spleen of the Notch2IC mice compared to controls. These Notch2IC-expressing B 
cells exhibit MZ B-cell characteristics with regards to their localization, their pre-activated 
phenotype: i.e. expression of surface markers, activation of Akt, ERK and JNK signaling and 
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enhanced response to stimulation by LPS and CD40 in vitro. This was found to be true even in the 
absence of a functional CD19 receptor in those Notch2IC-expressing B cells.  
1.10.3 The CD19-cre mouse strain (Rickert et al., 1997) 
The CD19-cre mouse strain has been described in 1997 by Rickert and colleagues (Rickert et al., 
1997) and it is by now widely used throughout the B-cell research community. CD19 functions as 
a co-receptor of the B-cell receptor and is expressed from the pro B-cell stage in the bone 
marrow onward with expression increasing as the B cell matures and migrates to the spleen.  
Hence, crossbreeding this mouse into the Notch2ICflSTOP and LMP1/CD40flSTOP mouse strains 
allows for a deletion of the STOP cassette preceding the Notch2IC as well as the LMP1/CD40-
transgene from B-cell precursor stages in the bone marrow onwards and allows an easy approach 
to test the effect of the two transgenes in the B-cell context. 
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2. AIM 
The Notch receptor as well as the CD40 receptor have well established roles in the biology of B 
lymphocytes. While CD40 is known to be essential to promote class switch in activated B cells, 
Notch2 plays a crucial role in the development of marginal zone (MZ) B cells. Contribution of 
constitutive Notch1 signaling in the development of T-cell lymphomas is well established, 
however the potential role of constitutive Notch signaling in B-cell lymphoma is less elucidated.  
Mice expressing either the CD40 or the Notch2 receptor in a constitutively active form and B-cell-
specific fashion have previously been established and characterized in our lab 
(LMP1/CD40//CD19-cre and Notch2IC//CD19-cre; Homig-Holzel et al., 2008; Hampel et al., 2011). 
Notch2IC//CD19-cre mice show an expansion of MZ B cells at the expense of the follicular (Fo) B 
cells, while B- and T-cell numbers resemble those of CD19-cre control mice. With age these mice 
do not develop B-cell lymphomas. The reason for this observation might be that constitutively 
active Notch2 signaling in B cells although able to induce proliferation, also leads to higher 
apoptosis rates. This hypothesis was supported by array data from Kohlhof of our group showing 
that Notch signaling leads to an up-regulation of both cell cycle genes as well as an increase in 
pro-apoptotic signals in the B cell (Kohlhof et al., 2009).  
In LMP1/CD40//CD19-cre mice on the other hand constitutively active CD40 leads to an 
expansion not only of B-, but also of T cells and LMP1/CD40-expressing B cells display a better 
survival rate conveyed by the constitutive CD40 signal that delivers anti-apoptotic signals to the B 
cell. These mice develop B-cell lymphoma with a high incidence from 12 months onward.  
From these findings it was hypothesized that Notch signaling in B cells might eventually lead to B-
cell lymphoma in combination with anti-apoptotic signals. These signals could be relayed to the B 
cell by a constitutive CD40 signal. 
With the aim to examine this question in vivo and in vitro, LMP1/CD40//CD19-cre and 
Notch2IC//CD19-cre mice were cross-bred to analyze their offspring for their B-cell phenotype, 
the developmental fate of the B cells (Fo versus MZ B cell), the proliferation and survival patterns 
and the potential effects the transgenic B cells have on the T cells and other cell populations. A 
small test group of Notch2IC//LMP1/CD40//CD19-cre animals will be kept to evaluate whether 
lymphomagenesis is potentially favored in this genetic background.  
Furthermore, in previous experiments ulcerations in the lower neck region of old 
LMP1/CD40//CD19-cre mice were observed. The potential reason behind this growth shall be 
examined and aged Notch2IC//LMP1/CD40//CD19-cre should be monitored for the recurrence of 
these ulcerations. 
RESULTS 20 
 
3. RESULTS 
3.1 Concomitant expression of constitutive Notch2IC and LMP1/CD40 in B cells 
has synergistic effects on increase in spleen size and weight 
 
LMP1/CD40flSTOPP mice and Notch2ICflSTOPP were crossed to CD19-cre mice, which resulted in 
the deletion of the floxed STOP cassette in the LMP1/CD40flSTOP//CD19-cre and 
Notch2ICflSTOP//CD19-cre mice. These mouse strains were cross-bred with each other to express 
both receptors in a B-cell specific fashion yielding offspring with a 
Notch2ICflSTOP//LMP1CD40flSTOP//CD19-cre genotype. Mice names were hence forth abbreviated 
to Notch2IC//CD19-cre, LMP1/CD40//CD19-cre and Notch2IC//LMP1/CD40//CD19-cre mice. All 
three genotypes were analyzed in parallel with a CD19-cre control mouse. 
In these mice deletion of the stop cassette by activation of the CD19 promoter and expression of 
Cre recombinase starts in the phase of early B-cell development in the bone marrow, but 
progressively continues as mature B cells migrate to and distribute in the spleen. As the spleen 
represents the largest secondary lymphoid organ, overt effects of transgene-expression in B cells 
can easily be monitored by changes in size and weight of the organ. 
It has been shown before that the spleens of Notch2IC//CD19-cre mice are slightly and spleens of 
LMP1/CD40//CD19-cre mice are markedly enlarged and the organs are correspondingly heavier 
than those of aged-matched CD19-cre control mice (Homig-Holzel et al., 2008; Hampel et al., 
2011). This is even potentiated when constitutively active CD40 and constitutively active Notch2 
are simultaneously expressed in the B cells of Notch2IC//LMP1/CD40//CD19-cre mice. The 
spleens of these eight to 20 week-old mice are markedly larger than of aged-matched control 
CD19-cre and Notch2IC//CD19-cre mice (Fig. 3.1A). And they usually present with an even more 
pronounced splenomegaly than spleens of LMP1/CD40//CD19-cre and are on the average 1.6-
fold as heavy as those of LMP1/CD40//CD19-cre mice (Fig. 3.1B).  
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Fig. 3.1 Notch2IC//LMP1/CD40//CD19-cre mice display a splenomegaly and heavier spleens than all 
control mice. 
(A) Spleen size of 10 week-old mice. The ruler indicates the size of the organ in cm. (B) Splenic weight in g. 
CD19-cre (blank circle), Notch2IC//CD19-cre (filled circle), LMP1/CD40//CD19-cre (blank rhombus), 
Notch2IC//LMP1/CD40//CD19-cre (filled rhombus). Points represent data from individual mice and 
horizontal bars mark the mean value indicated in numbers. *p < 0.05, ** p < 0.01, *** p < 0.005. 
3.2 Expression of the transgenes Notch2IC and LMP1/CD40 is a B-cell specific 
event 
In order to ensure that there was no leakage of the expression of the two transgenes in any other 
cell type than in B cells, other cell types including T lymphocytes were analyzed for the presence 
of the reporter protein hCD2. hCD2 is concomitantly expressed upon the expression of the 
Notch2IC transgene after deletion of the upstream stop cassette. Flow cytometric analysis 
(Fluorescence-activated cell sorting, in short FACS) showed that expression of hCD2 could only be 
detected in splenic B220pos B cells of Notch2IC//CD19-cre and Notch2IC//LMP1/CD40//CD19-cre 
mice (Fig. 3.2A), but not in B cells of CD19-cre and LMP1/CD40//CD19-cre mice. Furthermore, 
hCD2 expression was undetectable in CD3pos T cells (Fig. 3.2B) in mice of all genotypes, as well as 
in any other living cell type present in the spleen (Fig. 3.2C).  
The deletion efficiency of the stop cassette upstream of the LMP1/CD40-transgene can be 
checked indirectly via the highly specific up-regulation of CD95 in B cells of those animals. 
Therefore, staining cells simultaneously with α-hCD2 and α-CD95 antibodies and performing 
FACS analysis allows to determine the amount of successful deletion in the B cells of the 
respective animals with regard to both Notch2IC- as well as LMP1/CD40-expression (Fig. 3.2D). 
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The results displayed in Fig. 3.2D show that in all three transgene-carrying genotypes 
(Notch2IC//CD19-cre, LMP1/CD40//CD19-cre and Notch2IC//LMP1/CD40//CD19-cre) the 
deletion efficiency reached on the average at least 80 % or more according to up-regulation of 
the respective reporter marker (hCD2 or CD95 or both). In summary, these results show that the 
stop cassette deletion upstream of the respective transgenes is an unambiguously B-cell-specific 
event. 
 
 
Fig. 3.2 Transgene expression is a B-cell-specific event. 
Histograms show overlays of hCD2-expression of (A) lymphocyte-gated, living, B220pos B cells, (B) 
lymphocyte-gated, living, CD3pos T cells and (C) living, B220neg cells in the spleen of CD19-cre (grey line), 
Notch2IC//CD19-cre mice (orange line), LMP1/CD40//CD19-cre mice (purple line) and 
Notch2IC//LMP1/CD40//CD19-cre mice (green line). Data is representative for nine independent 
experiments. (D) Living, B220pos splenocytes were simultaneously stained for surface expression of hCD2 
and CD95. The FACS plots show average percentages and SDs, as determined by antibody staining of 
whole splenocytes and subsequent flow cytometric analysis. Topro-3pos (dead) cells were excluded from 
analysis. SD, standard deviation.  
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3.3 In Notch2IC//LMP1/CD40//CD19-cre mice total splenic cell numbers and B-
cell numbers are significantly higher than in control and Notch2IC//CD19-cre 
mice but B-cell numbers are significantly lower than in LMP1/CD40//CD19-
cre mice 
In order to determine to what extent the expression of the respective transgenes adds to 
increase in size and weight the spleens were analyzed with regard to their total splenic cell as 
well as their splenic B-cell numbers. CD19-cre and Notch2IC//CD19-cre mice display about the 
same amount of total cells in their spleens, as well as similar B-cell numbers (Fig. 3.3A and B). 
Notch2IC//LMP1/CD40//CD19-cre mice resemble LMP1/CD40//CD19-cre mice with regard to 
their total splenic cell numbers of 5.3×108 cells (versus 5.6×108 total splenic cells in 
LMP1/CD40//CD19-cre mice) and they harbor more than 6-fold more cells than control CD19-cre 
and Notch2IC//CD19-cre mice (Fig. 3.3A). Also, B- cell numbers of Notch2IC//LMP1/CD40//CD19-
cre mice (like LMP1/CD40//CD19-cre mice) display significantly increased splenic B‐cell numbers 
compared to CD19-cre and Notch2IC//CD19-cre mice. 
 
 
Fig. 3.3 Notch2IC//LMP1/CD40//CD19-cre mice display higher splenic cell numbers and increased B‐cell 
numbers compared to control CD19-cre and Notch2IC//CD19-cre mice, but lower B‐cell numbers than 
LMP1/CD40//CD19-cre mice. 
(A) Absolute numbers of counted, living cells and (B) living, lymphocyte-gated, B220pos B cells in the spleen 
of CD19-cre, Notch2IC//CD19-cre, LMP1/CD40//CD19-cre and Notch2IC//LMP1/CD40//CD19-cre mice as 
determined by antibody staining of whole splenocyte peparations and subsequent flow cytometric 
analysis. Topro-3pos (dead) cells were excluded from analysis. Points represent data from individual mouse 
and horizontal bars mark the mean value indicated in numbers above each data set for the respective 
genotype. *p < 0.05, ** p < 0.01, *** p < 0.005. 
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However, when comparing splenic B‐cell numbers of Notch2IC//LMP1/CD40//CD19-cre with 
LMP1/CD40//CD19-cre mice, the LMP1/CD40//CD19-cre mice display still significantly increased 
B-cell numbers versus Notch2IC//LMP1/CD40//CD19-cre mice (1.6×108 cells versus 3.2×108 
splenic B cells in LMP1/CD40//CD19-cre mice). 
Therefore surprisingly, Notch2IC//LMP1/CD40//CD19-cre mice display higher total splenic cell 
numbers and increased splenic B‐cell numbers compared to control CD19-cre and 
Notch2IC//CD19-cre mice, but lower splenic B‐cell numbers than LMP1/CD40//CD19-cre mice. 
Hence, the enlargement of the spleen had to be due to other cell populations. 
 
3.4 Notch2IC//LMP1/CD40//CD19-cre mice display an increased number of 
splenic accessory cells 
As aforementioned the elevated numbers of splenic B cells alone cannot account for the overall 
elevated total splenic cell numbers. This invited a broader look at cell populations that might be 
expanded in Notch2IC//LMP1/CD40//CD19-cre mice. In the forward scatter (FSC) versus side 
scatter (SSC) during flow cytometric analysis a population characterizing myeloid cells (Givan, 
2013) showed up unexpectedly in the splenic cell preparations of Notch2IC//LMP1/CD40//CD19-
cre mice repeatedly, however to varying extent (Fig. 3.4). Myeloid cells comprise all blood cells 
that do not belong to the group of lymphocytes and include mast cells, but also myeloblasts 
which can differentiate into neutrophils and monocytes the latter of which can further develop 
into macrophages and dendritic cells upon activation. In Notch2IC//CD19-cre and 
LMP1/CD40//CD19-cre mice percentages of these myeloid cells are with ≈3.6 % more or less on 
level of the spleens of control CD19-cre mice (with 2.8 %). However, since there is an overall 
increase in the splenic cell number of LMP1/CD40//CD19-cre mice this also translates into an 
increase in total myeloid cell numbers in these mice although the percentages vary strongly 
(±1.7-3.7 %). In Notch2IC//LMP1/CD40//CD19-cre mice there is a defined increase in the myeloid 
cell population which harbor on average 7.2 % myeloids in the splenocytes population. However, 
this varies strongly (±5.55 %), which indicates that spleens of Notch2IC//LMP1/CD40//CD19-cre 
mice have a tendency to harbor or attract more myeloid cells to the organ, but this cannot be 
observed to the same extent in all animals analyzed. 
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Fig. 3.4 Spleens of Notch2IC//LMP1/CD40//CD19-cre display an increase in the myeloid cell population. 
Myeloid cell population (green circle, Givan, 2013) as detected by FSC/SSC-analysis during FACS. Averages 
and SDs are given. FSC, forward scatter; SSC, sideward scatter; SD, standard deviation. 
3.4.1 Notch2IC//LMP1/CD40//CD19-cre mice display an increased number of granulocytes 
and macrophages 
Monocytes are an important subpopulation of myeloid cells. They are recruited to sites of tissue 
injury and inflammation where they help to resolve the infection and are important for tissue 
repair. Arriving at the site of infection or injury they quickly differentiate into DCs and 
macrophages. Therefore, the spleens of all mice were analyzed for the presence of macrophages 
and DCs and granulocytes which contribute to the myeloid cell population. 
A Gr1/Mac1 surface marker staining allows differentiating Gr1hi Mac1pos granulocytes from the 
Gr1pos Mac1pos macrophages (Zohren et al., 2012) (Fig. 3.5A) and permits to determine the 
number of macrophages and granulocytes in the respective sample as given in the methods 
section (“isolation of primary lymphocytes” and “Cell number calculations”). The results revealed 
an increase in macrophage cell numbers in LMP1/CD40//CD19-cre by roughly 3-fold in 
comparison to both Notch2IC//CD19-cre and CD19-cre mice (Fig. 3.5B). In 
Notch2IC//LMP1/CD40//CD19-cre mice however, the numbers were markedly increased by 10-
fold with respect to spleens of control CD19-cre mice. Fig. 3.5C displays the actual granulocyte 
cell numbers for the respective genotype. Again, the numbers found in Notch2IC//CD19-cre and 
CD19-cre mice are roughly the same, while in comparison those in LMP1/CD40//CD19-cre are 
increased by 4-fold and those in Notch2IC//LMP1/CD40//CD19-cre mice are increased by 10-fold 
in comparison. 
Performing immunofluorescent staining using the macrophage/granulocyte marker Mac1 on 
histological sections one can analyze the location of these macrophages and granulocytes within 
the spleen (Fig. 3.5D). In all four genotypes these cell populations are retained within the red 
pulp of the spleen, while the follicles are discernible as dark areas. One can see that the cells sit 
rather loosely in the red pulp in the spleens of CD19-cre and seem to be a little more clustered in 
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Notch2IC//CD19-cre mice. As expected due to the enlarged spleens the follicles in 
LMP1/CD40//CD19-cre and Notch2IC//LMP1/CD40//CD19-cre are rather large in comparison to 
Notch2IC//CD19-cre and CD19-cre (and will be analyzed in detail in section 3.11). In 
LMP1/CD40//CD19-cre and Notch2IC//LMP1/CD40//CD19-cre mice the macrophages and 
granulocytes also populate the red pulp areas where they seem to sit rather densely, while the 
follicles are devoid of Mac1pos cells. 
 
 
Fig. 3.5 Notch2IC//LMP1/CD40//CD19-cre mice display an increased number of granulocytes and 
macrophages. 
(A) Exemplary gating to differentiate Gr1hi Mac1pos granulocytes (Gr) from the Gr1pos Mac1pos macrophages 
(MΦ)(as described in e.g. Zohren et al., 2012). Cell numbers for the splenic macrophages (B) population 
and for the splenic granulocyte population (C) as determined by Mac1/Gr1-antibody staining and FACS 
analysis. Points represent data from individual mouse and horizontal bars mark the mean value indicated 
in numbers above each data set for the respective genotype. (D) Mac1-antibody was used in 
immunofluorescent stainings to determine the localization of macrophages/granulocytes in the spleen of 
different genotypes on splenic cryosections. Bar: 100 μm; *p < 0.05. 
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3.4.2 Notch2IC//LMP1/CD40//CD19-cre mice display an increased number of activated 
dendritic cells 
Next, since DCs are the other cell population into which monocytes can differentiate the spleens 
of all genotypes were analyzed for the presence of DC population. Although CD11c is being 
considered a marker for DCs as such (Metlay et al., 1990; Brocker et al., 1997) CD11c is also found 
on monocytes, tissue macrophages and NK cells (Hogg et al., 1986; Blasius et al., 2007; Drutman 
et al., 2012). Conventional DCs in the murine spleen however can be identified through 
examining the expression of both surface markers CD11c and CD8. FACS analysis was performed 
in order to determine whether this cell population was increased in 
Notch2IC//LMP1/CD40//CD19-cre mice. An increase in lymphocyte-gated, CD11cpos cells is 
detectable both in LMP1/CD40//CD19-cre and in the Notch2IC//LMP1/CD40//CD19-cre mice in 
which also the population of both CD11c and CD8pos conventional DC population is clearly 
discernible (Fig. 3.6A).  
 
Fig. 3.6 Notch2IC//LMP1/CD40//CD19-cre mice display an increased number of activated dendritic cells. 
(A) FACS analysis results of the different genotypes after staining splenocytes for CD11c and CD8 surface 
markers indicative of conventional murine splenic DCs (lymphocyte-gated, CD8pos and CD11cpos 
population). (B) Dot plot of lymphocyte-gated, MHCII versus CD11cpos cells as determined by flow 
cytometry in splenocytes preparations of all four genotypes with average and SDs. Data are representative 
for three independent experiments. DC, dendritic cell. SD, standard deviation. 
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Activated DCs -as other professional APCs- are characterized by up-regulation of MHCII. 
Interestingly, analyzing the CD11cpos cell population revealed not only that CD11cpos population is 
increased as such but these also up-regulate MHCII (Fig. 3.6B).  
Altogether, numbers of accessory cells as myeloid cells, macrophages and DCs were found to be 
elevated in Notch2IC//LMP1/CD40//CD19-cre mice. All these cell types are involved in 
inflammatory responses, which suggested also looking further into the activation states of the T 
lymphocytes.  
 
3.5 Notch2IC//LMP1/CD40//CD19-cre mice display significantly increased 
numbers of splenic T cells  
Next, the splenic T cells -representing the other large lymphocyte population besides B cells- 
were examined by flow cytometric analysis.  
 
 
Fig. 3.7 Notch2IC//LMP1/CD40//CD19-cre mice display higher splenic T‐cell numbers compared to 
control CD19-cre, Notch2IC//CD19-cre and LMP1/CD40//CD19-cre mice. 
Number of living, lymphocyte-gated, CD3pos T cells in the spleen of CD19-cre, Notch2IC//CD19-cre, 
LMP1/CD40//CD19-cre and Notch2IC//LMP1/CD40//CD19-cre mice as determined by antibody staining of 
whole splenocytes and subsequent flow cytometric analysis. Topro-3pos (dead) cells were excluded from 
analysis. Points represent data from individual mouse and horizontal bars mark the mean value indicated 
in numbers above each data set for the respective genotype. *p < 0.05, ** p < 0.01, *** p < 0.005 
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Splenic T-cell numbers in Notch2IC//CD19-cre mice are on the level of CD19-cre control mice, 
while they are roughly increased by 6-fold in LMP1/CD40//CD19-cre mice, as has been previously 
documented. Surprisingly, the splenic T-cell population (with an overall average number of 
roughly 2.4×108 cells) is even further increased in Notch2IC//LMP1/CD40//CD19-cre mice: this 
amounts to a 10-fold increase compared to CD19-cre control mice (Fig. 3.7). It is striking to see 
that although T cells do not express the transgenes (i.e. display an expression of hCD2; Fig. 3.2B) 
this lymphocyte population is vastly expanded in Notch2IC//LMP1/CD40//CD19-cre in the 
spleens of these animals. 
 
3.5.1 Notch2IC//LMP1/CD40//CD19-cre mice display a shift from CD4pos towards CD8pos splenic T cells  
Beyond their developmental stages in the thymus T cells can be grouped into CD4pos and CD8pos 
cells in the periphery.  
As displayed in Fig. 3.8A CD19-cre mice majorly have CD4pos T cells, while exhibiting lower 
percentages for CD8pos T cells. The same distribution pattern can be observed in Notch2IC//CD19-
cre mice. This is also reflected in similar cell numbers for the different T-cell populations in those 
two genotypes (Fig. 3.8B). In LMP1/CD40//CD19-cre mice however, the percentages for CD4pos 
cells are even increased, while the percentages for CD8pos cells are slightly reduced in comparison 
to CD19-cre and Notch2IC//CD19-cre mice. This is also reflected in the actual cell numbers of 
CD4pos cells in LMP1/CD40//CD19-cre mice which are significantly increased compared to CD19-
cre control mice. However, since these mice harbor more T cells in their spleens as such also the 
actual numbers for CD8pos cells are significantly increased in these mice versus the control mice. 
Interestingly, in comparison to CD19-cre mice the percentages for splenic CD4pos T cells are 
slightly decreased and the percentages of CD8pos are increased in Notch2IC//LMP1/CD40//CD19-
cre mice, however due to the high number of T cells in these mice the actual cell numbers as such 
are in both cases still significantly higher than in control CD19-cre and Notch2IC//CD19-cre mice. 
With regard to the CD8pos cells Notch2IC//LMP1/CD40//CD19-cre mice harbor significantly higher 
numbers than LMP1/CD40//CD19-cre mice. 
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Fig. 3.8 Notch2IC//LMP1/CD40//CD19-cre mice display higher CD4pos and CD8pos splenic T‐cell numbers 
compared to CD19-cre, Notch2IC//CD19-cre and LMP1/CD40//CD19-cre mice. 
(A) Average percentages and SDs of CD3pos/CD4pos or CD3pos/CD8pos splenic T cells of CD19-cre, 
Notch2IC//CD19-cre, LMP1/CD40//CD19-cre and Notch2IC//LMP1/CD40//CD19-cre mice as determined 
by FACS analysis. Data is representative of six independent experiments. Plots are gated on living 
lymphocytes. (B) Number of living, CD3pos and CD4pos (left panel) and CD3 and CD8pos (right panel) T cells in 
the spleen of CD19-cre, Notch2IC//CD19-cre, LMP1/CD40//CD19-cre and Notch2IC//LMP1/CD40//CD19-
cre mice as determined by antibody staining of whole splenocytes and subsequent flow cytometric 
analysis. Topro-3pos (dead) cells were excluded from analysis. Points represent data from individual mouse 
and horizontal bars mark the mean value indicated in numbers above each data set for the respective 
genotype. *p < 0.05, ** p < 0.01, *** p < 0.005; SD, standard deviation. 
3.5.2 Notch2IC//LMP1/CD40//CD19-cre mice display activation of splenic T cells  
In order to characterize the abnormally expanded splenic T-cell population in these mice and to 
determine which T-cell populations are majorly responsible for the observed expansion and 
activation levels of T cells, the distribution of naïve, memory and effector T cells and the 
populations (Th1, Th2, Treg) as such were examined more closely in murine spleens. This was 
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achieved mainly via flow cytometric analysis using antibodies binding to several different surface 
(α-CD62L, α-CD25, α-CD28, α-CD69) as well as intracellular markers (IFNγ, IL4 and Foxp3). 
3.5.2.1 Splenic T cells of Notch2IC//LMP1/CD40//CD19-cre mice show an enhanced 
expression of T-cell activation markers CD25 and CD69, but not of CD28 
The splenic T cells were examined for a number of surface antigens that are up-regulated if the T 
cells are activated. CD28 is one of these markers that can engage with the B7 proteins (CD80 and 
CD86) on APCs (such as DCs and B cells) and provides co-stimulatory signals. Unexpectedly, none 
of the four genotypes tested show an upregulation of CD28 (data not shown).  
Another molecule providing co-stimulatory signals to the T cell after the TCR has been engaged is 
CD69. Together with CD25, CD69 is one of the earliest and most prominent markers expressed by 
T cells upon activation and therefore has been dubbed very early antigen (VEA) (Yokoyama et al., 
1989; Hamann et al., 1993). When testing Thy1.2pos T cells for the expression level of CD69, 
Notch2IC//LMP1/CD40//CD19-cre and LMP1/CD40//CD19-cre mice display an increased number 
of splenic T cells with higher CD69 levels than CD19-cre and Notch2IC//CD19-cre mice (Fig. 3.9B). 
CD25 however is specifically up-regulated in the splenic T cells of Notch2IC//LMP1/CD40//CD19-
cre mice compared to all other genotypes tested (Fig. 3.9A). 
 
 
Fig. 3.9 Splenic T cells of Notch2IC//LMP1/CD40//CD19-cre show an enhanced expression of the T-cell 
activation markers CD25 and CD69. 
Splenocytes from two to five-month-old mice with genotypes as indicated were stained with antibodies 
specific for Thy1.2, CD25 (A) or CD69 (B) and subjected to FACS analysis. Histograms show overlays of 
representative FACS plots (pre-gated on lymphocytes and Thy1.2pos cells) of surface expression of the 
indicated molecules from CD19-cre (grey line), Notch2IC//CD19-cre mice (orange line), 
LMP1/CD40//CD19-cre mice (purple line) and Notch2IC//LMP1/CD40//CD19-cre mice (green line). 
Representative data from three independent experiments are shown. 
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3.5.2.2 Splenic T cells of Notch2IC//LMP1/CD40//CD19-cre mice show an increase in the 
percentage of both central memory as well as effector memory T cells  
Analyzing splenic T lymphocytes by staining of the surface markers CD4, CD8, CD62L and CD44, 
allows determining the percentages of naïve (CD62Lhi CD44neg), central memory (CD62Lhi CD44hi) 
and effector cells (CD62Lneg CD44hi) in the respective CD4pos or CD8pos T-cell population. 
The FACS analysis results revealed that Notch2IC//CD19-cre, LMP1/CD40//CD19-cre mice and 
Notch2IC//LMP1/CD40//CD19-cre compared to CD19-cre mice have a reduction in the naïve T 
cell compartment (CD62Lhi CD44low) in their spleens (Fig. 3.10A (CD4pos) and Fig. 3.10B (CD8pos)). 
This is observable for all three genotypes both in the CD4pos, as well as in the CD8pos T-cell 
population (upper and lower panel). In Notch2IC//CD19-cre mice the compartment of splenic 
central memory T cells (CD62Lhi CD44hi) for both the CD4pos and CD8pos cells resembles that of 
CD19-cre mice, since there are roughly 8 % CD4pos memory T cells and roughly 18 % CD8pos 
memory T cells. With regard to the splenic effector T cells (CD62Llow CD44hi) in Notch2IC//CD19-
cre mice however, there is a distinct increase both in the CD4pos (≈ 41 %) as well as the CD8pos 
population (≈ 26 %) compared to that of CD19-cre mice (26% in the CD4 and 17 % in the CD8pos 
cell populations).  
With regard to CD4pos splenic T cells Notch2IC//CD19-cre and Notch2IC//LMP1/CD40//CD19-cre 
mice display very similar patterns of expansion of splenic T-cell subgroups, although the 
subgroup of CD4pos central memory T cells is slightly decreased in Notch2IC//LMP1/CD40//CD19-
cre mice and the splenic effector T cells are even more expanded in these mice (on the average 
42 % in Notch2IC//CD19-cre versus 55 % in Notch2IC//LMP1/CD40//CD19-cre and only 26 % in 
CD19-cre mice). LMP1/CD40//CD19-cre mice have slightly increased CD4pos memory T cells and a 
stronger increase in the CD4pos effector cell compartment in comparison to CD19-cre mice. With 
respect to CD8pos splenic T cells the subgroup of central memory T cells is roughly three times 
reduced in percentage in the Notch2IC//LMP1/CD40//CD19-cre mice compared to all other 
genotypes, while effector T cells are with 39 % markedly increased both compared to mice 
Notch2IC-and LMP1/CD40-genotypes (27 % and 21 %, respectively, compared to 17 % in CD19-
cre animals). Considering that the CD8pos T cells are the largest group as such, the CD8pos effector 
cells therefore represent the largest T-cell subgroup in the spleen of 
Notch2IC//LMP1/CD40//CD19-cre mice by far. 
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Fig. 3.10 Splenic T cells of Notch2IC//LMP1/CD40//CD19-cre mice show an increase in the percentage of 
both central memory as well as effector T cells. 
Splenic cells were analyzed by flow cytometry for expression of CD62L and CD44 on either CD4pos (A) or 
CD8pos (B) lymphocyte-gated cells. Averages and standard deviations are calculated from six independent 
experiments. Naïve T cell compartment (CD62Lhi CD44low), central memory T cells (CD62Lhi CD44hi), 
effector T cells (CD62Llow, CD44hi), hi, high. 
 
A unique feature in which splenic T cells of LMP1/CD40//CD19-cre and the 
Notch2IC//LMP1/CD40//CD19-cre strongly resemble each other is the presence of a high 
percentage of CD8pos T cells that are low for the expression of both CD62L and CD44. This also 
holds true to a lesser degree in the CD4pos T-cell compartment. This might point towards 
exhaustion of the splenic T-cell compartment. Exhaustion is a commonly observed phenomenon 
that has been observed during persistent lymphocytic choriomeningitis virus (LCMV) infection of 
mice (Zajac et al., 1998) and in other sustained viral infections such as human immunodeficiency 
virus (HIV) infection and hepatitis B and C virus infection (Yamamoto et al., 2011; Rehermann et 
al., 2005). 
For actual numbers of splenic T-cell populations please refer to Tab. 9.1 (Supplements). 
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3.5.3 In Notch2IC//LMP1/CD40//CD19-cre mice splenic T cells display a Th1 activation pattern 
with and without PMA/Ionomycin stimulation  
There is not only a surge in myeloid and T cells in the spleens of Notch2IC//LMP1/CD40//CD19-
cre mice but splenic T cells of these mice are found to be activated after ex vivo isolation -as 
shown in the previous section. These findings already point towards the establishment of an 
inflammatory milieu in the spleens of Notch2IC//LMP1/CD40//CD19-cre mice. Since cyto- and 
chemokines are important mediators in inflammatory responses this led to the question whether 
the T cells were also showing an activation pattern with regard to the Th1 and Th2 cytokine 
production. 
CD4pos T cells are regarded as being the most prolific cytokine producers. This subset can be 
further subdivided into Th1 and Th2, and the cytokines they produce are known as Th1-type 
cytokines and Th2-type cytokines. Th1-type cytokines tend to produce the pro-inflammatory 
responses responsible for killing intracellular parasites and for perpetuating autoimmune 
responses. IFNγ is the main Th1 cytokine, while the Th2-type cytokines include interleukins 4, 5, 
and 13. Th17 cells produce IL17 and also IL22. This relatively newly discovered T-cell subset is 
implicated in autoimmunity. 
In order to examine cells of all genotypes with regard to their stimulation pattern splenic cell 
preparations were tested by polyclonal stimulation with phorbol myristate acetate (PMA) and 
calcium ionophore ionomycin (PMA/Ionomycin). This PMA/Ionomycin-treatment activates all 
cells in a sample unspecifically and is usually followed by Brefeldin A-treatment. This fungal 
metabolite interferes with protein transport from the Golgi apparatus to the endoplasmic 
reticulum and thereby ensures that the respective cytokine under investigation does not diffuse 
into the medium of the cell suspension. The analysis revealed that the PMA/Ionomycin 
stimulation of splenic T cells of Notch2IC//CD19-cre mice and of Notch2IC//LMP1/CD40//CD19-
cre mice induced a strong increase in the compartment of IFNγ-producing cells (not only in the 
CD4pos Th1 compartment), which could not be detected in CD19-cre and LMP1/CD40//CD19-cre 
(Fig. 3.11A, upper panel). Moreover, in splenic cell preparations of both Notch2IC//CD19-cre 
mice and of Notch2IC//LMP1/CD40//CD19-cre mice there is also an increase in the IFNγ-
production in non-CD4pos splenocytes, resulting from the stimulation. IFNγ is known to be 
produced by a multitude of different cells, e.g. NK and NKT cells. [NK cells were not responsible 
for the increase in IFNγ in the examined cases. NKT cells were not increased in these mice 
altogether (data not shown). The level of NKT IFNγ production was not determined]. 
There were no detectable differences between the four different genotypes tested with regard to 
the IL4-producing Th2 compartment (Fig. 3.11B, lower panel) or the Th17 subpopulation (data 
not shown) upon stimulation.  
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Fig. 3.11 T cells of Notch2IC//LMP1/CD40//CD19-cre and Notch2IC//CD19-cre mice display a Th1 and 
not a Th2 cytokine profile both with and without stimulation. 
(A) Upper panel: IFNγ production of PMA- and Ionomycin-stimulated splenic, lymphocyte-gated cells. 
Lower panel: IFNγ production of unstimulated splenocytes. (B) Upper panel: IL4 production of PMA- and 
Ionomycin-stimulated splenic, lymphocyte-gated T cells. Lower panel: IL4 production of unstimulated 
splenocytes. FACS analysis data was obtained by staining splenocytes with antibodies against the surface 
marker CD4 and antibodies detecting intracellular level of IL4 or IFNγ. Averages and SDs are calculated 
from three independent experiments for the stimulated cells and a representative result is shown for two 
experiments with unstimulated T cells. SD, standard deviation. 
It seemed intriguing to evaluate the status of splenic T cells immediately in ex vivo preparations 
without additional stimulation. Usually the levels of cytokine would be very low and mostly 
production will be just above or below the detection level. This was indeed the case for the 
RESULTS 36 
 
splenic T cells isolated from spleens of CD19-cre and LMP1/CD40//CD19-cre. In Notch2IC//CD19-
cre and the Notch2IC//LMP1/CD40//CD19-cre mice splenic cells showed a Th1 profile and again 
particularly an increase in non-CD4pos IFNγ secreting cells (Fig. 3.11A and B, lower panel 
respectively). Furthermore, there is an observable increase in the non-CD4pos fraction of cells that 
are IL4-producing without stimulation. 
Altogether, splenic T cells both in Notch2IC//CD19-cre and in Notch2IC//LMP1/CD40//CD19-cre 
mice show a tendency towards a Th1 profile both with and without stimulation. 
3.5.4 Splenic Treg are increased in splenic preparations of Notch2IC//LMP1/CD40//CD19-cre 
mice 
As shown in section 3.5.2 splenic T cells of Notch2IC//LMP1/CD40//CD19-cre mice exhibit high 
levels of the surface marker CD25. Cells that are specialized in steering cytokine release are Tregs, 
which are characterized by being CD25hi, CD4pos and positive for the transcription factor Foxp3. 
Tregs can regulate immune responses and they are of key importance in maintaining tolerance to 
self. In fact they can even prohibit the differentiation of naïve into effector T cells. Since the latter 
cell population is expanded in all transgene-expressing genotypes (except in CD19-cre mice) one 
could expect a decrease in the population of Tregs.  
When testing via intracellular FACS analysis for the presence of Tregs in the spleen of the four 
genotypes (CD19-cre, Notch2IC//CD19-cre mice, LMP1/CD40//CD19-cre mice, 
Notch2IC//LMP1/CD40//CD19-cre) there was no significant difference detectable in the 
percentage of Tregs in CD19-cre, Notch2IC//CD19-cre and LMP1/CD40//CD19-cre mice (Fig. 
3.12A). But in contrast to all other genotypes analyzed the spleens of 
Notch2IC//LMP1/CD40//CD19-cre mice display a much larger percentage (marked by a 2-fold 
increase) of Tregs and accordingly –since the spleens also harbor more cells- the actual splenic Treg 
numbers are increased.  
These findings could be confirmed with immunohistochemistry (IHC) on splenic cryosections. 
Stainings were performed with an antibody against nuclear Foxp3, which serves as a pan-Treg 
marker and an IgM staining in order to allow for a better localization of the Tregs within the 
follicular structure of the spleen (Fig. 3.12B). In spleens of CD19-cre mice the follicular structures 
are ordered and smaller and the Tregs are confined to the T-cell zone. In Notch2IC//CD19-cre 
spleens the Tregs seem to be somewhat dispersed in the B-cell zone as well. In LMP1/CD40//CD19-
cre mice the follicles are much larger as previously observed in the Mac1 stainings (Fig. 3.5D) and 
the Tregs are mainly located in the T-cell zone but also somewhat dispersed within the follicular 
structures. This observation was also made for the spleens of Notch2IC//LMP1/CD40//CD19-cre 
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mice. In these spleens however, the increase in Tregs becomes evident and the splenic structure 
almost seems enlarged but also dissolved and the Tregs are not so strictly confined to the T cell 
zone anymore.  
 
Fig. 3.12 Notch2IC//LMP1/CD40//CD19-cre mice display a substantial increase in Tregs. 
(A) Splenocytes were stained with antibodies against CD4, CD25 and after cell-permeabilization with α-
Foxp3. Dot plots were analyzed after pre-gating on CD4pos cells. Averages and SDs are calculated from 
three independent experiments. (B) IHC of splenic cryosections with antibodies detecting Tregs (Foxp3, 
blue) and B cells (IgM, red). Bar: 100 μm. IHC, immunohistochemistry. SD, standard deviation. 
3.6 Early concomitant expression of constitutive Notch2IC and CD40 partially 
blocks early B-cell development between pre- and immature B cells in the 
bone marrow 
All these observations described above are however indirect effects of the fact that the 
Notch2IC//LMP1/CD40//CD19-cre mice express constitutively active Notch2 and constitutively 
active CD40 in their B cells, which had to be characterized more in detail. As shown in section 3.3 
(Fig. 3.3B) splenic B-cell numbers of Notch2IC//LMP1/CD40//CD19-cre mice are overall increased 
compared to CD19-cre and Notch2IC//CD19-cre mice. However they are significantly reduced 
compared to LMP1/CD40//CD19-cre. Consequently, it was important to test whether expression 
of both transgenes has an effect on B-cell development. B-cell precursor subsets and immature B 
cells in the bone marrow from mice expressing the two transgenes were compared to those in 
CD19-cre mice alone as well as to that of Notch2IC//CD19-cre and LMP1/CD40//CD19-cre mice. 
To this end bone marrow samples were prepared from all genotypes for subsequent analysis. 
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3.6.1 Total and B-cell numbers are normal in bone marrow preparations of 
Notch2IC//LMP1/CD40//CD19-cre mice, but exhibit significantly increased T-cell 
numbers 
Overall cell numbers in the bone marrow were found to be similar and only slightly elevated in 
Notch2IC//LMP1/CD40//CD19-cre versus Notch2IC//CD19-cre and LMP1/CD40//CD19-cre mice 
in comparison to CD19-cre mice (Fig. 3.13A), but this can vary depending on the respective 
preparation.  
 
Fig. 3.13 Total and B-cell numbers are normal in bone marrow preparations of 
Notch2IC//LMP1/CD40//CD19-cre mice, but exhibit significantly increased T-cell numbers. 
(A) Total cell, (B) B and (C) T cell numbers of the bone marrow as determined by counting and FACS 
analysis with α-B220 and α-CD3 antibodies. Topro-3pos (dead) cells were excluded from analysis. Points 
represent data from individual mouse and horizontal bars mark the mean value indicated in numbers 
above each data set for the respective genotype. *p < 0.05; SD, standard deviation. 
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B-cell numbers in bone marrow of Notch2IC//LMP1/CD40//CD19-cre mice are slightly decreased 
compared to CD19-cre mice, this can also be observed in LMP1/CD40//CD19-cre mice (Fig. 
3.13B). By contrast T-cell numbers in bone marrow of Notch2IC//LMP1/CD40//CD19-cre mice are 
significantly higher than in all other genotypes (Fig. 3.13C). Considering the increase in T cells 
both in spleen and bone marrow in Notch2IC//LMP1/CD40//CD19-cre mice the T cells were 
analyzed for the presence of hCD2 on their surface indicating transgene expression which could 
lead to an increase in this lymphocyte population in the bone marrow. However, as previously 
shown for the splenic T cells (Fig. 3.3B) the T cells found in the bone marrow were negative for 
hCD2 (data not shown). It seems likely to assume that these T cells cannot localize all in the 
spleen and therefore rather home to other secondary lymphoid organs as well as the bone 
marrow.  
 
3.6.2 Early concomitant expression of constitutive Notch2IC and CD40 leads to a reduction in 
the pre- and immature B-cell populations in the bone marrow 
However, when examining the bone marrow-derived cells there were distinct changes with 
regard to the different B-cell subpopulations that became evident when staining the cells with 
antibodies against different surface markers and performing FACS analysis. The percentages of 
pro- and early pre- B cells (CD43pos B220pos) (Fig. 3.14A, upper panel) are slightly lower in 
Notch2IC//LMP1/CD40//CD19-cre than in LMP1/CD40//CD19-cre mice which are on level of 
CD19-cre mice. This was recapitulated in the IgM/B220 staining (Fig. 3.14A, lower panel), where 
B220pos IgMneg cells represent the pro/pre-B cells. While percentages for the pro/pre-B cells in 
bone marrow of Notch2IC//CD19-cre are more or less on level of the CD19-cre mice, these are 
reduced in LMP1/CD40//CD19-cre and are even lower in Notch2IC//LMP1/CD40//CD19-cre mice. 
Considering the percentages of pre/immature (CD43neg/low B220pos) or only immature B cells 
(B220pos IgMpos/hi), these are always lower in transgene-expressing B-cells and precursors. The 
levels of these cells in the bone marrow in Notch2IC//CD19-cre animals still resemble CD19-cre 
mice, percentages are further reduced in LMP1/CD40//CD19-cre and are lowest in 
Notch2IC//LMP1/CD40//CD19-cre mice (8.4 % CD43 neg/low B220pos cells versus 26.2 % in CD19-cre 
and 3.8 % B220pos IgMpos/hi cells versus 10.4 % in CD19-cre mice).  
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Fig. 3.14 Early concomitant expression of constitutive Notch2IC and LMP1/CD40 affects early B-cell 
development in the bone marrow leading to a reduction in pre- and immature B cells. 
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(A) Bone marrow preparations were analyzed by flow cytometry for the expression of B220 and CD43 
(upper panel) and B220 and IgM (lower panel), in order to determine the percentages of pro/early pre- 
(B220pos CD43pos), pre/immature (B220pos CD43neg/low), pro/pre (B220pos IgMneg) and immature (B220pos 
IgMhi) B cells with SD. Cells were pre-gated on lymphocyte gate. (B) Total cell numbers for pro/early pre- 
and pre/immature B-cell populations as calculated from CD43/B220-stainings (A; upper panel) after B220-
pre-gating. (C) Total cell numbers for pro/pre- and immature B cell populations as calculated from 
IgM/B220-stainings (A; lower panel) FACS plots: Numbers indicate mean percentages and SDs of 
lymphocyte-gated populations and were calculated from six independent experiments. Cell number 
calculations: Points represent data from individual mouse and horizontal bars mark the mean value, 
indicated in numbers above each point column. *p < 0.05; SD, standard deviation; Pro, pro B cells; Pre, pre 
B cells; R, recirculating B cells; I, immature B cells. 
These observations could be reconfirmed when calculating the actual cell numbers from B cell 
numbers (Fig. 3.14B and C). Considering the pre- to immature B-cell stage one can observe a 
partial block in the development of immature B cells in bone marrow of the 
Notch2IC//LMP1/CD40//CD19-cre mice compared to all other genotypes characterized by a 
significant drop in cell numbers for both of these two developmental stages (1.1×106 versus 
1.9×106 pro/pre B cells in CD19-cre and 0.25×106 versus 0.6×106 immature B cells in CD19-cre 
mice). 
In the case of Notch2IC//CD19-cre and Notch2IC//LMP1/CD40//CD19-cre mice the surface 
expression of hCD2 would allow to pinpoint the time point when expression of the transgenes 
can be observed in the developing B cells. Overall the percentage of hCD2pos B220pos B cells is low 
(on the average 12.2 % in Notch2IC-expressing B cells and 12.4 % in B cells expressing both 
transgenes). B cells pro/pre-B-cell and immature B-cell populations as determined by the 
IgM/B220 staining were gated on hCD2 to see where the reduction in these B-cell stages is 
stronger.  
The results (Tab. 3.1) show that while Notch2IC//CD19-cre mice display on average 38 % 
immature B cells that are hCD2pos in the bone marrow, Notch2IC//LMP1/CD40//CD19-cre mice 
only display hCD2pos 31 % immature B cells. With regard to the pro/pre B-cell population in the 
bone marrow this population is also reduced in Notch2IC//LMP1/CD40//CD19-cre mice with 20 % 
versus 26 % pro/pre B cells in Notch2IC//CD19-cre mice. These results point towards a partial 
block in both the pro/pre and the immature B-cell population in Notch2IC//LMP1/CD40//CD19-
cre compared to Notch2IC//CD19-cre mice as previously established. However, comparing the 
ratios derived from the percentages of the respective B-cell compartment (1.2 in the immature 
and 1.3 in the pre/pro B-cell compartment) it is not possible to determine in which 
developmental stage the reduction is stronger Notch2IC//LMP1/CD40//CD19-cre mice. 
All in all, this strongly suggests that there is either a negative selection of the bone marrow B cells 
expressing both transgenes in this B-cell stage compared to Notch2IC//CD19-cre mice.  
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Tab. 3.1 Early concomitant expression of constitutive Notch2IC and LMP1/CD40 affects early B-cell 
development in the bone marrow leading to an equal reduction in pre - and immature B-cell population. 
Average percentages with SDs of hCD2pos Pro/Pre and immature B cells as determined from IgM/B220-
stainings (Fig. 3.14A; lower panel) after lymphocyte gate-, B220- and hCD2-pre-gating for 
Notch2IC//CD19-cre and Notch2IC//LMP1/CD40//CD19-cre mice. Calculations based on six independent 
experiments. SD, standard deviation. 
 Immature B cells 
(hCD2pos) 
Pro/Pre B cells 
(hCD2pos) 
Notch2IC//CD19-cre 37.7 ±8.9 25.8 ±6.8 
Notch2IC//LMP1/CD40//CD19-cre 30.5 ±5.2 20.3 ±5.4 
 
 
 
3.6.3 Recirculation of mature B cells into the bone marrow is restricted in 
Notch2IC//LMP1/CD40//CD19-cre mice 
The percentages of B220hi cells in the stainings described above (Fig. 3.14A, refer to labeling of 
gates) hint at a reduction in immature and recirculating B cells in the bone marrow particulariy in 
the Notch2IC//LMP1CD19-cre compared to CD19-cre mice. A more precise evaluation for 
recirculating B cells can be achieved via staining of bone marrow cells with IgM/IgD/B220-
antibodies and pre-gating on B220pos cells (Fig. 3.15A). The previously observed reduction in 
mature recirculating B cells could indeed be further confirmed since there is a drop in the 
percentage of B220pos IgDhi IgMpos cells in all transgene-expressing mice versus the CD19-cre 
control, but especially in Notch2IC//LMP1/CD40//CD19-cre mice (3 % versus 17 % in CD19-cre 
mice). This translates to significantly reduced numbers of recirculating B cells in Notch2IC//CD19-
cre and LMP1/CD40//CD19-cre versus CD19-cre mice. This is even more pronounced in 
Notch2IC//LMP1/CD40//CD19-cre mice with 0.06×106 recirculating B cells versus 0.57×106 in 
CD19-cre and 0.22×106 recirculating B cells in LMP1/CD40//CD19-cre mice (Fig. 3.15B).  
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Fig. 3.15 Recirculation of mature B cells into the bone marrow is restricted in 
Notch2IC//LMP1/CD40//CD19-cre mice. 
(A) FACS analysis results for IgM and IgD stainings of B220pos cells to determine percentages of mature 
recirculating (IgMpos IgDlow/pos) and immature B cells (IgMpos IgDneg) in the bone marrow with SDs. (B) Total 
cell numbers for recirculating B220pos B-cell populations as calculated from IgM/IgD/B220-stainings (in A) 
in lymphocyte gate. Numbers indicate mean percentages and SDs of lymphocyte-gated, B220pos B-cell 
populations and were calculated from six independent experiments. Cell number calculations: Points 
represent data from individual mouse and horizontal bars mark the mean value, indicated in numbers 
above each point column. SD, standard deviation; R, recirculating B cells; I, immature B cells. 
3.7 AA4.1pos transitional B cells are not reduced in the spleens of 
Notch2IC//LMP1/CD40//CD19-cre mice 
With the aim to follow up on the reduced numbers of pro-, pre- and immature B cells in 
Notch2IC//LMP1/CD40//CD19-cre mice, the levels of AA4.1pos cells in the spleens of all four 
genotypes were examined. The surface marker AA4.1 characterizes transitional B cells that can 
only be found in the spleen. The flow cytometric analysis revealed that the percentages for 
transitional B cells of Notch2IC//LMP1/CD40//CD19-cre as well as in LMP1/CD40//CD19-cre mice 
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are rather reduced than increased compared to CD19-cre and Notch2IC//CD19-cre mice (Fig. 
3.16A). This is in line with the finding that Notch2IC//LMP1/CD40//CD19-cre and 
LMP1/CD40//CD19-cre mice display less immature B cells in the bone marrow. However, since 
there is an overall increase in B cells both in the spleens of LMP1/CD40//CD19-cre and 
Notch2IC//LMP1/CD40//CD19-cre mice this percentile decrease does not lead to a reduction but 
rather a slight yet non-significant increase in overall cell numbers of transitional B cells in these 
two genotypes (Fig. 3.16B) pointing to an expansion of transitional B cells in the transitional B cell 
stage in both genotypes. 
 
 
 
Fig. 3.16 AA4.1pos transitional B-cell numbers are not reduced in spleens of 
Notch2IC//LMP1/CD40//CD19-cre mice.  
Splenocytes were analyzed by flow cytometry for the expression of surface marker AA4.1, which 
characterize immature (transitional) B cells in the spleen. (A) Numbers indicate mean percentages and SD 
of lymphocyte-gated, IgMpos AA4.1pos populations. (B) Actual cell numbers were calculated from flow 
cytometric data in (A). Data was obtained from six independent experiments. Cell number calculations: 
Points represent data from individual mouse and horizontal bars mark the mean value, indicated in 
numbers above each point column. SD, standard deviation. 
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3.8 Marginal zone B cells are expanded in Notch2IC//LMP1//CD40//CD19-cre 
mice while the follicular B-cell population is decreased 
With the aim to better characterize the different B-cell populations splenocytes from all four 
genotypes (CD19-cre, Notch2IC//CD19-cre, LMP1//CD40//CD19-cre and 
Notch2IC//LMP1//CD40//CD19-cre) were prepared and stained with antibodies against different 
surface markers and subjected to flow cytometric analysis. Firstly, surface markers (namely CD21, 
CD23, IgM and IgD) were employed as to allow making a distinction between MZ B cells and Fo B 
cells.  
The surface CD21/CD23-staining allows for the unambiguous distinction between Fo B cells 
(CD21int CD23pos) and MZ B cells (CD21hi CD23low). The results of the flow cytometric analysis 
revealed that spleens of CD19-cre mice harbor few MZ B cells (6 % CD21hi CD23low) as opposed to 
Fo B cells (75 % CD21int CD23pos). Notch2IC-expressing splenic B cells show a strong shift of B cells 
adopting a MZ B-cell phenotype (≈63 %) at the expense of the Fo B-cell population (≈17 %). These 
Notch2IC-expressing B cells exhibit high levels of surface CD21 and have almost completely 
down-regulated CD23. LMP1/CD40-expressing splenic B cells display an intermediate phenotype 
(CD21hi CD23int) with B cells strongly trailing off from the Fo B-cell into the MZ B-cell 
compartment (Fig. 3.17B; upper panel) and display what can be characterized as a MZ B-cell-like 
phenotype. B cells additionally expressing constitutively active Notch2IC also display a shift of B 
cells towards adopting a MZ B-cell phenotype (≈48 %, Fig. 3.17A, upper panel), while only few 
cells exhibit a Fo B-cell type (≈20 %). Interestingly, the Notch2IC//LMP1/CD40-expressing MZ B 
cells rather resemble the CD19-cre MZ B cells since they do not down-regulate CD23 as strongly 
as the Notch2IC-expressing B cells do. 
The findings concerning the MZ B-cell status of the B cells expressing both constitutively active 
Notch2IC as well as constitutively active CD40 were confirmed with the help of an IgM/IgD-
staining. The gate comprising cells with high IgM and low IgD contains MZ B cells, but also 
transitional and B1 B cells whereas IgMpos/low IgDpos B cells are Fo B cells. The B cells of CD19-cre 
mice display a normal distribution pattern with the large majority of cells being IgMpos/low IgDpos 
and therefore Fo B cells (≈74 %). Only a small percentage of B cells of CD19-cre carries the 
surface markers characterizing MZ, B1 and transitional B cells (≈17 % IgMhi IgDlow). 
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Fig. 3.17 Marginal zone B cells are expanded in Notch2IC//LMP1/CD40//CD19-cre mice while the 
follicular B-cell population is decreased. 
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(A) Flow cytometric analysis of Fo (CD21int CD23pos) and MZ B cells (CD21hi CD23low) in the spleen. CD21neg 
CD23neg cells comprise immature and non-B cells. Numbers indicate mean percentages and SD of 
lymphocyte-gated, B220pos B cells displaying the respective phenotypes. Re-gating the cells on hCD2 
allows for identification of the phenotype of the cells expressing the transgenes (lower panel). 
Calculations are based on six independent experiments. (B) Splenocytes were analyzed by flow cytometry 
for the expression of surface IgM and IgD. Numbers indicate mean percentages and SD of lymphocyte-
gated populations of B220pos B cells displaying a Fo (IgMpos IgDpos) or MZ and transitional (IgMpos IgDlow) B 
cell phenotype (upper panel). Re-gating the cells on hCD2 allows for identification of the phenotype of the 
cells expressing the transgenes (lower panel). (C) Histograms show overlays of CD1d-expression of splenic 
B cells of in CD19-cre (grey line), Notch2IC//CD19-cre mice (orange line), LMP1/CD40//CD19-cre mice 
(purple line) and Notch2IC//LMP1/CD40//CD19-cre mice (green line). Fo B, follicular B cell; MZ B, marginal 
zone B cell; SD, standard deviation. 
In the flow cytometric analysis of the B cells expressing constitutively active Notch2IC, most B 
cells exhibit high levels of IgM, while intermediate to low IgD-levels in accordance with their MZ 
B-cell phenotype. LMP1/CD40-expressing B cells are positive for both IgM and IgD, but the cells 
strongly trailing off becoming intermediate in their IgD expression, therefore they display an 
intermediate phenotype similar as observed in the CD21/CD23 staining. However, when B cells 
express both the Notch2- as well as the CD40-transgene they can be clearly classified as MZ B 
cells with regard to their high IgM- and low IgD-level (Fig. 3.17B; upper panel), even though the 
effect is not as pronounced as in Notch2IC-expressing B cells alone (≈48 % MZ B cells versus 
≈63 % in Notch2IC//CD19-cre mice). 
Overall, constitutive Notch2IC-expression in B cells seems to be the decisive factor whether these 
cells present with a clear MZ B-cell phenotype. 
Re-gating the previous FACS staining results for IgM/IgD and CD21/CD23 on hCD2pos reveals that 
expression of Notch2IC is indeed correlated with the MZ B-cell phenotype, since the hCD2pos cells 
of Notch2IC//CD19-cre and Notch2IC//LMP1/CD40//CD19-cre mice can be found within the MZ B 
cell gates (IgMpos IgDlow and CD21hi CD23low, respectively).  
Furthermore, splenic B cells of the respective genotype were analyzed for the presence of the MZ 
B-cell surface marker CD1d. Both Notch2IC-expressing B cells and B cells of 
Notch2IC//LMP1/CD40//CD19-cre mice are also high in their CD1d expression confirming their 
MZ B-cell phenotype (Fig. 3.17C) 
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3.9 Splenic B cells of Notch2IC//LMP1/CD40//CD19-cre mice display an 
activated phenotype 
MZ B cells have a pre-activated phenotype and are larger than their follicular counterparts. 
Activated lymphocytes generally have a tendency to increase in volume, this was previously 
observed in LMP1/CD40-expressing splenic B cells which show an increase in cell size and an 
upregulation of activation markers. This could also be recapitulated in the MZ Notch2IC-
expressing B cells. These also express various MZ B-cell-characteristic surface markers such as 
CD1d, CD36, and CD9 and are increased in size compared to CD19-cre controls (Hampel et al., 
2011). This is the reason that could account for the slight, but significant splenomegaly in those 
Notch2IC//CD19-cre animals versus the CD19-cre mice. Therefore, splenocytes of all genotypes 
were analyzed with regard to both cell size (through comparison of the FACS FSC, which is 
indicative of cell size) and with regard to expression of activation surface markers (such as CD80, 
CD86, CD95, MHCII and ICAM1 (CD54)).  
Fig. 3.18A confirms the increase in cell size in both single transgene expressing splenic 
lymphocytes, which is even furthered in the Notch2IC//LMP1/CD40//CD19-cre animals. Up-
regulation of activation marker CD95 is –as shown in section 3.2- a CD40-mediated event and is 
found to be even slightly increased in the splenic B cells of Notch2IC//LMP1/CD40//CD19-cre 
mice (Fig. 3.18B). This also seems to be the case for the expression of the B7 protein CD80, which 
mediates B-T-cell interactions like the B7 protein CD86. CD80 is found to be up-regulated only in 
B cells of LMP1/CD40//CD19-cre and even slightly stronger in Notch2IC//LMP1/CD40//CD19-cre 
mice, while levels of CD86 seem widely unchanged in all genotypes with respect to the CD19-cre 
control.  
Concomitant expression of Notch2IC and LMP1/CD40 seems to have an additive effect on the 
level of ICAM1-expression. The expression levels of this cell surface marker are higher both in 
Notch2IC-expressing, as well as in LMP1/CD40-expressing B cells compared to CD19-cre mice. 
ICAM1 levels are even further increased in B cells expressing both transgenes. 
MHCII expression however only showed a slight shift towards higher expression in splenic B cells 
of Notch2IC//CD19-cre, LMP1/CD40//CD19-cre and Notch2IC//LMP1/CD40//CD19-cre mice 
compared to CD19-cre mice (data not shown).  
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Fig. 3.18 Notch2IC//LMP1/CD40-expressing splenic B cells show an increase in cell size and enhanced 
expression of cell surface activation markers. 
(A) Splenocytes were analyzed for cell size and surface expression of (B) CD80, CD86, CD95 and ICAM1 by 
flow cytometric analysis. Histograms show overlays of cell size (FSC) or overlays of surface expression of 
the indicated molecules on lymphocyte-gated, B220pos B cells from CD19-cre (grey line), Notch2IC//CD19-
cre mice (orange line), LMP1/CD40//CD19-cre mice (purple line) and Notch2IC//LMP1/CD40//CD19-cre 
mice (green line). Data are representative for six independent experiments. FSC, forward scatter. 
3.10 B-cell numbers are reduced and B-cell subsets are altered in inguinal lymph 
nodes of Notch2IC//LMP1/CD40//CD19-cre mice 
3.10.1 T-cell numbers are normal but B-cell numbers are significantly reduced in inguinal 
lymph nodes of Notch2IC//LMP1/CD40//CD19-cre mice compared to CD19-cre and 
LMP1/CD40-cre mice 
With the aim to further examining B cells in the periphery inguinal lymph nodes were prepared 
from mice of all genotypes (CD19-cre, Notch2IC//CD19-cre, LMP1/CD40//CD19-cre and 
Notch2IC//LMP1/CD40//CD19-cre). Evaluation of the actual B- and T-cell numbers (based on data 
obtained from flow cytometric analysis) showed that T-cell numbers were overall similar 
between the different genotypes (Fig. 3.19; right panel). However, B-cell numbers are only 
increased in lymph nodes of LMP1/CD40//CD19-cre mice, but they are significantly reduced both 
in Notch2IC//CD19-cre and Notch2IC//LMP1/CD40//CD19-cre compared to CD19-cre mice (Fig. 
3.19; left panel).  
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Fig. 3.19 T-cell numbers are normal but B-cell numbers are reduced in inguinal lymph nodes of 
Notch2IC//LMP1/CD40//CD19-cre mice 
Total B-cell (lymphocyte-gated, B220pos) and T-cell (lymphocyte-gated, CD3pos) numbers of iLN. Topro-3pos 
(dead) cells were excluded from the analysis. Calculations are based on six independent experiments. 
Points represent data from individual mouse and horizontal bars mark the mean value, indicated in 
numbers above each point column. iLN, inguinal lymph nodes; SD, standard deviation. 
 
3.10.2 B cells in inguinal lymph nodes of Notch2IC//LMP1/CD40//CD19-cre mice display a shift 
towards a MZ B-cell phenotype 
MZ B cells represent a B-cell population that is rather sessile in the spleen, while Fo B cells can 
freely circulate in blood and lymph until they encounter antigen. Hence, the presence of MZ B 
cells in lymph nodes is not expected. Nonetheless, previous analysis of the Notch2IC//CD19-cre 
(Hampel et al., 2011) also showed that B-cell subsets are altered in the inguinal lymph nodes of 
Notch2IC//CD19-cre mice in the sense that they display a tendency towards adopting a MZ B-cell 
phenotype. This prompted further analysis of this secondary lymphoid organ in 
Notch2IC//LMP1/CD40//CD19-cre mice and controls with respect to their phenotype.  
With regard to the results of CD21/CD23 staining the majority of all inguinal lymph node B cells of 
all genotypes displays a Fo B-cell phenotype (CD21int CD23pos; Fig. 3.21A). These findings could 
be confirmed with the results of the IgM/IgD staining where B cells were IgMpos/low and IgDpos 
(Fig. 3.21C). 
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Fig. 3.20 B-cell subsets are altered in the inguinal lymph nodes of Notch2IC//LMP1/CD40//CD19-cre 
mice. 
(A) Lymphocytes of iLN were analyzed by flow cytometry for the expression of IgM and IgD. Numbers 
indicate mean percentages and SD of lymphocyte-gated populations of B220pos B cells displaying a Fo 
(IgMpos IgDpos) or MZ and transitional (IgMpos IgDlow) B-cell phenotype. (B) Average hCD2 percentages with 
SD in B220pos B cells of iLN as determined by FACS analysis for the respective genotypes. Lower panel: Re-
gating the cells in the IgM/IgD staining results on hCD2 allows for identification of the phenotype of the 
cells expressing the transgenes. (C) Flow cytometric analysis of Fo (CD21int CD23pos) and MZ B cells (CD21hi 
CD23low) in the iLN. CD21neg CD23neg cells comprise immature and non-B cells. Numbers indicate mean 
percentages and SD of lymphocyte-gated, B220pos B cells displaying the respective phenotypes (upper 
panel). Calculations are based on six independent experiments. iLN, inguinal lymph nodes; SD, standard 
deviation. 
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Nonetheless, the percentages of B cells that display a MZ B-cell phenotype (CD21hi CD23low) are 
strongly increased in Notch2IC//CD19-cre, LMP1/CD40//CD19-cre and 
Notch2IC//LMP1/CD40//CD19-cre mice in the CD21/CD23 staining in comparison to the CD19-cre 
control mice. This could again be reconfirmed with the results of the IgM/IgD staining where 
percentages of MZ B-cells (IgMpos IgDlow) in inguinal lymph nodes were strongly increased 
compared to CD19-cre mice. However it has to be kept in mind that the fraction of cells that are 
IgMpos IgDlow comprises besides MZ B cells also B1 B and is a less specific indicator for a MZ B-cell 
phenotype. 
In the inguinal lymph nodes of Notch2IC//CD19-cre and Notch2IC//LMP1/CD40//CD19-cre mice B 
cells fewer B cells had deleted the stop cassette upstream of the Notch2IC-transgene than in the 
spleen (≈18 % hCD2pos B cells in inguinal lymph nodes in Notch2IC//CD19-cre and ≈7 % in 
Notch2IC//LMP1/CD40//CD19-cre mice; Fig. 3.20B, upper panel). Pre-gating the inguinal lymph 
node B cells on hCD2 in the CD21/CD23 staining analysis however shows that roughly half of the 
B cells that have successfully deleted the stop cassette and express the transgene adopt a MZ B-
cell phenotype (47 % in Notch2IC//CD19-cre and 35 % in Notch2IC//LMP1/CD40//CD19-cre mice 
Fig. 3.21B; lower panel). This is recapitulated in the expression of surface IgM and IgD expression 
in the hCD2pos lymph node B cells of Notch2IC//CD19-cre and Notch2IC//LMP1/CD40//CD19-cre 
mice with increased percentages of lymph node B cells that are IgMpos/low IgDpos (data not shown).  
All in all, considering the low numbers of B cells and particularly hCD2pos B cells in inguinal lymph 
nodes of Notch2IC//CD19-cre and Notch2IC//LMP1/CD40//CD19-cre mice one could assume that 
the mature hCD2-expressing B cells are rather retained in the spleen, which would be in line with 
their physiological sessile character. Nonetheless, the cells in the inguinal lymph nodes that are 
positive for hCD2 rather display a MZ B-cell phenotype. 
3.11 Splenic architecture is grossly disrupted in Notch2IC//LMP1/CD40//CD19-cre 
mice 
In order to better characterize the splenomegaly as well as to define the follicular space and to 
localize the different B- and T-lymphocyte populations in general immunohistochemistry (IHC) on 
splenic cryosections was performed (Fig. 3.21). Spleens were stained for IgMpos B cells, for CD3pos 
T cells and MOMA1, which stains monocytes and metallophilic macrophages. Metallophilic 
macrophages line the inner border of the MZ and employing the antibody in the staining allows 
for a visual separation of the MZ B cells from the Fo B cells.  
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Fig. 3.21 Splenic architecture is grossly disrupted in Notch2IC//LMP1/CD40//CD19-cre mice.  
IHC staining of splenic cryosections from Notch2IC//CD19-cre and control mice for monocytes and 
metallophilic macrophages (α-MOMA-1; dark blue), lining the marginal zone at the sinus, B cells (α-IgM; 
red) and T cells (α-CD3; light blue). Bar: 100μm. IHC, immunohistochemistry; MZ, marginal zone. 
The triple staining showed that the follicles in CD19-cre mice are small with a small ring of MZ B 
cells surrounding them. The follicle holds the majority of Fo B cells and a well-defined, localized 
T-cell zone. In Notch2IC//CD19-cre mice as previously documented (Hampel et al., 2011) follicles 
are still small, which is in accordance with the fact that overall cell numbers are not increased 
compared to spleens of CD19-cre mice (Fig. 3.1A).  
However, the area of MZ B cells is markedly enlarged, and the Fo B cells are rather reduced, but 
the T-cell zone is equal in size compared to that in CD19-cre mice. Nonetheless, overall follicular 
structure is retained in Notch2IC//CD19-cre, which is also the case for the spleen of 
LMP1/CD40//CD19-cre mice. However, the spleens of the latter genotype display an enlargement 
of follicles as such and of the MZ- and T-cell zone which is in accordance both with the increase in 
overall spleen size, total cell and lymphocyte numbers. Nonetheless, one can determine that the 
ring of MOMA1pos cells is less distinct but rather appears as a rather diffuse pattern that extends 
well into area of the Fo B cells. The assessment of the IHC of splenic cryosections of 
Notch2IC//LMP1/CD40//CD19-cre mice delivered completely different results: the follicles are 
enlarged as was expected according to spleen size, total cell and lymphocyte numbers, but 
microachitectural order is severely affected. The otherwise defined ring of MOMA1pos cells is 
disintegrated and merges with the B and T cells in the follicle. Notch2IC//LMP1/CD40//CD19-cre 
mice exhibit a strongly enlarged MZ, nonetheless the majority of B cells seems to reside in the Fo 
area. The T cells are almost dispersed throughout the entire follicle, which allows for constant B- 
and T-cell interaction. 
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3.11.1 Splenic B cells of Notch2IC//LMP1/CD40//CD19-cre mice are intermediate in their 
CXCR4 expression 
Chemokine receptors, including CCR7, CXCR4, and CXCR5, are known to be of key importance in 
the regulation of B-cell trafficking and retention (Cyster, 1999; Okada et al., 2002; Ebisuno et al., 
2003). Expression of CXCR5 can be detected on mature B cells and is essentially responsible for 
guiding B cells into the B-cell zones of secondary lymphoid organs. In CXCR4-deficient mice 
mature B-cell populations were reduced in the marginal zone and primary follicles and they show 
defective follicle formation (Nie et al., 2004).  
In order to clarify what might be the factors contributing to the observed mispositioning of B cells 
in the Notch2IC//LMP1/CD40//CD19-cre mice CXCR4 and CXCR5 stainings were performed with 
splenocytes preparations from all four genotypes and subjected to FACS analysis. Additional 
staining for the presence of CD21/CD23-surface markers permits to analyze the respective MZ 
and Fo B-cell populations in greater detail. 
The results (Fig. 3.22A) were most distinct with regard to the MZ B cell compartment (CD21hi 
CD23low). They show that CXCR4–expression is up-regulated in Notch2IC-expressing MZ B cells in 
comparison to all other genotypes. MZ B cells (CD21hi CD23low) B cells from LMP1/CD40//CD19-
cre mice on the other hand displayed the lowest CXCR4 surface marker expression. This might 
explain that the majority of their B cell residing rather in the follicle, although the population 
strongly trails off into the MZ B cell compartment. Interestingly, MZ B cells from CD19-cre mice 
had an intermediate CXCR4 surface marker expression just like the B cells in 
Notch2IC//LMP1/CD40//CD19-cre mice display a rather intermediate CXCR4-level phenotype. 
With regard to the Fo B cell compartment (CD21int CD23pos), LMP1/CD40 also exhibited slightly 
lower levels, Notch2IC-expressing B cells still exhibited higher number for CXCR4hi B cells. This 
pattern could also be observed to a lesser degree when gating the cells on the B-cell marker 
CD19 alone without prior pre-gating on MZ and Fo B cells (data not shown) and the levels 
remained similar with minor shifts in CXCR4 expression strength when Fo B cells were compared 
to MZ B cells of the same genotype, i.e. CD19-cre (Fig. 3.22B).  
CXCR5 levels were equally examined in the four genotypes. However, distinct differences were 
undetectable among the B cells of the different genotypes (data not shown).  
All in all, one could assume that constitutive CD40- and constitutive Notch2-activity oppose each 
other with regard to positioning of the respective Notch2- or CD40-expressing cell and up- or 
down-regulation of CXCR4. These might be the forces at work in B cells of 
Notch2IC//LMP1/CD40//CD19-cre expressing both transgenes. However, CXCR4 levels as such do 
not provide hints as to where a given B cell will be positioned, since B cells of CD19-cre mice also 
display rather intermediate level of this chemokine receptor. 
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Fig. 3.22 B cells of Notch2IC//LMP1/CD40//CD19-cre mice display intermediate level in their CXCR4 
expression.  
(A) Flow cytometric analysis results of the CXCR4-levels of pre-gated B cells (CD19pos cells) for the different 
genotypes. Histogram represents an overlay of all genotypes analyzed. CD19-cre (grey line), 
Notch2IC//CD19-cre mice (orange line), LMP1/CD40//CD19-cre mice (purple line) and 
Notch2IC//LMP1/CD40//CD19-cre mice (green line). Data are representative for three independent 
experiments. (B) Flow cytometric analysis results of the CXCR4-levels of MZ B (light grey) versus Fo B cells 
(dark grey) of the same genotype (CD19-cre). 
 
3.12 Notch2IC//LMP1/CD40//CD19-cre mice show distinct changes in the 
expression of cyto- and chemokines  
Cyto- and chemokines might be the major factors leading or contributing to the surge in 
accessory cells and disrupted follicular structures in Notch2IC//LMP1/CD40//CD19-cre mice. 
These messenger substances can act both over long distances as well as only in situ. Aiming to 
identify them both on a systemic and local scale, arrays were used to detect changes in serum 
levels and mRNA-levels specifically in B cells of a broad range of cyto- and chemokines in mice of 
all four genotypes.  
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3.12.1 CXCR3 and IL13ra1, IL2Rγ, LTβ and TGFβ mRNA levels in splenic B cells of 
Notch2IC//LMP1/CD40//CD19-cre mice are differentially up-regulated by Notch2IC and 
LMP1/CD40 
In order to examine the level of cyto- and chemokines that were exclusively produced by the B 
cells, splenic B cells from all four genotypes were purified using the MACS-separation system to 
deplete CD43pos (i.e. non-B) cells from the samples. From these splenic B cells mRNA was 
extracted from which cDNA (complementary DNA) was synthesized. The cDNA was subsequently 
employed as template in a RT-PCR (real-time polymerase chain reaction) run. The RT-PCR was 
carried out in a 96-well format obtained from SA Biosciences with pre-spotted primers in each 
well for each cyto- and chemokine to be analyzed. Results were normalized to values obtained 
for the control CD19-cre mice (Fig. 3.23). 
The mRNA analysis of splenic B cells revealed that only few cyto- and chemokines were up-
regulated. Usually the respective cyto- or chemokine was up-regulated in either one of the two 
transgene-expressing B cells and rather exhibited intermediated mRNA levels in splenic B cells 
expressing both transgenes simultaneously.  
Those cyto- and chemokines that were up-regulated particularly in Notch2IC-expressing B cells 
were CXCR3 and IL13Rα1.  
CXCR3 is highly expressed on activated T cells, but usually not found on resting T lymphocytes, 
monocytes and granulocytes (Loetscher et al., 1996), but is increased on MZ versus Fo B cells (S. 
Ehrenberg, personal communication).  
IL13ra1 is a subunit of both IL13R and IL4R and together with the common γ chain and other 
subunits it forms the respective receptor for the Th2 cytokines. Both cytokines are known for 
their anti-inflammatory character (Watson et al., 1999; Zaccone et al., 1999; Kaminski et al., 
2007), however in a B-cell context IL4 together with CD40 can induce a burst in proliferation, 
division and class switching (Rush et al., 2001).  
The cyto- and chemokines that were up-regulated particularly in LMP1/CD40-expressing splenic B 
cells and to a lesser degree in Notch2IC//LMP1/CD40-expressing splenic B cells were the cytokine 
receptor IL2Rγ, lymphotoxinβ (LTβ) and TGFβ. 
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Fig. 3.23 CXCR3 and IL13ra1, IL2Rγ, LTβ and TGFβ mRNA levels in B cells of 
Notch2IC//LMP1/CD40//CD19-cre mice are differentially up-regulated by Notch2IC and LMP1/CD40.  
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Splenocytes from all four genotypes were purified by MACS-separation to deplete CD43pos (i.e. non-B) cells 
from samples. mRNA from B cells was used as template for cDNA synthesis, which was used in a RT-PCR 
run. The RT-PCR was carried out in a 96-well format obtained from SA Biosciences with pre-spotted 
primers for each cyto- and chemokine to be analyzed and controls per well. Results were normalized to 
values obtained for the control CD19-cre mice. LTβ, lymphotoxinβ; MACS, magnetic cell separation, TGFβ, 
transforming growth factor β. 
IL2Rγ also more commonly known as the common γ chain that is a subunit of some different ILRs, 
not only of IL2R, but also of the IL4-, IL7-, IL9-, IL15- and IL21-receptors (Takeshita et al., 1992; 
Russell et al., 1993; Asao et al., 1993; Sugamura et al., 1995; Asao et al., 2001) which play a 
pivotal role in development and function of B-, T- and NK-cells.  
TGFβ is known to be influence numberous cellular processes rangeing from cell cycle regulation, 
differentiation, programmed cell death, adhesion and motility (Padua et al., 2009; Akhurst et al., 
2012).  
LTβ has been found to be of key importance during the initial organization of the lymphoid tissue 
during development (Murphy et al., 1998). The stromal cells in the spleen express the receptor 
while the ligand is majorly found on B cells (McDonald et al., 2005), which is important for 
positioning processes within the lymphoid follicles and proper development of the T-cell zone 
(Ngo et al., 2001). Combination of Notch2 and LMP1/CD40 signaling up-regulated genes might 
lead to the disruption of the splenic architecture. 
 
3.12.2 Notch2IC//LMP1/CD40//CD19-cre mice show an upregulation of CXCL9 and CXCL10 in 
serum 
In order to examine levels of different cytokines on a systemic level, serum samples from mice of 
all four genotypes were collected and applied to nitrocellulose membranes onto which capture 
antibodies have been spotted in duplicate. Adding streptavidin-horseradish peroxidase and a 
common chemiluminescent detection reagents, a signal is produced in proportion to the amount 
of the respective cytokine bound. Detection is performed as for common Western blots and level 
of cytokine was quantified from comparative analysis of three cytokine arrays per genotype with 
the TINA software (Raytest) by Lothar Strobl of our group (Fig. 3.24). 
For most cytokines the results were out of range (i.e. either too strong or weak) in the 
comparative analysis. However, three cytokines were found to be reliably up-regulated in the 
sera of Notch2IC//LMP1/CD40//CD19-cre mice, namely IL16, chemokine (C-X-C) ligand (CXCL)10 
and CXCL9, while IFNγ was slightly and CXCL12 (ligand for CXCR4) was distinctly reduced in these 
mice. 
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As suggested by their alternative names monokine-induced by IFN-γ, MIG (CXCL9) and IFNγ 
inducible protein-10, IP10 (CXCL10) these CXCLs are induced by IFNγ and are therefore also 
termed Th1-type cytokines. 
 
Fig. 3.24 Notch2IC//LMP1/CD40//CD19-cre mice show an up-regulation of CXCL9 and CXCL10 and a 
down-regulation of CXCL12 in serum.  
Serum samples were prepared from heart blood and applied to R&D Proteome Profiler Mouse Cytokine 
Array Kit membranes. Using SA-HRS peroxidase and detection agents the amount of chemiluminescence is 
proportional to the amount of cytokine detected. Amount of chemiluminescent signal was quantified 
using TINA software. The displayed result is derived from comparative analysis of three independent 
experiments. Values for CD19-cre were set to 1 for normalization. SA-HRS peroxidase, streptavidin-
horseradish peroxidase.  
 
3.13 Notch2IC//LMP1/CD40-expressing splenic B cells show an increased 
proliferation in in vitro culture regardless of the supply of stimuli 
Having observed that the splenic B cells are highly activated, it would be interesting to observe 
their growth behavior under controlled conditions. Primary wild type B cells die within 1 week of 
in vitro cultures without activating stimuli. The inherently activated phenotype of LMP1/CD40-
expressing splenic B cells induces an increase in proliferation as well as enhanced survival in in 
vitro cultures in comparison to B cells from CD19-cre mice (Homig-Holzel et al., 2008). Also, the 
pre-activated phenotype of Notch2IC-expressing splenic B cells leads to an increased proliferation 
rate in comparison to controls (Hampel et al., 2011). Moreover, both CD40 and Notch are found 
up-regulated in various cancers. Taken together, this led to the assumption that cells expressing 
both Notch2IC as well as LMP1/CD40 in constitutively active forms would also show enhanced 
proliferation rates. This hypothesis was tested with the help of Carboxyfluorescein succinimidyl 
ester (CFSE)-analysis. CFSE is a fluorescent dye that labels intracellular molecules through its 
succinimidyl group. It is passed on to daughter cells during cell division and thereby provides a 
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method to measure proliferation of a cell population by the decrease in CFSE-fluorescence of the 
labeled cells.  
Splenocytes from all four genotypes were prepared and depleted of all other cell types by MACS-
separation to obtain 95-98 % pure primary B-cell samples. These were thereafter labeled with 
CFSE and cultivated in 10 % medium with and without stimuli. These stimuli comprised agonistic 
antibody against CD40 and the cytokine IL4, which are of importance in T-cell-mediated B-cell 
activation. Stimuli were applied both together and separately. Thereby stimulated or 
unstimulated splenic B cells were cultivated and analyzed on day 1, 3 and 5 for CFSE-staining 
intensity after excluding Topro-3pos (dead) cells. Data from day 1 served to set the resting peak of 
CFSE-labeling intensity. 
Evaluating the obtained data with FlowJo software delivers beside the estimates of the percent 
of culture that divided (percent divided) the division index and the proliferation index. The 
division index is an overall average of the number of cell divisions that cells in the original 
population have undergone. It includes the cells that never divided and therefore includes those 
of the resting or “undivided peak”. The proliferation index, however, gives the total number of 
divisions of a cell that went into division at least once. In contrast to the division index it only 
takes into account cells that respond in the culture system and therefore considers only the 
fraction of cells in the “divided peak”. One can say that the division index reflects the biology of 
responding part of the system, while the proliferation index considers also the dynamics of the 
entire system (www.flowjo.de).  
As one can see in Fig. 3.25 there is a clear reduction in the resting peak population on day 3 that 
transformed into a considerable shift of the “divided peak” in the cultured B cells of 
Notch2//LMP1/CD40//CD19-cre mice (Fig. 3.25A, upper panel). The same pattern can also be 
observed for the cultures that received an IL4-stimulus. With roughly 20 % divided B cells 
expressing both transgenes exhibit the highest proliferation rate of all genotypes tested.  
When examining the genotypically different B cells in their entirety (division index) on day 3 the B 
cells expressing both transgenes display by far the highest division indices both with and without 
IL4-stimulus (around 0.4 versus 0.1 in CD19-cre and 0.1/0.2 in Notch2//CD19-cre and 
LMP1/CD40//CD19-cre mice). With regard to the proliferation index one is able to observe that 
out of the cells that did proliferate, the B cells carrying constitutively active Notch2IC do so most 
strongly of all genotypes although overall the proliferation index levels of Notch2IC-, LMP1/CD40- 
and Notch2IC//LMP1/CD40-expressing splenic B cells are similar upon IL4 stimulation and tend to 
be lower in the CD19-cre splenic B cells. The aforementioned is also recapitulated in the data 
obtained for day 5 (Fig. S.1; Supplements). 
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Fig. 3.25 Notch2IC//LMP1/CD40-expressing splenic B cells show an increased proliferation in in vitro 
culture. 
Splenocytes were prepared and splenic cell preparations were depleted of CD43pos (i.e. non-B) cells and 
labeled with CFSE. The B cells were subsequently cultivated either with or without stimuli. These stimuli 
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included α-CD40 antibody, IL4 as well as both IL4 and α-CD40 antibody. Cells were analyzed by flow 
cytometric analysis on day 1, 3 and 5 of culture. Dead cells were excluded from the analysis by excluding 
Topro-3pos cells. (A) Results for respective genotypes on the indicated days without stimulus, with IL4-
stimulus, with CD40-stimulus and with both CD40- and IL4-stimulus. The displayed result is representative 
for four independent experiments. (B) Statistical evaluation of day 3 of percent divided, proliferation and 
division index for all genotypes without stimulus, with IL4-stimulus, with CD40-stimulus and both with IL4- 
and CD40-stimulus. CFSE, Carboxyfluorescein succinimidyl ester. *p < 0.05, ** p < 0.01, *** p < 0.005.  
The pattern becomes more divers when adding CD40 or both IL4 and CD40 to the respective 
cultures. Notch2IC//LMP1/CD40-expressing B cells maintain the previously described high 
proliferative states for both stimulation scenarios (CD40 or both IL4 and CD40), but the value for 
percent divided never further increases over 20 %. Furthermore, the division index also remains 
unchanged. Concerning B cells that already express constitutively active CD40 addition of CD40 
antibody alone also has little effect on B-cell proliferation. CD40-stimulation has the strongest 
effects on cultures of B cells isolated from CD19-cre and Notch2IC//CD19-cre mice. There is a 
strong increase in the percentage of dividing cells. In the case of B cells expressing constitutively 
active Notch it even excels those of LMP1/CD40 and Notch2IC//LMP1/CD40-expressing B cells, 
which is mirrored by the fact that the division index (around 0.7) rises above the levels found in 
LMP1/CD40 and Notch2IC//LMP1/CD40-expressing B cells (still 0.2 and 0.4. respectively).  
As expected this effect is even stronger in B cells that received both IL4 and CD40 in their 
medium. This leads to a further increase in the percentage of divided cells in the control B-cell 
population and their division index rises to that of Notch2IC//LMP1/CD40-expressing B cells. 
However, the Notch2IC-expressing B cells remain those with the highest level percentage of 
divided cells and division indices of all genotypes in the analysis. 
The pattern described above for the proliferative behavior of B cells of the different genotypes 
on day 3 is recapitulated on day 5. The major difference however is, that by this time 
simultaneous addition of α-CD40 and IL4 to B-cell cultures leads to a similar division indices in  
CD19-cre, Notch2IC//CD19-cre and Notch2IC//LMP1/CD40//CD19-cre mice (Fig. S.1; 
Supplements). 
3.13.1 Unstimulated Notch2IC//LMP1/CD40-expressing splenic B cells survive better in culture 
than Notch2IC-, but not than LMP1/CD40-expressing splenic B cells  
The CFSE-labeled and cultured splenic B cells were stained with the fluorescent dye Topro-3, 
which is only able to penetrate damaged but not intact cellular membranes. It was used in order 
to ensure the exclusion of dead cells from the analysis. These Topro-3pos cells can also be used as 
a measure of the amount of dead versus living cells with the respective culture. 
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The results of the Topro-3neg cells with the respective stimuli at the different time points are 
summarized in Fig. 3.26. 
Fig. 3.26A gives an overview of the B-cell cultures that did not receive any stimulus. Already at 
day 1 there is a distinct drop in the Notch2IC-expressing cells. By day 3 both B-cell cultures from 
spleens of CD19-cre and Notch2IC//CD19-cre mice are low in their content of living cells (around 
15 %), while LMP1/CD40- and Notch2IC//LMP1/CD40-expressing B cells still harbor 40 % living 
cells in their cultures. Therefore, the better survival of these cells is an effect mediated by 
constitutively active CD40, since at day 5, LMP1/CD40-expressing B cells still display 50 % of living 
cells. However, there is a drop to 25 % living cells in cultures of splenic B cells of 
Notch2IC//LMP1/CD40//CD19-cre mice. This seems to be a Notch2IC-mediated effect since the 
Notch2IC-expressing B cells, like the control B cells display on the average a mere 4-6 % of living 
cells. 
Fig. 3.26B gives an overview of the B-cell cultures that did receive an IL4-stimulus with regard to 
the percentage of living cells in culture. The addition of IL4 enhances the especially survival of B 
cells of CD19-cre mice. But the overall pattern remains the same as in the cultures that did not 
receive a stimulus (Fig. 3.26A). 
Fig. 3.26C gives an overview of the cell cultures that did receive a CD40-stimulus with regard to 
the percentage of living cells in culture. As expected the effects of an increased survival are 
majorly observed for the cells that do not have an intrinsic activated CD40, i.e. B cells of CD19-cre 
and Notch2IC//CD19-cre mice. 
Fig. 3.26D gives an overview of the B-cell cultures that did receive both an IL4- and CD40-stimulus 
with regard to the percentage of living cells in culture. This combination provides a rather strong 
stimulus prompting the cells to strongly proliferate, hence there is no loss in viability from day 0 
to day 1. At day 3, B cells expressing constitutively active CD40 still display 40 % of viable cells, 
while all other genotypes including CD19-cre controls display around 28 % viable B cells. At day 5 
all genotypes with the exception of LMP1/CD40-expressing B cells (25 % viable cells) drop below 
values of less than 20 % viable cells. Although those values are still higher than when splenic B 
cells were left unstimulated at day 5 these values are still lower than when cells were stimulated 
with α-CD40 only. This is likely due to the fact that splenic B cells receiving a simultaneous CD40- 
and IL4-stimulation proliferate the strongest and at some point outcompete each other for 
nutrients. In favor for this hypothesis is the fact that already from day 3 onward the medium 
starts to turn slightly yellow for all genotypes. Therefore, drop in cell viability also on day 3 can be 
explained by a number of possible reasons: an overall increase in cell number and at the same 
time, increasing lack of nutrients and an accumulation of metabolites leading to an increase in 
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dead cells. Also, cells might die due to a limited number of cell divisions for each cell or cells stop 
growing and die because of contact inhibition. 
 
 
Fig. 3.26 Unstimulated Notch2IC//LMP1/CD40‐expressing B cells survive better in culture than 
Notch2IC-, but not than LMP1/CD40-expressing B cells. 
Splenocytes of all genotypes were prepared and B cells were depleted of CD43pos cells. The B cells were 
subsequently cultivated either with or without stimuli. These stimuli included α-CD40 antibody, IL4 and 
both (IL4 and α-CD40 antibody). Cells were labeled with Topro-3 prior to flow cytometric analysis on day 
0, 1, 3 and 5 of culture. Statistical evaluation of the percentage of living cells is given on the respective 
days (x-axis) without stimulus (A), with IL4-stimulus (B), with CD40-stimulus (C) and both with IL4- and 
CD40-stimulus (D). The averages and SDs are calculated from three independent experiments. SD, 
standard deviation. 
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3.14 Notch2IC//LMP1/CD40‐expressing splenic B cells are highly and actively 
cycling cells  
Previous studies in our lab showed that Notch1IC/2IC were able to drive cells into the S-phase of 
the cell cycle. However, cell numbers did not increase which was assumed to be due to an 
increased apoptosis rate in Notch1IC/2IC-expressing cells due to upregulation of pro-apoptotic 
genes (Kohlhof et al., 2009). All of this is in line with the results obtained in the CFSE-and Topro-
3-analysis presented above, considering that compared to CD19-cre B cells Notch2IC-expressing 
splenic B cells display decreased viability. Constitutive CD40 on the other hand -as was observed 
with the B cells expressing LMP1/CD40- might deliver the survival signals that enable increased 
proliferation also in Notch2IC-expressing B cells.  
This scenario could be further tested in detail with regard to the cell cycling characteristics in the 
B cells of Notch2IC//LMP1/CD40//CD19-cre mice supplied with both a constitutively active CD40 
as well as a constitutively active Notch2 to see whether these are driven into S-phase of cell cycle 
–through the activity of Notch-signaling- and allow for continuous proliferation and prevention of 
apoptosis –through the activity of CD40-signaling. 
Therefore, primary splenic B cells depleted of CD43pos cells by MACS-separation were taken into 
culture for three days and labeled with Bromodesoxyuridine (BrdU) at day 0, day 1 and day 3 for 
four hours. BrdU is a synthetic nucleoside and thymidine analogue. If given to cells during their 
proliferative S-phase BrdU-dye will be incorporated into the cell’s DNA and can later be visualized 
by intracellular staining with fluorochrome-coupled α-BrdU antibodies. This allows for inference 
on the proliferation rate of the cells. Simultaneous staining of the cells with 7-amino-actinomycin 
D (7AAD; a fluorescent DNA marker) permits to determine the full scope of the cell cycle of any 
culture of cells under investigation. In order to ensure functionality of the assay LPS was added to 
B-cell cultures of CD19-cre mice. LPS is a potent, polyclonal stimulus, activating the cells and 
driving them into proliferation.  
 
On day 0 (Fig. 3.27), reflecting the immediate ex vivo situation splenic B cells from all genotypes 
still resemble each other with regard to their cells in G0/G1 of the cell cycle (around 80 % of cells) 
and G2/M (roughly around 5 % of cells). As expected the B cells of CD19-cre mice did hardly 
proliferate and quickly died in culture without stimulus (as merely roughly 15 % of cells were 
viable at day 3 as previously shown; Fig. 3.26A). Stimulating control B cells of CD19-cre mice with 
LPS had little effect after the initial 4 hours of BrdU-labeling and simultaneous LPS-stimulation. 
But after 1 day of in vitro culture cells with LPS-stimulus displayed a strong increase of cells in S-
phase of the cell cycle (6 %), as well as in G2/M-phase (9 %), indicating a strong increase in 
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proliferation. The effect LPS had on cells was even more pronounced at day 3 of culture with an 
even expanded percentage of cells in S-phase (35 %), but less cells in G2/M (2 %), hinting at the 
possibility that cells were so activated that they did not accumulate in the G2 phase but rather 
re-entered the cell cycle.  
Notch2IC- as well as Notch2IC//LMP1/CD40-expressing splenic B cells displayed a much larger 
percentage of cells in S-phase after ex vivo isolation (about 2 % in both genotypes). This 
percentage increases over 24 hours: it doubles in Notch2IC-expressing cells and triples in B cells 
expressing both transgenes. Simultaneously, there is a subtle drop in the percentage of cells in 
G2/M-phase (from 6 to 4 %) in Notch2IC-expressing B cells, which is also observable in 
Notch2IC//LMP1/CD40‐expressing B cells (from 6 to 5 %). This could either be symptomatic of an 
increase in B cells re-entering cell cycle or simply of cells dying. The latter seems to be the case 
for only Notch2IC-expressing B cells since by day 3 of culture these cells display a massive 
increase of apoptotic/necrotic cells as has been observed in culture of control cells. Moreover, 
this is accompanied by a considerable drop of viable cells, in all phases of cell cycle but especially 
in S-phase.  
The drop of viable splenic B cells, in all phases of cell cycle but especially in S-phase was not 
observable for B cells expressing both transgenes, which even displayed a further increase on 
cells in S-phase (from 6 % on day 1 to 10 % on day 3), with only a small drop of the percentage of 
cells in G0/G1. This effect was likely to be mediated by CD40. LMP1/CD40-expressing B cells in 
contrast to CD19-cre control cells already after ex vivo isolation harbor more cells in S-phase, but 
this portion doubles over 24 hrs (day 1) and triples within 72 hrs (day 3). Furthermore, in line 
with the anti-apoptotic properties of active CD40-signaling LMP1/CD40-expressing B cells display 
no drop in cell viability at the analysis endpoint (day 3).  
Therefore, the herein presented data strongly support the hypothesis that simultaneous 
expression of both constitutively active Notch2 and CD40 in B cells leads to an increase in B-cell 
proliferation by Notch activity driving cells into S-phase but also apoptosis, which can be 
counteracted by CD40 which can provide strong anti-apoptotic, pro-survival stimuli. 
Of note, only medium of wells with Notch2IC//LMP1/CD40‐expressing B cells or B cells having 
received an LPS stimulus (CD19-cre) turned light yellow, indicating a change in pH due to the 
accumulation of metabolites in the medium (data not shown) and further underlines the highly 
proliferative state of Notch2IC//LMP1/CD40‐expressing B cells. 
RESULTS 67 
 
 
Fig. 3.27 Notch2IC//LMP1/CD40‐expressing splenic B cells are highly and actively cycling cells. 
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Splenocytes were prepared and B cells were depleted of CD43pos (i.e. non-B) cells and labeled with BrdU 
for 4 hrs. B cells were cultivated either with LPS (in the case of CD19-cre B cells) or without stimuli. 
Polyclonal stimulus LPS was used on CD19-cre B cells as positive control to test for assay functionality. 
Cells were analyzed by flow cytometric analysis on day 0 (upper panel), day 1 (middle panel) and day 3 
(lower panel) of culture. X-axis shows 7AAD intensity which corresponds to DNA content and y-axis 
represents APC intensity which corresponds to BrdU-incorporation. In the FSC/SSC cell debris was gated 
out and by plotting FSC-A versus FSC-W was used to discriminate doublets from single cells. The displayed 
result is representative for four independent experiments. 7AAD, 7-amino-actinomycin D; APC, 
allophycocyanin (fluorochrome); BrdU, Bromdesoxyuridine; FSC (-A, -W), foward scatter (-area, -width); 
hrs, hours; LPS, Lipopolysaccharide; SSC, sideward scatter.  
3.15 Aged Notch2IC//LMP1/CD40//CD19-cre mice are prone to develop B-cell 
lymphomas 
As shown before, B cells of Notch2IC//LMP1/CD40//CD19-cre mice have a highly activated 
phenotype and proliferate strongly in culture. Not surprisingly both Notch and CD40 are found to 
be up-regulated in a number of cancers (Kuppers et al., 2012). LMP1/CD40//CD19-cre mice 
develop B- cell lymphomas with a high incidence after 1 year (Hoemig-Hoelzl et al., 2008). 
Therefore, some mice were saved for over a year (13 to 16 months) to test whether the co-
expression of constitutive active Notch2 and CD40 has an impact on lymphomagenesis in 
Notch2IC//LMP1/CD40//CD19-cre mice. 
All five Notch2IC//LMP1/CD40//CD19-cre mice developed hyperplasia, both of the spleens as 
well as three tissue abnormalities in the lower neck region (Tab. 3.2). There are distinct variations 
in this small test group, spleens of Notch2IC//LMP1/CD40//CD19-cre mice were up to 13 times 
heavier than their control counterparts, harboring up to 26-fold more cells in total. The mice can 
be assigned into two groups: those that do present with overt signs of lymphomas and those that 
only show mild signs of lymphoma. Both groups can present with or without tumors in the lower 
neck region.  
Three out of five mice (# 3142, # 1779 and # 1778) display a splenic B-cell expansion (3 to 27-fold 
increase) and a splenic T-cell expansion (8 to 70-fold increase in mouse # 1778 compared to 
controls). Therefore, the T-cell expansion in the spleen is not lost during ageing of the mice and is 
still a hallmark of lymphocyte expansion in Notch2IC//LMP1/CD40//CD19-cre mice. Two mice 
(# 1717 and # 1760) do not present with a splenic B-cell expansion and/or a splenic T-cell 
expansion but still had an increase in splenic weight and total cell number. Mouse # 1717 had a 
tumor in the lower neck region which made the sacrifice of the mice necessary. No mice of the 
Notch2IC//LMP1/CD40//CD19-cre genotype lived longer than 16 months, since all mice 
developed abnormalities that required putting the animals down. In order to ensure that this is 
an effect of the constitutive expression of both transgenes in these mice and not of the ageing 
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process and the accumulation of random mutations over time, one CD19-cre mouse was 
analyzed along with every Notch2IC//LMP1/CD40//CD19-cre mouse. However, although there 
are also variations in splenic weight and splenic cell number in CD19-cre control mice none of 
these mice developed signs of illness. 
 
Tab. 3.2 Overview of 13-16 month-old Notch2IC//LMP1//CD19-cre mice that developed hyperplasia of 
the spleen or the lower neck region. 
The respective aged-matched controls were summarized in the first row, n=5. The data given in the three 
last columns were obtained through flow cytometric analysis of splenocytes stained for B220pos (B cells), 
CD3pos (T cells) and hCD2pos/B220pos (B cells expressing transgenes). n.d., not determined; SGT, salivary 
gland tumor. 
 
 
age splenic 
weight (g) 
total cell 
no. (×10
7
) 
B-cell no. 
(×10
7
) 
T-cell no. 
(×10
7
) 
% of hCD2
pos 
B cells 
SGT 
CD19-cre matched 0.22 ±0.1 4.9 ±1.7 2.7 ±1.2 1.2 ±0.3 - - 
Notch2IC//LMP1/CD40// 
CD19-cre 
       
# 3142 13 m 2.92 125.0 84.6 19.4 89.4 - 
# 1779 14 m 0.72 87.5 37.0 30.4 96.7 1 
# 1760 14 m 1.59 64.9 0.8 11.9 5.4 - 
# 1778 14 m n.d. 130.0 30.3 63.4 67.7 1 
# 1717 16 m 0.30 9.0 1.3 3.9 23.2 1 
 
 
3.15.1 Aged Notch2IC//LMP1/CD4//CD19-cre mice display increased numbers of splenic 
Mac1pos cells 
Since some of the old mice examined did not display an increase in the lymphocyte compartment 
in the spleen the question arose whether these cells could be accessory cells as an expansion of 
such cells was already observed in the young mice. Preparing splenocytes and analyzing them for 
Mac1 surface expression, while excluding B220pos B cells, allowed estimating the presence of 
these cells in the spleens.  
While the percentages of Gr1hi cells in aged Notch2IC//LMP1/CD4//CD19-cre were not increased 
in comparison to CD19-cre mice, only slightly higher in mouse # 1760. But as observed in the 
younger mice the absolute number of Mac1pos cells were overall elevated in the spleens in aged 
Notch2IC//LMP1/CD4//CD19-cre mice. Especially in mouse # 1760 (which had almost no B cells in 
the spleen, while displaying a high splenic weight of 1.59 g), the number of Mac1pos cells is 
particularly high (16×107 versus 0.5×107 on the average in CD19-cre mice; Fig. 3.28).   
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Fig. 3.28 Aged Notch2IC//LMP1/CD4//CD19-cre mice display increased numbers of splenic Mac1pos cells.  
Splenocytes were prepared and stained for B220 and Mac1 surface marker expression. Cell numbers of 
Mac1pos B220neg were determined by flow cytometric analysis and given for each mouse. Data for CD19-
cre control mice (n=5) were averaged and SD is given. SD, standard deviation. 
3.15.2 Aged Notch2IC//LMP1/CD40-expressing B cells display distinctly altered surface marker 
expression in the spleen  
Young Notch2IC//LMP1/CD40//CD19-cre mice display a MZ B-cell phenotype as previously shown 
(section 3.8, Fig. 3.17). Therefore, with the aim to test whether this phenotype is maintained in 
aged mice, splenic B cells of aged mice were analyzed for their MZ B-cell status with the help of 
IgM/IgD and CD21/CD23 staining and flow cytometric analysis. The FACS analysis revealed that 
staining overall is very diverse and therefore no averages can be calculated, instead the 
CD21/CD23- and IgM/IgD-staining pattern of those mice displaying high splenic B-cell numbers 
(# 3142, # 1779, # 1778 and # 1717) is presented individually (Fig. 3.29). 
The CD21/CD23-staining allows for a direct analysis of MZ B- versus Fo B-cell phenotype. Two out 
of five old Notch2IC//LMP1/CD40//CD19-cre mice (# 1778 and # 1717) still show a tendency to 
gate into the MZ-B-cell compartment gate as the young mice do. However, they display a 
tendency towards down-regulation of CD21. In two out of five old mice (# 3142 and # 1779) the 
majority of B cells showed an clear down-regulation of CD21 (CD21low CD23low). Interestingly, in 
mouse # 1717 this was particularly the case for the hCD2pos splenic B cells.  
With regard to the IgM/IgD-staining of B cells three out of five old Notch2IC//LMP1/CD40//CD19-
cre mice (# 3142, # 1778 and # 1717) still gate for majority into the MZ B-cell gate (IgMhi IgDlow) 
however with strongly varying degrees and one out of five mice (# 1779) exhibits a shift towards 
IgMhi IgDlow-MZ B-cell gate with a tendency to acquiring an IgM/IgD double-negative status.  
Gating on hCD2 usually allows screening for the status of the actual transgene-expressing cells. 
The majority of hCD2pos B cells would also gate like the majority of the entire splenic B-cell 
population in the individual mice, meaning in case there is a down-regulation in one or both 
markers (either CD21 and CD23 or IgM and IgD) in the entire splenic B-cell population this was 
found recapitulated in the hCD2 B cells of the mice. 
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Fig. 3.29 Aged Notch2IC//LMP1/CD40-expressing splenic B cells display distinctly altered surface marker 
expression in the spleen. 
(A) Flow cytometric analysis of Fo (CD21hi CD23pos) and MZ B cells (CD21hi CD23pos/low) in the spleen of mice 
# 3142, # 1779, # 1778, # 1717 and of a representative control CD19-cre mouse (with percentages of 
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averages and SDs). Numbers indicate percentages of lymphocyte-gated, B220pos B cells displaying the 
respective phenotypes. Re-gating the cells on hCD2 allows for identification of the phenotype of the cells 
expressing the transgenes (lower panel). (B) Splenocytes of mice # 3142, # 1779, # 1778, # 1717 and a 
control CD19-cre mouse were analyzed by flow cytometry for the expression of surface IgM and IgD. 
Numbers indicate percentages of lymphocyte-gated populations of B220pos B cells displaying a Fo (IgMpos 
IgDpos) or MZ and transitional (IgMpos IgDlow) B cell phenotype (upper panel). Re-gating the cells on hCD2 
allows for identification of the phenotype of the cells expressing the transgenes (lower panel). Data for 
CD19-cre mice (n=5) were averaged and SDs are given. Fo B, follicular B cell; MZ B, marginal zone B cell; 
SD, standard deviation. 
3.15.3 Aged Notch2IC//LMP1/CD40-expressing splenic B cells display differential up-regulation 
of activation markers 
Young Notch2IC//LMP1/CD40//CD19-cre mice display an activated B-cell phenotype as previously 
shown with the help of various surface markers (section 3.9, Fig. 3.18). However, when analyzing 
splenic B cells of the aged mice for CD80, CD86 and CD95 the activation marker are still up-
regulated, but with varying intensity. Only in mouse # 3142 the same robust, LMP1/CD40-
induced upregulation of CD95 can be observed (Fig. 3.30A), leading the entire splenic B-cell 
population to assume a higher CD95 expression. In all other aged mice (# 1779, # 1778 and 
# 1717) the up-regulation of CD95-expression is not as strong. Furthermore, the flow cytometric 
analysis show in all mice analyzed not only the previously observed up-regulation of CD80, but 
also of CD86 compared to controls (Fig. 3.30B) in their splenic B cells, however with strongly 
varying levels. Old mice are also diverse with regard to their hCD2-status (Fig. 3.30C), mouse 
# 1760 for example has almost completely down-regulated hCD2 in its few remaining splenic B 
cells, when comparing them to a young Notch2IC//LMP1/CD40//CD19-cre mouse.  
The different levels of activation marker expression could be explained by activity and up-
regulation of different signaling pathways that can differ from mouse to mouse as has previously 
shown for lymphoma-bearing LMP1/CD40//CD19-cre mice (Homig-Holzel et al., 2008). The 
variation in expression of transgene reporter (CD95, indirectly or hCD2, directly) might be due to 
two reasons: A) mainly B cells that do not express the transgenes are expanding or B) there is a 
transcriptional down-regulation of both transgenes and thereby down-regulation of hCD2- and 
CD95 expression with age or onset of B- cell lymphomagenesis. 
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Fig. 3.30 Aged Notch2IC//LMP1/CD40-expressing splenic B cells display up-regulation of activation 
marker.  
Splenocytes were analyzed by FACS for level of surface molecules (A) CD95, (B) CD80 and CD86 (B7-
proteins) and C) hCD2. Overlays of surface expression were made of lymphocyte-gated, B220pos B cells 
from aged Notch2IC//LMP1/CD40//CD19-cre mice (green lines) or controls (CD19-cre or young 
Notch2IC//LMP1/CD40//CD19-cre mice; grey lines).  
CD5 is a surface marker that is usually expressed on T cells as well as B1a cells, but it is also found 
on activated mature B cells. An up-regulation of activation marker CD5 in splenic B cells could be 
observed in all aged Notch2IC//LMP1/CD40//CD19-cre mice with the exception of mouse # 1760 
(Fig. 3.31 and Tab. 3.3). In this mouse (# 1760) the percentage of CD5pos/B220pos B cells is even 
diminished compared to the average in CD19-cre (0.3 % versus 4 % in CD19-cre) but overall levels 
of CD5 are comparable to the CD19-cre control mice. It should be further evaluated whether 
these splenic B cells adopt a B1 B-cell phenotype. 
 
Fig. 3.31 Aged Notch2IC//LMP1/CD40//CD19-cre mice display distinctly altered surface marker 
expression with regard to CD5 and B220 expression.  
Flow cytometric analysis of lymphocyte-gated, CD5pos and B220pos cells in the spleen as analyzed by flow 
cytometry. Notch2IC//LMP1/CD40//CD19-cre mouse # 1778 is shown along aged-matched CD19-cre 
control.  
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Tab. 3.3 Aged Notch2IC//LMP1/CD40//CD19-cre mice display distinctly altered surface marker 
expression with regard to CD5 and B220 expression.  
Flow cytometric analysis of CD5pos and B220pos cells in the spleen as analyzed by flow cytometry. Data for 
CD19-cre mice (n=5) were averaged and SDs are given. SD, standard deviation. 
 
 
CD5 (in %) CD5
pos
/B220
pos
 (in %) 
CD19-cre 22.5 ±6.5 4.1 ±1.3 
Notch2IC//LMP1/CD40// 
CD19-cre 
  
# 3142 17.2 54.6 
# 1779 36.2 24.2 
# 1760 27.1 0.3 
# 1778 53.6 27.7 
# 1717 55.6 9.5 
3.15.4 Aged Notch2IC//LMP1/CD40//CD19-cre mice maintain shift towards effector T-cell 
compartment  
As shown in Tab. 3.2 splenic T-cell expansion (8 to 70-fold increase in mouse # 1778 compared to 
controls) is preserved in the aged Notch2IC//LMP1/CD40//CD19-cre mice. In order to better 
characterize the also expanded T-cell population in the old mice the splenic lymphocytes were 
tested for the expansion of the CD4pos and CD8pos T-cell compartment and furthermore tested for 
T-cell activation via CD4, CD8, CD44 and CD62L staining and subsequent FACS analysis like the 
young mice (section 3.5.2).  
With respect to the distribution of CD4pos versus CD8pos splenic T cells, one can observe that there 
is no tendency towards an expansion of a particular T-cell subpopulation (Fig. 3.32). 
 
Fig. 3.32 Aged Notch2IC//LMP1/CD4//CD19-cre mice display increased numbers of T cells.  
Splenocytes were prepared and analyzed for CD3, CD4 and CD8 surface marker expression. Cell numbers 
of lymphocyte-gated, CD3pos/CD4pos and CD3pos/CD8pos were determined by flow cytometric analysis. 
Points represent data from individual mouse and the horizontal bar marks the mean value for CD19-cre 
control mice (n=5) were averaged and SD is indicated above control mice data set. SD, standard deviation. 
With respect to the T-cell activation the aged Notch2IC//LMP1/CD40//CD19-cre mice displayed a 
similar pattern as in the young mice since they maintain a shift towards T-cell effector 
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compartment (Fig. 3.33). However, as observed for mainly all other staining results in the old 
mice they present with variations (Tab. 3.4).  
 
Fig. 3.33 Gating scheme for T-cell activation after CD4pos or CD8pos pre-gating of T cells. 
Naïve T-cell compartment (CD62Lhi CD44low), central memory T cells (CD62Lhi CD44hi), effector T cells 
(CD62Llow, CD44hi). Data for CD19-cre mice (n=5) were averaged and SDs are given. SD, standard deviation. 
There is a general reduction in the naïve T-cell compartment and moreover a reduction in central 
memory (CD62Lhi CD44hi) both in CD4pos and CD8pos cells, with the exception of CD4pos T cells of 
mouse # 1778 in which both effector and memory T-cell compartment are increased at the 
expense of the naïve T-cell compartment. The marked increase in the effector T-cell 
compartment (CD62Llow CD44hi) in the spleen in the respective CD4pos or CD8pos T-cell population 
can also still be observed in the old mice, with the exception of CD8pos T cells of mouse # 1779 
which resemble CD19-cre mice rather than other aged Notch2IC//LMP1/CD40//CD19-cre mice. 
Tab. 3.4 Splenic T cells of aged Notch2IC//LMP1/CD40//CD19-cre mice show an increase in the 
percentage of both central memory as well as effector memory T cells.  
Splenic cells were analyzed by flow cytometry for the CD62L and CD44 expression on either (A) CD4pos or 
(B) CD8pos T cells. 
(A) 
CD4pos 
 
naïve T-cells 
(CD62L
hi
 CD44
low
) 
memory T cells 
(CD62L
hi
 CD44
hi
) 
effector T cells 
(CD62L
low
, CD44
hi
) 
% CD62L
low
, 
CD44
low
 
CD19-cre 43.6 ±7.1 6.6 ±1.0 40.7 ±5.6 9.1 ±0.8 
Notch2IC//LMP1/CD40// 
CD19-cre 
    
# 1760 0.28 2.9 86.3 10.5 
# 1778 9.9 23.9 59.4 6.8 
# 1717 5.3 4.1 68.4 22.3 
 
(B) 
CD8pos 
 
naïve T-cells 
(CD62L
hi
 CD44
low
) 
memory T cells 
(CD62L
hi
 CD44
hi
) 
effector T cells 
(CD62L
low
, CD44
hi
) 
% CD62L
low
, 
CD44
low
 
CD19-cre 22.8 ±12.8 33.7 ±5.7 35.7 ±14.8 8.1 ±3.2 
Notch2IC//LMP1/CD40// 
CD19-cre 
    
# 1779 34.5 28.7 21.5 15.4 
# 1760 2.2 6.1 41.1 50.6 
# 1778 10.9 21.4 52.9 14.7 
# 1717 5.6 6.2 51.8 36.3 
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Overall, there is an expansion in the compartment of activated T cells and again not only, but in 
particular the CD8pos T cells of aged Notch2IC//LMP1/CD40//CD19-cre mice that display the same 
shift into the CD44low CD62Lneg compartment as previously observed in the young mice.  
3.15.5 Aged Notch2IC//LMP1/CD40//CD19-cre mice develop monoclonal B-cell lymphoma  
In order to determine whether the expansion in splenic size, weight and lymphocyte cell number 
in aged Notch2IC//LMP1/CD40//CD19-cre mice is due to the expansion of one or several B-cell 
clones –which would confirm lymphoma development- Southern blots with DNA prepared from 
total splenocyte samples were prepared. Southern blot analysis also allows to determine 
whether the lymphoma originates from the expansion of one or more B-cell clones, so whether it 
is mono- or oligoclonal in nature. Using a radioactively-labeled IgH-probe on membrane-bound 
DNA that has been digested with the EcoRI-restriction enzyme, one is either able to detect the 
germline configuration of the IgH-locus or one or more distinct bands signifying the expansion of 
one or more B-cell clones carrying the same rearrangement of the BCR.  
Only four of the five mice could be tested since no DNA was kept from the mouse # 1778. These 
samples were subjected to analysis along with two control DNA samples from aged-matched 
CD19-cre mice and one DNA samples from an aged-matched LMP1/CD40//CD19-cre mouse 
(# 3143). The results of the blot revealed that two of the four samples (# 3142 and # 1779) tested 
were positive for two further IgH-rearrangements (Fig. 3.34). This could be due to an oligoclonal 
expansion, however is more likely to be a monoclonal expansion since in most B cells both Ig-
alleles tend to be rearranged. This leads to exactly two Ig-gene rearrangements and therefore 
monoclonal expansions of their splenic B-cell pool that present as oligoclonal. For the 
LMP1/CD40//CD19-cre DNA sample the band(s) appear very weak, therefore an expansion of one 
or B-cell clones could not be determined unambiguously. 
One of these two mice (# 3142) displayed the highest splenic weight and had the second highest 
cell numbers of all mice analyzed (2.9 g and 12.5×108). The other mouse (# 1779) however, had 
primarily to be sacrificed since it displayed a tumor in the lower neck region. The mouse had only 
a slightly elevated splenic weight compared to young Notch2IC//LMP1/CD40//CD19-cre mice 
(0.72 g versus an average of 0.65 g in young mice). Moreover, the total cell numbers in 
comparison to young Notch2IC//LMP1/CD40//CD19-cre mice were also only slightly elevated 
(8.7×108 cells versus 5.3×108 in young mice).  
Despite the comparatively low total cell numbers, the mouse evidently suffered from a B-cell 
lymphoma. This might be an indication that some B-cell lymphomas in younger mice have gone 
unnoticed as they do not present themselves as for example those in LMP1/CD40//CD19-cre 
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mice with an overt splenomegaly and an overt B-cell expansion. On a key note, the two mice that 
developed monoclonal B-cell lymphomas were also those expressing high hCD2 levels (Tab. 3.2 
and Fig. 3.30C) and high levels of CD95 (Fig. 3.30A). This provides further evidence to our 
hypothesis that if both transgenes are expressed within one B cell this leads to development of 
lymphoma. 
 
Fig. 3.34 Aged Notch2IC//LMP1/CD40//CD19-cre mice develop monoclonal B-cell lymphoma. 
Southern Blot of EcoRI-digested DNA isolated from whole splenocyte preparations. By use of a 
radioactively-labeled IgH-probe the samples were tested for configurations of their IgH-locus. The arrow 
points to the band indicating the germline configuration of the respective sample as found in B cells and in 
any other cell type. The asterisk points to the additional bands indicative of the change in the IgH-locus 
and monoclonal B-cell expansion in mouse # 3142 and mouse # 1779. The lane carrying the marker is on 
the left. 
Of note, mouse # 1717 and # 1760 that do not display IgH rearrangements are those mice that 
hardly harbor any B cells in their spleens (Tab. 3.2: # 1717 14 % and # 1760 1,2 % B cells). Since 
whole splenocyte preparations were used for the Southern blot analysis it is conceivable that the 
percentage of B cells with a rearranged IgH-locus is simply too small to be noticeable. These mice 
might carry mono- or oligoclonal expansions in their respective B-cell pools, but they remain 
undetectable by Southern blot analysis.  
3.16 Aged Notch2IC//LMP1/CD40//CD19-cre mice develop salivary gland 
carcinomas 
As shown in Tab. 3.2 (overview of tumor mice) there were mice that had to be sacrificed not only 
because they developed splenomegalies, but also because three mice developed overt 
hyperplasias in the lower neck regions (Fig. 3.35A and B). These could be identified by Leticia 
Quintanilla-Fendt (mouse pathologist, senior physician at the Institute for Pathology, University 
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of Tübingen) as poorly differentiated carcinomas of the submandibular salivary gland. These 
carcinomas were henceforth abbreviated to SGTs (salivary gland tumors). She did all the 
immunohistological characterization of the tissue in the following sections.  
The tumor tissue can be visualized by cytokeratin staining on paraffin sections. Fig. 3.35C shows 
exemplary staining of SGTs of LMP1/CD40//CD19-cre and Notch2IC//LMP1/CD40//CD19-cre 
mice. In both cases the tumor tissue looks similar and is intergrowing with the rest of the 
glandular tissue and an ordered gland structure is lost.  
 
Fig. 3.35 SGT localization in mouse.  
(A) SGT on animal (courtesy of C. Hoemig-Hoelzel). (B) Schematic drawing of localization of SG in healthy 
mice. (C) Tumor tissue as visualized by cytokeratin staining of paraffin sections of SGTs in 
LMP1/CD40//CD19-cre and Notch2IC//LMP1/CD40//CD19-cre mice. SGT, salivary gland tumor. 
These tumor do not only occur in aged Notch2IC//LMP1/CD40//CD19-cre mice, but they have 
also been observed in LMP1/CD40//CD19-cre mice by former colleagues C. Hoemig-Hoelzel and 
C. Hojer. An overview of incidence of SGT and/or B-cell lymphoma and age in old 
LMP1/CD40//CD19-cre mice is given in Tab. 3.5.  
Roughly 2/3 of the mice analyzed develop a B-cell lymphoma and half of these have also 
developed a SGT. However, some few old LMP1/CD40//CD19-cre mice only display SGT 
development, which means that overall roughly half of the old mice develop a SGT with age. 
In aged Notch2IC//LMP1/CD40//CD19-cre mice three out of five mice develop SGTs. From these 
one mouse (# 1779) has developed an oligoclonal B-cell lymphoma. The two other mice that 
developed a SGT are # 1778 and # 1717. # 1778 had splenomegaly and a B-cell expansion, 
presence of a B-cell lymphoma could not be detected by Southern blot analysis due to lack of 
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DNA material. The other mouse with a SGT (# 1717) had no splenomegaly and rather reduction in 
B lymphocytes even compared to CD19-cre mice. The other mouse with a B-cell lymphoma 
(# 3142) had a normal gland. This shows that lymphoma development is not necessarily 
correlated with development of an SGT. 
Tab. 3.5 Overview over LMP1/CD40//CD19-cre mice age in months with SGTs and B-cell lymphoma. 
SGT, salivary gland tumor; CH, C. Hojer; CHH, C. Hoemig-Hoelzel 
Mouse # Age (months) B-cell lymphoma SGT Analyzed by 
492 10 no yes CH 
282 12 no yes CHH 
201 14 no yes CHH 
740 18 no yes CH 
     
947 10 yes no CH 
849 12 yes no CH 
445 13 yes no CH 
787 13 yes no CH 
197 14 yes no CHH 
686 14 yes no CH 
850 14 yes no CH 
748 18 yes no CH 
386 18 yes no CH 
851 19 yes no CH 
     
364 12 yes yes CHH 
685 12 yes yes CH 
142 14 yes yes CHH 
247 15 yes yes CHH 
384 15 yes yes CH 
34 17 yes yes CHH 
176 18 yes yes CHH 
 
The main question is to uncover the mechanism behind the tumorigenesis. Two scenarios can be 
envisioned: either the SGTs are elicited by proxy through the activated/lymphatic B- and/or T 
cells and the SGTs are rather secondary tumors with lymphocytic infiltrates. Or, on the other 
hand the stop cassette might have been deleted at some time at least in some epithelial cells 
leading to constitutively active CD40 and constitutively active Notch2IC in the SGs of the 
respective mice.  
With the aim to elucidate this question the paraffin sections of the SGs were stained for the 
presence of CD3pos and B220pos cells to evaluate them for the presence of lymphocytic infiltrates, 
for hCD40 (although an antibody detecting the extracellular part of CD40 was used) and hCD2 
which is the marker protein that indicates successful deletion of the stop cassette and expression 
of the targeting construct. hCD2 could deliver clues as to whether carcinogenesis occurs due to a 
somewhat leaky expression of the transgene(s). 
The lymphocyte staining (Fig. 3.36A and B) revealed that both B220pos B cells (B) and also CD3pos T 
cells (A) are found in higher densities at the capsule lining the SGTs. Interestingly, the B220pos B 
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cells appear to be rather few compared to the T cells and particularly the CD3pos T cells can also 
be found in low numbers within the glandular tissue. This staining shows that there are no heavy 
lymphocyte infiltrates to be found within SGTs, but they rather sit in the surroundings. This is in 
line with literature findings that strong lymphocyte infiltrates in the salivary glands of wild type 
mice are only observed upon infection, such as with the Murine cytomegalovirus (MCMV) which 
displays a strong tropism for the salivary gland (Pilgrim et al., 2007). 
 
 
Fig. 3.36 Histological evaluation of lymphocytic infiltrates and surface marker expression in the SGTs of 
Notch2IC//LMP1/CD40//CD19-cre mice.  
IHCs on paraffin sections of SGTs of CD3pos T (A) and B220pos B cells (B), hCD40pos cells (C), hCD2pos cells and 
cytokeratin (D). IHC, immunohistochemistry; SGT, salivary gland tumor. 
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The CD40 staining (Fig. 3.36C) shows that only a few cells are positive for CD40. The staining as 
such appears to be specific since CD40 is a membrane-bound molecule which is where the 
staining can be observed. These cells could be epithelial cells that up-regulated CD40 
independently or infiltrating B cells with CD40. 
On the other hand the hCD2 staining (Fig. 3.36D, upper left panel) reveals that the marker 
surface molecule is prominently distributed throughout the entire tumor tissue in SGTs of 
Notch2IC//LMP1/CD40//CD19-cre mice, while it is absent in SGTs of LMP1/CD40//CD19-cre mice 
(Fig. 3.36D, upper right panel) which indicates specificity. Interestingly, the staining patterns 
appear to be a “photo negative” of the cytokeratin staining, meaning it is especially strong in the 
areas of the tumor where the cytokeratin staining is weaker and vice versa. (Fig. 3.36D, lower left 
panel). Furthermore, the hCD2 expression seems to start from the lumen of the vessels that run 
through the SG tissue (small insert, Fig. 3.36D, lower right panel).  
All in all, these histological findings do not deliver final insight what might be the contributing 
factor for tumor development in the SGs. One would expect the lymphocyte infiltrates to be less 
discrete at the rim of the tissue, if the infiltrates were the major contributing factor for 
carcinogenesis. This seems to be supported by the high expression of hCD2 through the entire 
diseased tissue in the SGTs of Notch2IC//LMP1/CD40//CD19-cre mice, while it is absent in 
LMP1/CD40//CD19-cre mice.  
Southern blot analysis of SGTs shows a partial deletion of stop cassette 
The strong hCD2 expression within the tissue (and not just on the connective tissue surrounding 
the SG where the majority of the hCD2pos B cells are located) rather points toward expression of 
the transgenes due to excision of the stop cassette in the carcinoma. In order to determine on a 
molecular level whether the stop cassette has been deleted DNA was extracted from tissue from 
a normal inconspicuous SG of a LMP1/CD40//CD19-cre mouse and SGT of a LMP1/CD40//CD19-
cre mouse and analyzed by Southern blot after EcoRI digest. The probe binds upstream of the 
first exon of the locus and allows to detect (A) the wild type conformation of the Rosa26 locus, 
(B) whether the targeting construct has been inserted into the locus and (C) whether there has 
been a deletion of the stop cassette as part of the targeting locus. 
The results of the blot are shown in Fig. 3.37. Only mice having the LMP1/CD40 inserted in only 
one allele were chosen for analysis. Accordingly one can still see the 15.4 kb band in the blot that 
indicates the wild type conformation of the targeted locus in one allele. In the SG without tumor 
there is one additional band at the height 7.2 kb indicative of the successful insertion of the 
construct into the rosa26-locus, which has been analyzed with the TINA software and was found 
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to be equimolar to the band at 15.4 kb. In the SGT, there is an additional third band at the height 
of 5.1 kb that indicates the excision of the stop cassette in the targeting construct that 
successfully inserted into the Rosa26-locus. This band was again quantitatively analyzed with the 
TINA software and was found to be equimolar to the band at 7.2 kb in the sample. This is a strong 
hint that half of the cells in the SGT tissue present with a deleted stop cassette. Considering that 
the B cells seemed to be rather few that are mainly sitting in the connective tissue capsule it 
seems unlikely that these account for this amount of deletion of the stop cassette in the tissue. 
Nonetheless, it cannot be ruled out that these B cells contribute since the material used for the 
Southern blot analysis was whole tissue preparation because no means of purification of SGT 
cells were available. DNA material from microdissections of SGT material and controls was 
prepared, however PCRs detecting the deletion of the stop cassette also remained inconclusive 
(data not shown).  
 
 
Fig. 3.37 Southern blot analysis of SGTs shows a partial deletion of stop cassette.  
(A) Schematic representation of the target locus in wild type configuration (upper panel), with the 
inserted targeting construct (middle panel) and upon excision of the stop cassette (lower panel). The 
length (in kb) of the region indicated in the area of the red lines that is detected by the probe (dark red) 
after EcoRI digest. (B) Southern blot of inconspicuous SG of a LMP1/CD40//CD19-cre mouse and SGT of a 
LMP1/CD40//CD19-cre mouse showing band sizes upon EcoRI digest and blotting as indicated on the left. 
kb; kilobase; SG, salivary gland; SGT, salivary gland tumor. 
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4. DISCUSSION 
The rationale behind the cross-breeding mice expressing constitutively active Notch2IC and CD40 
in their B cells was to re-create a situation that is found in a number of tumors including B-cell 
lymphomas such as cHL that display high and constitutive expression of both surface molecules.  
Indeed with the work at hand it could be shown that such B cells have an activated phenotype, 
they highly proliferate and cycle actively, that T cell numbers are increased in the spleen and that 
these T cells are activated and moreover that increased numbers of accessory cells -which also 
display an activated phenotype- are recruited to the spleen. Moreover, with age these mice seem 
to be prone to tumorigenesis. These factors shall be examined in more detail in the following 
sections. 
4.1 Notch2IC//LMP1/CD40//CD19-cre mice display an increase in reactive 
accessory cells in their spleens 
The splenomegaly in the Notch2IC//LMP1/CD40//CD19-cre mice is not only due to an increase in 
the lymphocyte compartment. They also display an increase in accessory cells as for example 
macrophages. Moreover, macrophages are cells that are –in line with their phagocytic 
capabilities- inherently larger than most other cell types encountered in the spleen, further 
adding to the splenomegaly in Notch2IC//LMP1/CD40//CD19-cre mice. The increase in accessory 
cells in Notch2IC//LMP1/CD40//CD19-cre mice raises of course the question of the mechanism 
behind the attraction of such cells in the mice. Since the accessory cells as such did not express 
the transgenes themselves which was demonstrated by the fact that they are hCD2neg, the effect 
had to be B-cell-mediated. Indeed it has previously been shown that B cells are not necessarily 
the mere “followers” of inflammatory cues, but in fact can induce inflammation themselves.  
This is illustrated by data gathered by Chu and colleagues (Chu et al., 2011). They generated a 
mouse model with a B-cell-specific knock-out of the ubiquitin-modifying enzyme A20 and 
demonstrated that this led to a hyperactivation of splenic B cells as well as enhanced 
proliferation and survival of the B cells. Furthermore, the mice displayed a surge in inflammation-
related cells such as myeloid cells (i.e. dendritic cells and macrophages), effector T cells as well as 
Tregs in murine spleens. Ultimately these mice exhibit a severe autoimmune syndrome. The 
molecule A20 in fact was found to restrict NF-κB signaling downstream of CD40 (Tavares et al., 
2010). Therefore it is expectable that B-cell specific loss of a negative regulator of CD40 or 
constitutive activation of the receptor can lead to the creation of an inflammatory milieu in the 
spleen of the respective mouse model. This effect seems to be further heightened by 
DISCUSSION 84 
 
constitutively active Notch2, since the mice expressing both transgenes in their B cells still harbor 
more granulocytes and significantly more macrophages in their spleens than LMP1/CD40//CD19-
cre mice alone. 
Interestingly, with regard to LMP1, the viral homologue of CD40 it could also be shown that it can 
have similar effects even outside of the lymphocyte compartment as was shown by Hannigan and 
colleagues (Hannigan et al., 2011). They established a transgenic model of multistage 
carcinogenesis that was induced by epithelial expression of LMP1. Hannigan et al. were able to 
show an influx of innate immune cells such as macrophages and neutrophils in the skin of mice 
along with an increase of soluble molecules and inflammatory factors, such as CXCL10, CXCL13, 
soluble L-selectin and further cytokines. Furthermore, they were able to register that there was a 
significant increase in activated CD8pos and CD4pos T cells including Tregs cells in the dermis of the 
mice.  
Overall the spleens of Notch2IC//LMP1/CD40//CD19-cre mice represent an inflammatory milieu 
with regard to the influx of reactive innate immune cells. In physiological states upon infection 
this is desirable and the milieu would subside when infection resolves. However, in states of 
chronic infection continuous presence of innate immune cells and the sustained release of cyto- 
and chemokines by these cells themselves as well as the additionally attracted lymphocytes 
usually have detrimental effect for the individual’s health. Recently the term “sterile 
inflammation” has been coined describing the situation in which the inciting stimulus might not 
be as harmful to the individual compared to the prolonged “answer” of the immune system 
towards it (Chen et al., 2010; Rock et al., 2010). Indeed, there is a growing body of evidence 
illustrating the link between inflammation and tumorigenesis. Prominent examples are gastric 
cancer which can often be traced back to an initially relatively harmless gastritis induced by 
Helicobacter pylori (Hatakeyama, 2004; Matysiak-Budnik et al., 2006). In the liver chronic 
hepatitis B virus (HBV) infection can similarly induce hepatocellular carcinoma (Farazi et al., 2006) 
and 30-50 % of all hepatocellular carcinoma-related deaths can be attributed to HBV-infection 
(Lavanchy, 2004).  
At this point of course it is not clear whether the presence of the accessory cells actually adds to 
the onset of tumorigenesis or whether they present an innate force that keeps the transgene-
expressing B cells in check. Nonetheless, the increase of myeloid cells in general and granulocytes 
and macrophages in particular rather points towards a tumor-promoting environment.  
Macrophages have long been identified as diagnostic markers for in many solid tumors (Qian et 
al., 2010) and this could also be confirmed with the most recent data from lymphoid tumors with 
regard to FL and cHL where an increase in macrophages numbers was negatively correlated with 
disease outcome (Farinha et al., 2005; Kamper et al., 2011). Of note in the latter study, the high 
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numbers of macrophages were further correlated with presence of EBV in the tumor cell 
population. Considering the data from LMP1/CD40//CD19-cre and 
Notch2IC//LMP1/CD40//CD19-cre this effect of macrophage recruitment towards the tumor is 
likely due to the influence of LMP1 or constitutive CD40 activation. 
Nonetheless, tumor-associated macrophages represent a heterogeneous group (Mantovani et 
al., 2005; Sica, 2010) with diverging roles in tumorigenesis and maintenance: M1 macrophages 
(classically activated cells) are activated upon LPS and IFNγ-encounter (Th1 phenotype) and 
rather initiate cytotoxic T cells for an anti-bacterial, anti-viral and anti-tumor response. This could 
be the case in the spleen of Notch2IC//LMP1/CD40//CD19-cre mice presenting with a tendency 
for high IFNγ-levels in the tissue. On the other hand, M2 macrophages arise from monocytes 
upon IL4-and IL13-stimulus. They can promote angiogenesis, tissue-remodeling and dampen the 
effect of their M1 counterparts (Mantovani et al., 2004a). 
Conventional DCs are increased and have an activated phenotype in the spleen of 
Notch2IC//LMP1/CD40//CD19-cre mice which might hint at a tumor-promoting function by 
attracting and activating T cells and thereby adding to the inflammatory milieu. In epithelial 
tumors it was moreover shown that carcinoma cells may condition local DCs to promote 
proliferation of Tregs (Ghiringhelli et al., 2005). On the other hand DCs can act-tumor-suppressing 
by priming cytotoxic T cells with high efficiency (Steinman et al., 2007). The presence and effect 
of DCs in solid tumors is quite controversially discussed in the literature (Tsujitani et al., 1990; 
Troy et al., 1998; Lespagnard et al., 1999). In the field of lymphoma research immature DCs have 
been proposed to promote survival of malignant T cells (Ni et al., 2011), but mature DCs have 
also been linked to improved clinical outcomes in cohorts of DLBCL patients (Chang et al., 2007). 
It has to be kept in mind that they represent a highly heterogeneous group that can be classified 
by their phenotypes, stages of maturation, degrees of activation and functions and accordingly 
few generalizations can be made. It was not clarified in the thesis at hand whether the spleens of 
Notch2IC//LMP1/CD40//CD19-cre mice harbor more DC subtypes than the detected 
conventional DCs.  
Interestingly, in the older Notch2IC//LMP1/CD40//CD19-cre mice the expansion of the 
macrophages in the spleen is still present, but their presence in numbers can vastly differ 
between individual mice although of the same genotype, hinting at the fact that the long-term 
outcome of constitutively active CD40 and Notch2IC can lead to different results or types of 
tumors and necessitates a “second hit” of signaling deregulation.  
Future experiments should also examine the level of lymphocytes and myeloids in the blood in 
order to clarify whether elevated cell numbers are contained to the spleen or present a systemic 
response to the transgene expression of the B cells. 
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4.2 Notch2IC//LMP1/CD40//CD19-cre mice display an increase of activated T 
cells and increase in the percentage of both central memory as well as 
effector memory T cells in their spleens 
The splenic T-cell population in Notch2IC//LMP1/CD40//CD19-cre mice is significantly larger than 
the already increased B-cell population in these mice. However, predominance of a T-cell over a 
B-cell population cannot be regarded as diagnostic marker of malignancy per se. The atypical 
distribution of CD4pos versus CD8pos T cells however, can count as considerably better criterion 
whether the situation at hand is abnormal. In Notch2IC//LMP1/CD40//CD19-cre mice both T-cell 
subsets were increased in the spleen, however with a clear bias towards the CD8pos 
compartment. In a FACS approach to characterize T-lymphoproliferative disorders Gorczyca and 
colleagues showed that while in concordance with previous data HL displayed a clear tendency 
towards CD4pos T-cell expansion (Gorczyca et al., 2002). On the other hand immunocompromised 
individuals such as HIVpos patients, as well as individuals with certain viral infections such as EBV 
an expansion of an increased number of CD8pos T cells in relation to CD4pos T cells can be 
observed (Borowitz et al., 1982; Weisberger et al., 2003). 
Notch2IC//LMP1/CD40//CD19-cre mice show a distinct up-regulation of CD25 and CD69 in a 
subpopulation of their splenic T cells. Moreover a reduction of the naïve T cells can be observed 
in Notch2IC//LMP1/CD40//CD19-cre mice like in the single transgene-expressing mice. The single 
transgene-expressing controls resemble the Notch2IC//LMP1/CD40//CD19-cre mice also in the 
distribution of splenic T cells with regard to CD44 and CD62L marker expression, more precisely 
in their tendency to adopt an effector phenotype (CD44hi CD62Llow). The down-regulation or 
shedding of CD62L (L-selectin) could be due to a number of reasons. On the one hand, Meijer and 
colleagues were able to identify tumor-specific type 1 T cells from lymph nodes draining an 
autologous tumor cell vaccine that are characterized by reduced CD62L expression (Meijer et al., 
2004). Furthermore, a group around Morgan was able to show that shedding of CD62L occurs 
when T cells encountered specific tumor antigen and it regulates lytic activity in human tumor 
reactive T lymphocytes (Yang et al., 2011). Moreover, myeloid-derived suppressor cells (MDSCs) 
were found to down-regulate CD62L expression on CD4pos and CD8pos T cells (Hanson et al., 
2009). MDSCs represent a population of myeloid cells which -due to interference through tumor-
derived factors- are unable to differentiate into granulocytes, macrophages and DCs and 
accumulate at individual’s blood, in lymphoid organs and at tumor sites and might provide an 
important link between inflammation and cancer (Sinha et al., 2008; Ostrand-Rosenberg et al., 
2009). These cells might be of interest in Notch2IC//LMP1/CD40//CD19-cre mice, since they 
harbor high percentages of myeloid cells in their spleens in general and exhibit a down-regulation 
not only of CD62L but in fact of both CD62L and CD44 in their splenic T cells. However, this would 
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have to evaluated carefully since MDSCs exhibit their tumor promoting function by suppressing 
T-cell activation and proliferation (Bronte et al., 2000; Terabe et al., 2003; Rodriguez et al., 2005; 
Rodriguez et al., 2008). This seems to argue against presence of such cells in 
Notch2IC//LMP1/CD40//CD19-cre mice because of the high splenic T-cell number in these mice. 
However, MDSCs might account for the fact that not all of the T cells in the spleen exhibit high 
levels of the activation markers (CD65, CD25) throughout and as aforementioned they might be 
responsible for the overt down-regulation of both CD62L and CD44.  
The shift from effector T cells (CD62Llow CD44hi) versus CD62Llow CD44 low/neg that is discernible in 
the splenic T cells of Notch2IC//LMP1/CD40//CD19-cre mice could also be observed in 
LMP1/CD40//CD19-cre mice. This observation might indicate exhaustion of T cells.  
Exhaustion is a commonly observed phenomenon for example in sustained viral infections such 
as HIV infection. This was shown to be reinforced by the presence of the inhibitory receptor PD1 
(programmed cell death 1) on T cells (Barber et al., 2006; Blackburn et al., 2009; Mueller et al., 
2010). When testing for PD1 expression via flow cytometric analysis in mice of all genotypes 
tested the obtained results indeed showed a distinct up-regulation of the inhibitory receptor in 
splenic CD4pos T cells of LMP1/CD40//CD19-cre and Notch2IC//LMP1/CD40//CD19-cre mice 
compared to CD19-cre controls (data not shown; CD8pos were not tested). However, this up-
regulation was unexpectedly also observed for Notch2IC//CD19-cre mice. Hence, PD1 up-
regulation might contribute, but does not necessarily lead to the potential T-cell exhaustion in 
LMP1/CD40//CD19-cre and Notch2IC//LMP1/CD40//CD19-cre mice.  
Interestingly, PD1 has been found on T cells only when they are activated (Keir et al., 2008) and it 
has also been implicated in the development of Tregs or inducible iTregs in the periphery. The 
receptor is highly expressed on this cell type and seems to be involved at various levels in 
functioning of (i)Tregs (Polanczyk et al., 2007; Francisco et al., 2009; Francisco et al., 2010; Gotot et 
al., 2012). Hence, PD1 expression or up-regulation of the surface molecule could offer an 
explanation why especially CD8pos T cells display a down-regulation of CD44 and CD62L and also 
why there is an increase in Tregs in the spleen of Notch2IC//LMP1/CD40//CD19-cre mice and 
should be further evaluated in the future.  
4.2.1 Tregs are increased in splenic preparations of Notch2IC//LMP1/CD40//CD19-cre mice 
As shown, Notch2IC//LMP1/CD40//CD19-cre mice display an increase in Tregs in their spleens. Tregs 
are known to play a role in suppressing autoimmunity, but they are also able to dampen anti-
tumor response and are suspected to support tumor immune escape (Kryczek et al., 2009; 
Boursier et al., 2012; Mailloux et al., 2013). All in all, Tregs can be “a double-edged sword”. 
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Considering the impact of Tregs in patients with B-cell lymphomas, those with a high number of 
tumor infiltrating Foxp3pos cells (Tregs) have a better survival than patients with few Foxp3
pos cells 
as was shown for DLBCL, FL and cHL patients (Alvaro et al., 2005; Carreras et al., 2006; Lee et al., 
2008; Tzankov et al., 2008; Wahlin et al., 2010; Koreishi et al., 2010; Kelley et al., 2007). Indeed, 
in the context of B-cell malignancies Tregs seem to have rather tumor-suppressing role owing to 
their physiological role to keep B cells in check and even kill defective B lymphocytes in order to 
prevent autoimmunity (Lindqvist et al., 2012). 
Thus, the presence of these cells in the spleen of the Notch2IC//LMP1/CD40//CD19-cre mice 
could be one of the key factors why these mice develop B-cell tumors rather late in their lifetime 
(from 13 months onward). It will be highly interesting to further evaluate the role of Tregs in the 
Notch2IC//LMP1/CD40//CD19-cre mice: to test for the presence of Tregs particularly in older mice 
and examine whether the expansion of this particular T-cell subgroup is diminished or disappears 
altogether. The presence of B-cell-derived IL10 is vital for the proper development and 
maintenance of Tregs (Carter et al., 2011), moreover B7 proteins (CD80 and CD86) on B cells have 
been implicated to play a role in the development and activation of the T-cell subgroup 
(Tsukahara et al., 2005; Mann et al., 2007). While IL-10 was not found to be up-regulated in 
serum or in splenic B cells themselves, CD80 was up-regulated in splenic B cells expressing both 
transgenes whereas CD86-levels were basically unchanged compared to controls in the young 
mice. Interestingly, these B7 molecules have been suggested to have diverging roles in Treg 
regulation (Zheng et al., 2004): while blockage of CD86 appears to enhance Treg suppressive 
function, blockage of CD80 rather seems to lead to Treg division. This might point towards why 
even high Treg numbers in the mice might not be able to ward off disease in the long run. And 
finally in the old mice CD80 is also up-regulated, which is likely to be unrelated to presence or 
absence of Tregs, since CD80 is also found to be highly expressed on HRS cells (Vooijs et al., 1997). 
As aforementioned, it will be interesting to monitor aged mice particularly for the presence of 
Tregs routinely to examine possible correlation of their presence, absence or decline with the 
onset of tumorigenesis in the Notch2IC//LMP1/CD40//CD19-cre mice. Also, since there is data 
showing that the effect of Tregs in the outcome of disease might be closely linked with the 
composition of cells in the respective tumor infiltrate (Schreck et al., 2009) this will have to be 
evaluated in relation to a panel of analysis regarding the presence of different subtypes of 
accessory cells in the aged Notch2IC//LMP1/CD40//CD19-cre mice .  
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4.3 Concomitant expression of constitutively active Notch2IC and CD40 has 
synergistic effects on spleen size and activation status of the splenocytes 
Spleens of Notch2IC//LMP1/CD40//CD19-cre animals are significantly larger and heavier than all 
control counterparts, which is an additive effect of the constitutively active signaling of CD40 and 
Notch2IC in the B cells of these mice. Any de- or increase in size and weight of the organ is 
influenced by basically two factors: A) activation status of the splenic cells which influences cell 
size and which can also be linked to cell type and B) actual cell number.  
Notch2IC//LMP1/CD40-expressing splenic B cells are activated with regard to their levels of 
activation markers -i.e. CD80 and ICAM. This finding can be attributed to expression of both 
transgenes in the B cells. It is known that activation of cells also leads to an increase in cell size. 
LMP1/CD40-expressing splenic B cells were previously shown to display a shift in various 
activation markers (of which CD95 is specific for LMP1/CD40 expression in the cell) and 
accordingly they display an increase in cell size. Moreover, these mice exhibit an increase both in 
the splenic B- and T-cell numbers. With regard to Notch2IC//CD19-cre mice, B cells are also 
activated but in this case this is probably primarily due to the fact that these splenic B cells –as in 
mice expressing both transgenes- adopt a MZ B-cell phenotype and MZ B cells are inherently pre-
activated. This also explains the slight, but significant splenic weight difference between CD19-
cre and Notch2IC//CD19-cre mice, even though the splenic B- and T-cell compartments are not 
expanded in these mice. The overall increase in splenic size in Notch2IC//LMP1/CD40//CD19-cre 
mice can be attributed to the impact of constitutive CD40 signaling on the lymphocyte 
compartment leading to an increase of both B- and T-cell compartments and additionally of the 
macrophage and granulocyte numbers in their spleen, as well as the B-cell size, which is 
increased due to their activation status. Cell size and increased activation are also due to 
Notch2IC-induced MZ B-cell phenotype of the Notch2IC//LMP1/CD40-expressing B cells. 
4.4 Marginal zone B cells are expanded in Notch2IC//LMP1//CD40//CD19-cre 
mice at the expense of the follicular B-cell population 
It is by now a well-established fact that Notch plays a role in MZ B-cell development (Tanigaki et 
al., 2002; Saito et al., 2003; Kuroda et al., 2003; Hozumi et al., 2004; Hampel et al., 2011). 
Therefore it was not unexpected that both in Notch2IC//CD19-cre and 
Notch2IC//LMP1//CD40//CD19-cre mice this population of mature B cells is expanded at the 
expense of Fo B cells, with regard to CD21/CD23-, IgM/IgD- and CD1d-status.  
Both in vitro and in vivo studies have shown that Notch signaling enhances expression of 
CD21/35 in B cells (Saito et al., 2003; Strobl et al., 2000). The mechanism behind this being the 
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fact that the first intron of the murine CD21 gene has three regulatory RBP-J sites and the 
commitment to high CD21 levels have been suggested to let the B cells develop into MZ B cells 
(Makar et al., 2001; Zabel et al., 2002).  
MZ B cells are suggested be mostly generated from the T1 transitional stage, but are also thought 
to develop from T2 B cells and pre-MZ B cells (Pillai et al., 2005). T2 and pre-MZ B cells down-
regulate surface expression of CD23 as they differentiate into MZ B cells. In the physiological in 
vivo situation this is likely to be supported by ADAM 10, the metalloproteinase that accounts for 
the S2 cleavage of the Notch receptor and thereby initiates Notch signaling cascade. Moreover, 
ADAM10 leads to shedding of CD23 as shown by both in vitro and in vivo studies (Weskamp et 
al., 2006; Lemieux et al., 2007; Gibb et al., 2010), further defining the MZ B-cell phenotype and 
amplifying it by inducing Notch signaling. 
LMP1/CD40-expressing B cells with regard to CD21/CD23 surface marker rather display an MZ B-
cell-like phenotype, whereas Notch2IC-expressing B cells do not only present with a MZ B-cell 
phenotype but they are almost CD23neg. Therefore, additional expression of constitutive CD40 in 
B cells aside from constitutive expression of Notch2 leads to an attenuation of this almost “overt” 
MZ B-cell phenotype in Notch2IC//LMP1//CD40//CD19-cre mice. Splenic B cells expressing both 
transgenes indeed rather resemble MZ B cells of CD19-cre controls. Also, LMP1/CD40 signaling 
leads to different localization cues in splenic B cells compared to constitutive Notch2 signaling 
alone. This shall be further discussed in the next chapter.  
4.5 Splenic architecture is grossly disrupted in Notch2IC//LMP1/CD40//CD19-cre 
mice 
In the FACS analysis the B cells of LMP1/CD40//CD19-cre mice appear to have an MZ B-cell-like 
phenotype. Nonetheless, for the majority the B cells in these mice were still able to reside within 
the follicle. The border separating follicle from MZ can -in IHC analysis- be optically determined 
by the localization of MOMA1pos macrophages. These are already quite dispersed in spleens of 
LMP1/CD40//CD19-cre in contrast to CD19-cre and Notch2IC//CD19-cre mice, which might hint 
at a very mild disruption of structure and a very low difficulty of the B cells to localize properly. 
Notch2IC-expressing B cells display a clear MZ B-cell phenotype at the expense of Fo B cells, both 
in the FACS analysis results as well as with regarding to the localization of the B cells in the actual 
MZ. Surface marker expression in Notch2IC//LMP1/CD40//CD19-cre mice as shown in the FACS 
analysis- suggests that B cells expressing both transgenes exhibit a clear MZ B-cell phenotype and 
did not insinuate a diffuse splenic structure as observed in the IHC staining. However, the splenic 
architecture of Notch2IC//LMP1/CD40//CD19-cre mice is very unique with still high number of B 
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cells residing in the Fo zone despite the MZ marker expression profile on the one hand and loss of 
defined T- and B-cell zones on the other. 
CXCR4 is known to be responsible for homing of B cells to the bone marrow (Petit et al., 2002). 
CXCR4-deficient mice are impaired in B-lymphopoeisis, myelopoeisis and unable to produce 
normal numbers of viable mature B cells (Ma et al., 1998; Nie et al., 2004). CXCR4 was previously 
not reported to influence the MZ versus Fo B-cell lineage decision (Nie et al., 2004). This was 
underlined by the data presented in this thesis finding no noticeable difference in expression 
level between Fo and MZ B cells in control mice. However, the difference in expression levels 
between LMP1/CD40-expressing splenic B cells and Notch2IC-expressing splenic B cells were 
quite large and considering the localization of the majority of B cells in the respective mouse 
(LMP1/CD40-expressing rather in the Fo; Notch2IC-expressing rather in the MZ), there could be a 
however complex connection between these observations (CXCR4 level and localization of B cells 
in the spleen). However, this positional information conveyed by CXCR4 is lost in splenic B cells 
expressing both transgenes, since they express intermediate level between Notch2IC- and 
LMP1/CD40-expressing B cells. This could add to the effect that these B cells despite their MZ B-
cell phenotype rather reside in the Fo area. It would be interesting to determine the level of the 
CXCR4 ligand SDF1 (stromal-derived factor1) in the cells of the red pulp where SDF1 level are 
usually high (Cyster, 2005). This could deliver clues as the actual positional clues that 
Notch2IC//LMP1/CD40-expressing splenic B cells are actually exposed to with regard to CXCR4 
signaling. 
The evaluation of normal CXCR4 levels in correlation with low serum levels of the ligand SDF1 (i.e. 
lower than in the CD19-cre controls and single transgene expressing mice) might also account in 
part to the low B-cell numbers in inguinal lymph nodes and low numbers of recirculating B cells in 
the bone marrow. Yet, this still leaves low numbers of Notch2IC-expressing B cells in the 
aforementioned compartments unexplained. 
Another factor that could have implications for the localization of splenic B cells is LTβ, which was 
found up-regulated with regard to its mRNA levels both in LMP1/CD40-expressing and in 
Notch2IC//LMP1/CD40-expressing B cells. In physiological conditions signaling disruption via the 
LTα/β complex leads to severe impairment in development even complete loss of secondary 
lymphoid organs (Rennert et al., 1996; De Togni et al., 1994). The signaling axis is also important 
during the remodeling of lymphoid tissue during viral infections and the process is mediated by B 
lymphocytes (Kumar et al., 2010). More precisely loss of LTβ signaling leads to loss of splenic MZs 
marginal zones and T/B-cell segregation (Futterer et al., 1998). Inversely, adverse effects could 
also be anticipated if LTβ expression is unusually high as found in splenic B cells of 
LMP1/CD40//CD19-cre and Notch2IC//LMP1/CD40//CD19-cre mice.  
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This leads to the other aspect of abnormal splenic architecture in these mice. As aforementioned 
it is not only an open question why the B cells expressing both transgenes do not localize strictly 
in the MZ according to their surface marker expression, but also what is the reason for the loss of 
a defined T/B-cell zone. Also under this aspect it would be valuable to examine the increased LTβ 
level since the engagement of LTβR on splenic stroma cells prompts them to release further 
cytokines such as CCl21. CCL21, like CCL19, is a ligand for CCR7. CCR7 level and those of its 
ligands play an important role both for B- as well as T cells in order to localize properly in the 
spleen (Forster et al., 1999; Luther et al., 2000; Okada et al., 2007). In fact this receptor although 
it is only subtly expressed on B cells enables them -along with CXCR4 and CXCR5- to leave the 
blood stream and to enter secondary lymphoid tissues such as lymph nodes and intestinal 
Peyer’s patches (Okada et al., 2002; Ebisuno et al., 2003). Moreover, it can be hypothesized that 
the loss of structure contributes to the activation of the B- and especially the T cells, since the 
region of interaction between the lymphocytes is not limited to the T/B-cell border. 
4.6 Notch2IC//LMP1/CD40//CD19-cre mice show distinct changes in the 
expression level of cyto- and chemokines in serum and splenic B cells 
CXCR3 and IL13rα1, IL2Rγ, LTβ and TGFβ mRNA levels in splenic B cells of 
Notch2IC//LMP1/CD40//CD19-cre mice were found to be differentially up-regulated by Notch2IC 
and LMP1/CD40. Cyto- and chemokines that were up-regulated on mRNA level particularly in 
Notch2IC-expressing B cells were CXCR3 and IL13Rα1. The cyto- and chemokines that were up-
regulated particularly in LMP1/CD40-expressing B cells and to a lesser degree in 
Notch2IC//LMP1/CD40-expressing B cells were IL2Rγ, LTβ and TGFβ. 
Notch2IC//LMP1/CD40//CD19-cre mice furthermore show an up-regulation of CXCL9 and CXCL10 
and IL16 in serum compared to all other genotypes.  
It effect that the up-regulation of the mRNA levels of interleukin receptor subunits IL13Rα1 and 
IL2Rγ has in splenic B cells of Notch2IC//LMP1CD40//CD19-cre mice is probably complex, since 
both are subunits function as part of a number of different ILRs. IL13R mediates both IL13 as well 
as IL4 signaling. Both IL4 and IL13 were shown to have anti-inflammatory capabilities, e.g. they 
have been related to the protection of pancreatic β-cells (Zaccone et al., 1999; Kaminski et al., 
2007) and the prevention of destructive insulitis (Rabinovitch et al., 1998). However IL4 is also a 
potent B-cell stimulus necessary for class switching and B-cell proliferation (Mandler et al., 1993; 
Rush et al., 2002; Kim et al., 2007). IL2Rγ on the other hand is also known as the common γ-chain 
and is part of the respective ILR mediating IL2-, IL4-, IL7-, IL9-, IL15- and IL21-responses (Takeshita 
et al., 1992; Russell et al., 1993; Asao et al., 1993; Sugamura et al., 1995; Asao et al., 2001), which 
DISCUSSION 93 
 
are involved in a number of developmental processes not only in B cells, but also T- and NK cells. 
Taken together these findings of higher subunit level suggest an increased responsiveness of 
Notch2IC//LMP1/CD40-expressing B cells towards further cytokine stimulation.  
TGFβ has been implicated to play a role in numerous biological processes, i.e. cell growth, 
inflammation, matrix synthesis and apoptosis (Taipale et al., 1998). With regard to tumorigenesis 
in solid tissues TGFβ has been implicated in metastasis and angiogeneisis (Yu et al., 2000; Padua 
et al., 2009). On the other hand, in the context of B-cell lymphoma it has been shown to induce 
growth arrest (Bakkebo et al., 2010), moreover TGFβ has also been implicated in recently 
discovered regulatory function of B cells in the tumor environment (Yang et al., 2010). The latter 
rather points towards a counter reaction to overt B-cell activation and proliferation in the 
LMP1/CD40//CD19-cre and Notch2IC//LMP1/CD40//CD19-cre animals. 
LTβ is likely to have implications in the localization of Notch2IC//LMP1/CD40-expressing B cells as 
laid out in the previous section. Furthermore, signaling via the LTβ receptor in classical DCs has 
been shown to be of importance in their development (Kabashima et al., 2005). Blocking the 
pathway also leads to an decrease in Tregs but also inflammation in mice treated with a receptor 
antagonist (Nakayama et al., 2012). Considering this, overt LTβ signaling -besides its implications 
in T/B-cell positioning- might be a contributing factor leading to the surge in Tregs and DCs in the 
spleen of Notch2IC//LMP1/CD40//CD19-cre mice. Moreover a role for this signaling pathway has 
been proposed in establishing a lymphoma-supporting niche in the spleen fostering a 
microenvironment with the involvement of various cell types as observed in cHL (Kuppers, 2011; 
Rehm et al., 2011). 
Along the lines of accessory cell recruitment one can interpret the data for increased IL16 serum 
levels. IL16 is a chemoattractant for all CD4-expressing cells. It is a cytokine that can as well 
attract myeloid cells, DCs, macrophages and other cell types as was observed in the spleens of 
Notch2IC//LMP1/CD40/CD19-cre animals. Furthermore, IL16 is able to induce up-regulation of 
IL2R (CD25) on T cells (Parada et al., 1998). Therefore it can influence T-cell dynamics 3-fold: it 
can lead to a better reactivity towards T-cell-activating IL2, and lead to both the increase in 
CD25pos T cells as well as the overall increase of Tregs (which are CD25
pos).   
 
Most interestingly is probably the finding of increased CXCR3 mRNA level in splenic B cells as well 
as increased serum level of CXCL9 and CXCL10 (its ligands) in the Notch2IC//LMP1/CD40//CD19-
cre mice liking data from the mRNA and serum analysis 
Although hardly detectable on Fo B cells, CXCR3 is known to be higher expressed on MZ B cells, 
which is in line with the higher level of the receptor in Notch2IC- and 
Notch2IC//LMP1/CD40//CD19-cre mice that display a MZ B-cell phenotype. This was further 
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underlined by results of an mRNA array by Stefanie Ehrenberg from our lab (personal 
communication). Therefore, it is not so surprising that the level of the receptor are also high in B-
cell lymphomas associated with this particular entity of mature B cells i.e. the MZ B cells. For 
example, strong expression of CXCR3 was observed patients with B-CLL, FL, in SMZL and in the 
monocytoid and plasmacytic cells in extranodal marginal zone lymphoma (Jones et al., 2000; 
Ohshima et al., 2003). 
The level of ligands for CXCR3, i.e. CXCL11, CXCL10 and CXCL9 are increased in serum of 
Notch2IC//LMP1/CD40//CD19-cre mice. Together they form a group of homologous proteins that 
elicit their chemotactic function via binding to the G-protein-coupled receptor CXCR3 (Loetscher 
et al., 1996; Luster et al., 1995; Lasagni et al., 2003). CXCR3 is also rapidly induced on naïve T cells 
following activation (Groom et al., 2011). In fact, engagement of CXCR3 facilitates the shift of 
CD8pos cells towards differentiation into effector cells (Kurachi et al., 2011). Receptor blockage via 
an agonist leads to strong inhibition of the migration of T cells and the role of CXCL10 and CXCL9 
in the recruitment of effector T lymphocytes to sites of inflammation has been documented 
(O'Boyle et al., 2012). Moreover, these cytokines are secreted not just by T cells through a 
positive feedback loop but CXCL9 and CXCL10 are also produced by DCs, B cells, and 
macrophages (Park et al., 2002) and the receptor was also found on endothelial cells and in 
infiltrating lymphocytes with an activated phenotype in inflammatory diseases. The fact that the 
ligands can be produced by B cells as well combined with the fact of higher level of their receptor 
strongly supports the hypothesis of a positive feedback loop in Notch2IC- and 
Notch2IC//LMP1/CD40//CD19-cre mice. Interestingly, CXCR3 is expressed by certain DC subsets, 
specifically myeloid-derived CD11cpos cells in normal and inflammatory conditions (Garcia-Lopez 
et al., 2001). This supports the findings that there is a distinct increase in accessory cells such as 
macrophages and CD11cpos DCs of an activated phenotype in the Notch2IC//LMP1/CD40//CD19-
cre mice due to systemic presence of these ligands. Up-regulation of CXCR3 in splenic B cells 
compliments the high serum level of its ligands in these mice and might help to establish and 
maintain the inflammatory milieu in these mice and maybe even the MZ B-cell phenotype.  
 
A factor that was synergistically down-regulated in serum of Notch2IC//LMP1/CD40/CD19-cre 
mice was CXCL12, also termed SDF1 which is a homeostatic chemokine. The major function of 
this chemokine is to regulate hematopoietic cell trafficking, since it induces intracellular actin 
polymerization needed for cell motility (Bleul et al., 1996) and also secondary lymphoid tissue 
architecture (Teicher et al., 2010). The chemokine has two receptors, i.e. CXCR4 and CXCR7, the 
former of which was not found to be down- or up-regulated in splenic B cells of 
Notch2IC//LMP1/CD40//CD19-cre compared to CD19-cre animals, but found to be up-regulated 
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in Notch2IC//CD19-cre and down-regulated in LMP1/CD40//CD19-cre mice. In the spleen CXCL12 
is mainly found in the red pulp (Cyster, 2005), and its down-regulation with constant CXCR4-
levels might contribute to the positioning defects observed in the spleen of 
Notch2IC//LMP1/CD40//CD19-cre mice.  
It would be highly interesting to evaluate the cyto- and chemokine profile of the splenic cells in 
situ in order to decipher the respective contribution of the different cellular compartment that 
were found to be expanded in mice expressing both transgenes in their B cells.  
4.7 Notch2IC//LMP1/CD40-expressing splenic B cells show an increased 
proliferation in in vitro culture regardless of the supply of stimuli 
Many of the parameters that were examined in the Notch2IC//LMP1/CD40//CD19-cre mice were 
clearly due to the expression of one or the other transgene, for example the MZ B-cell phenotype 
is an effect that can be clearly be attributed to constitutively active Notch2IC in the B cells of 
these animals. By contrast, the effect concomitant expression of both transgenes in the splenic B 
cells has on their proliferative behavior is derived from both LMP1/CD40 and Notch2IC signaling.  
As has been shown before Notch can convey proliferative signals to the cell in which it is 
expressed, however activity of the pathway also leads to apoptotic signals (Kohlhof et al., 2009). 
This outcome can differ depending on cell type and potential disease state. On the one hand 
pharmacological inhibition of the Notch pathway can lead to apoptosis in immortalized Kaposi’s 
sarcoma and B-CLL cells (Curry et al., 2005; Rosati et al., 2013) and Notch inhibition has been 
discussed as a possible approach in treatment of cancer especially with regard to subduing 
cancer stem cells (Purow, 2012). On the other hand Notch2 signaling was found to sensitize 
endothelial cells to apoptosis through negative regulation of apoptosis regulator Survivin 
(Quillard et al., 2009), to induce apoptosis in neural progenitor cells through a p53-dependent 
pathway (Sakurada et al., 1992). Generally, Notch signaling has been recognized as a powerful 
initiator of growth arrest and apoptosis in a number of B-cell malignancies (Zweidler-McKay et 
al., 2005). In the data presented here it could also be observed that Notch2IC-expressing splenic 
B cells survived less well in in vitro culture without stimulus than LMP1/CD40-expressing splenic B 
cells or B cells expressing both transgenes. However, the results of the BrdU analysis also showed 
a high percentage of Notch2IC-expressing B cells in S-phase of the cell cycle which underlines that 
Notch signaling strongly supports the proliferation of the splenic B cells. The proliferative state of 
Notch2IC-expressing cells is in line with data showing that Notch can in fact induce a number of 
cell cycling genes such as CyclinE1, CyclinE2, CyclinA2 and CDK6 (cyclin-dependent kinase6) and 
CDK4 (Kohlhof et al., 2009). Moreover, Notch is known to induce the transcription factor c-myc, 
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which plays a key role in inducing cell cycle regulation, proliferation and growth (Palomero et al., 
2006). C-myc is deregulated in a number of cancers, in the field of hematopoietic malignancies it 
is probably best characterized for its Notch-induced role in T-ALL (Weng et al., 2006; Riz et al., 
2010) and Burkitt lymphoma (Li et al., 2003; Mirandola et al., 2009).  
CD40 is vital for the growth, survival and differentiation processes of the B cell (Gordon, 1995; 
Kehry, 1996) and has moreover shown to also enhance survival in DCs and other cells (van 
Kooten et al., 1997), it can also induce apoptosis in hepatocytes through up-regulation of CD95 
(Afford et al., 1999; Afford et al., 2001). These effects can be overpowered by TRAF-signaling-
induced up-regulation of the anti-apoptotic proteins Bcl-xL and Bfl-1/A1 that is NF-κB-mediated 
(Lee et al., 1999).  
In the in vitro culture one could clearly see the survival advantage LMP1/CD40-expressing B cells 
had over Notch2IC-expressing B cells, due to the effects of constitutively active CD40 relaying 
strong survival signals to the B cell. However, with regard to their proliferation state or more 
precisely the percentage of strongly proliferating B cells in S-phase they actually lagged behind 
Notch2IC-expressing B cells. Examining the dynamics of cell cycle and survival of B cells of 
Notch2IC//LMP1/CD40//CD19-cre mice one can observe the synergies that arise from the 
combination of both constitutively active CD40 and Notch2IC: While these B cells display better 
overall survival (CFSE- and Topro-3-staining data) without any stimulus, they display higher 
percentages of B cells that are actively cycling in S-phase of the cell cycle (BrdU data), leading in 
the sum to proliferation rates surpassing those of all genotypes tested in parallel. 
At this point one can only hypothesize as to what the exact mechanisms behind these 
proliferative capacities are. As aforementioned c-myc is a potential candidate, but this should be 
evaluated carefully. A further candidate for evaluation would be the cell cycle regulator p53 for 
which Notch1 has been described to be a target and various crosstalk levels between the two 
signaling pathways have been suggested (Dotto, 2009; Wickremasinghe et al., 2011; Roemer, 
2012). p53 could also be regulated by active CD40 signaling as has been shown for multiple 
myeloma cell lines (Teoh et al., 2000; Tai et al., 2002).  
4.8 Aged Notch2IC//LMP1/CD40//CD19-cre mice are prone to develop B-cell 
lymphomas 
With regard to B-cell lymphoma development one year-old LMP1/CD40//CD19-cre mice started 
to develop lymphomas with a high incidence, whereas with one year none of the 
Notch2IC//CD19-cre mice developed obvious signs of lymphoma (Homig-Holzel et al., 2008; 
Hampel et al., 2011), which implies that in contrast to constitutively active CD40, constitutively 
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active Notch2 signaling alone is not sufficient to drive B-cell lymphomagenesis. However, as seen 
in the in vitro data the combination of both transgenes greatly enhances proliferation and 
survival of the cells. And in fact, although the test population that was kept for long-term 
observation was rather small, it seems that these mice also develop lymphomas with a high 
incidence: since three out of five mice showed a vast increase in the lymphocyte compartment 
and two out of five mice could be diagnosed with a monoclonal expansion of their splenic B-cell 
population. However, although the Southern blot did not deliver definite confirmation for the 
expansion of several B-cell clones in the other mice, does not confirm their absence. Especially in 
the aged mice with low B cell numbers the method of Southern blot analysis might not be 
sensitive enough to detect several, maybe more subtle expansion of B cells with different 
clonalities. This is indeed the case in cHL, where only a fraction of the tumor mass consists of the 
actual lymphoma cells which are surrounded by large numbers of various accessory cells. 
Furthermore, it is conceivable that some of the mice developed T-cell lymphoma. Already in 
young mice the splenic T-cell population is expanded and activated and is still present in the aged 
Notch2IC//LMP1/CD40//CD19-cre mice. Therefore, these aged mice should be examined for the 
presence of T-cell tumors. This could be accomplished via special probes for the TCR similar as 
done for the IgH-locus in the B cell of the whole cell preparations in Southern blot analysis. In a 
faster approach the clonality of T cells of aged mice could be characterized by FACS analysis with 
regard to their TCR-Vβ chain repertoire (Pechloff et al., 2010). Similar to the young mice the old 
mice shall be routinely examined for presence and status of accessory cells.  
Interestingly, a staining for the reporter cell surface marker hCD2 revealed that only in two out of 
the five mice tested, the splenic B-cell population displayed a large percentage of hCD2pos B cells. 
This might be an indication that although Notch2IC//LMP1/CD40//CD19-cre mice in contrast to 
the control mice did develop overt hyperplasia, that the expression of the transgenes (which can 
be monitored by staining for surface hCD2) might provide the tipping point towards lymphoma 
development but might not be necessary to be maintained afterwards.  
Furthermore, the fact that all splenic B cells of aged Notch2IC//LMP1/CD40//CD19-cre mice -with 
exception of CD80 and CD86- showed a great diversification of surface markers, might be 
suggestive of a higher than detected tumor incidence. In the tumors observed in 
LMP1/CD40//CD19-cre mice (Homig-Holzel et al., 2008) all mice exhibited differential activation 
of examined signaling pathways.   
Another crucial point to consider when evaluating the observed tumor incidence in mice is the 
weight of the spleen, since one of the aged mice with a tumor detectable by Southern blot did 
not exhibit increased splenic weight nor overtly increased B-cell numbers (# 1779). This might 
hint at the fact that a number of tumors might have gone unnoticed in the young mice simply 
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because they did not manifest themselves with an overt splenomegaly. Therefore, mice that are 
considerably younger than 12 months of age should be routinely checked for tumor 
development. 
With regard to the increase of accessory cells and especially the Tregs in the younger mice and the 
potential impact they are having, i.e. whether they act rather tumor-promoting or tumor-
suppressing, it will be of utmost importance to examine the outgrowth behavior of B cells 
transplanted into NSG mice (i.e. NOD/LtS z-scid IL2Rγnull or NOD/SCID/γ mice). These have no T-, 
B- and NK cells and moreover many defects in the innate immune compartment (Shultz et al., 
2005). Consequently, they rank amongst the most immunodeficient strains of mice. If the onset 
of tumorigenesis is accelerated, these transplantation experiments could provide valuable hints 
as to whether the onset of B-cell lymphoma is kept in check by innate immune cells and T cells. 
Together with further analysis of the chemo- and cytokine panel of these accessory cells this 
could provide a rather comprehensive picture of the mechanisms at work concerning 
tumorigenesis due to deregulated CD40- and Notch2IC-signaling in vivo. 
4.9 Aged Notch2IC//LMP1/CD40//CD19-cre mice develop salivary gland 
carcinomas 
Apart from the observed B-cell lymphomas the old Notch2IC//LMP1/CD40//CD19-cre mice also 
develop salivary gland carcinomas, this phenomenon had also been observed for aged 
LMP1/CD40//CD19-cre mice by former colleagues C. Hoemig-Hoelzel and C. Hojer (unpublished 
data). Like in LMP1/CD40//CD19-cre mice carcinoma development in 
Notch2IC//LMP1/CD40//CD19-cre mice seemed rather independent of whether these mice also 
developed an overt B-cell lymphoma or not. Some old Notch2IC//CD19-cre mice also showed 
hyperplasia in their SGs, however with a much lower incidence and the animals were older (> 18 
months; S. Ehrenberg, personal communication); therefore, it was assumed that the SGT 
development was majorly a CD40-mediated event.  
The question is however, whether tumorigenesis in the SGs is a B-cell-mediated effect or whether 
there was an aberrant expression of LMP1/CD40 or rather Notch2IC//LMP1/CD40. Both scenarios 
seem equally likely since CD40 rather conveys survival promoting qualities to the expressing 
epithelial cell and on the other hand overt activation of the lymphocyte compartment -as seen in 
chronic inflammation- can in fact lead to cancer (Coussens et al., 2002). Unfortunately, with the 
data at hand the question what the causative behind carcinogenesis could not be resolved 
unambiguously. 
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CD40 was originally identified as a B-cell costimulatory receptor and a tumor-antigen expressed 
in bladder carcinoma (Paulie et al., 1985) and the transforming capacity of LMP1 –the viral 
homologue of CD40- was first shown in rodent fibroblasts (Wang et al., 1985; Baichwal et al., 
1988; Moorthy et al., 1993). Moreover, initial studies on the functions of CD40 have been 
primarily performed in transiently transformed epithelial cells since B lymphocytes used to be 
more challenging to manipulate experimentally, thereby it became obvious that the functions of 
CD40 can vary depending on the cell type in which it is expressed. The function of active CD40-
signaling in an epithelial cell context has been well-characterized, but even within the same 
compartment the outcome of CD40 expression can vary. On the one hand activity of the CD40 
pathway can contribute to the proinflammatory function of intestinal epithelial cells in 
pathological states like inflammatory bowel disease and expression of its viral homologue LMP1 
is closely associated with nasopharyngeal cancer, it can promote cell survival through activation 
of the phosphatidylinositol 3-(PI3) kinase/Akt pathway and inhibit epithelial cell differentiation 
(Dawson et al., 1990; Raab-Traub, 2002; Dawson et al., 2003; Lo et al., 2004; Borcherding et al., 
2010). Moreover, the SGTs under investigation were all carcinomas with a low differentiation 
degree resembling a human neoplasm called “lymphoepithelioma-like carcinoma of the 
submandibular salivary gland associated with Epstein-Barr virus” (L. Quintanilla-Fendt, personal 
communication). Furthermore, the high tumor incidence in the mice, the fact that a considerable 
portion of the tumor tissue displayed the deletion of the stop cassette (Southern blot data), the 
high presence of hCD2 while B cells were virtually absent from the tumor sites, all argue in favor 
of a temporarily ectopic expression of the Cre-recombinase (Schmidt-Supprian et al., 2007), 
leading to deletion of the stop-cassette and ultimately to tumorigenesis due to the growth 
promoting effects of CD40.  
When evaluating the hypothesis that SG tumorigenesis could be due to a B cell intrinsic effect we 
could actually identify a possible human correlate called Sjogren’s syndrome. Sjogren’s syndrome 
is an autoimmune disease which is characterized by obstruction of the lacrimal and salivary 
glands. This is accompanied among other symptoms by parotitis (i.e. an inflammation of the 
major SG) and its most serious complication of Sjogren’s is the development of non-HL (Johnsen 
et al., 2012). B cells have been shown to play a pivotal role in this disease (Mackay et al., 2007; 
Coca et al., 2009). A number of models have been developed which try to facilitate studying the 
diverse aspects of the disease in mice (Delaleu et al., 2011). The model proposed by Qian and 
colleagues displays similarities with Notch2IC//LMP1/CD40//CD19-cre mice (Qian et al., 2008). 
Qian et al. showed that genetic deficiency of a negative regulator (Act1) of CD40 and B-
lymphocyte-activating factor (BAFF) leads to development of Sjogren's syndrome in those mice. 
This is manifested by an overall increase in B-cell number in those mice, hyperactivation and 
DISCUSSION 100 
 
enhanced survival of B cells, enlarged lymph nodes and SGs. All these features are also found in 
Notch2IC//LMP1/CD40//CD19-cre mice. Howver, Qian et al., also found α-La-, as well as α-Ro 
autoantibodies in the sera of the knock-out mice. The presence of these could not expected in 
LMP1/CD40//CD19-cre or Notch2IC//LMP1/CD40//CD19-cre mice, since these transgenic mice 
are impaired in their Ig isotype switching.  
Nonetheless, the involvement of B cells as mediators cannot be ruled out categorically, if only as 
mediators of inflammation. Another point to consider is that even though no B cells were found 
in the SG of Notch2IC//LMP1/CD40//CD19-cre mice, B cells have been demonstrated to exert 
procarcinogenic capabilities even distal from the site of tumor origin as demonstrated by de 
Visser and colleagues (de Visser et al., 2005).  
Considering the strong hCD2 staining in the SGTs one has to keep that expression of CD2 can be 
up-regulated in basal cell carcinoma, human urogenital system and in adult kidney tumours 
(Taylor et al., 1990; Tienari et al., 2005) and has been implicated in mutagenesis in human 
embryonic carcinoma cells (Do et al., 2009). Therefore strong expression of hCD2 could rather be 
a consequence of carcinomagenesis in the SGT cells and not marker of transgene expression.  
The SGs seem a peculiar organ to develop tumors, however it is conceivable that this organ even 
when mice kept in ultra-clean conditions is still exposed to certain amounts of antigen, similar as 
Peyer’s patches in the intestines of the animals. Again, antigenic insult would rather hint towards 
involvement of B cells in development of SGT.  
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5. SUMMARY 
CD40- and Notch-receptor signaling were found to be deregulated in a number of tumors such as 
Hodgkin lymphoma. Mice expressing either one of the receptors in a constitutively active form 
and B-cell-specific fashion have previously been established and characterized in our lab 
(LMP1/CD40//CD19-cre and Notch2IC//CD19-cre; Homig-Holzel et al., 2008; Hampel et al., 2011). 
In order to study the effects of the constitutive activation of both receptors in B cells in an in vivo 
setting, mice expressing constitutively active Notch2 and mice expressing constitutively active 
CD40 were cross-bred so that offspring concomitantly express both receptors in a CD19-
dependent and hence B-cell-specific manner. This resulted in the Notch2IC//LMP1/CD40//CD19-
cre. All mouse analyses were carried out with aged-matched CD19-cre, Notch2IC//CD19-cre and 
LMP1/CD40//CD19-cre as controls. 
Notch2IC//LMP1/CD40//CD19-cre mice display a significant increase in splenic size and weight. 
There was a significant increase in total splenic cell numbers and splenic B-cell numbers in 
Notch2IC//LMP1/CD40//CD19-cre compared to CD19-cre and Notch2IC//CD19-cre mice, 
however splenic B-cell numbers were significantly lower than in LMP1/CD40//CD19-cre mice. 
Therefore, it was evaluated what other cell types contribute to the enlarged spleen and increased 
total cell numbers. 
Increased numbers of accessory cells, namely myeloid cells, macrophages, granulocytes and 
dendritic cells could be identified in spleens of Notch2IC//LMP1/CD40//CD19-cre mice. 
Moreover, these mice display significantly increased numbers of splenic T cells compared to 
controls. The T cells in the Notch2IC//LMP1/CD40//CD19-cre mice display an enhanced 
expression of the T-cell activation markers and an increase in the percentage of both central 
memory, as well as effector memory T cells. Furthermore, regulatory T cells (Tregs) that represent 
important regulators of cellular immune responses are increased in spleens of 
Notch2IC//LMP1/CD40//CD19-cre mice. 
Mice of the Notch2IC//LMP1/CD40//CD19-cre genotype exhibit a partial block in early B-cell 
development between pre- and immature B cell stage in the bone marrow, probably due to 
deleterious effects that early expression of both transgenes has on the developing B cell. 
Considering the pool of mature B cells in Notch2IC//LMP1/CD40//CD19-cre animals they display - 
like Notch2IC//CD19-cre mice - an expansion of the marginal zone (MZ) B cells and decrease of 
the follicular (Fo) B cells as determined by flow cytometric analysis. Although they unambiguously 
display MZ B-cell surface marker expression, the splenic architecture was observed to be 
disrupted in Notch2IC//LMP1/CD40//CD19-cre mice with very diffuse B- and T-cell zones. Distinct 
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changes in the expression of cyto- and chemokines in Notch2IC//LMP1/CD40//CD19-cre mice 
(both with regard to mRNA levels of the respective splenic B cells as well as serum levels) could 
be contributing to this. There was an up-regulation of CXCL9 and CXCL10 in serum and an 
increase of CXCR3 and IL13 receptor α1, IL2 receptor γ, Lymphotoxin β and Transforming Growth 
Factor β mRNA levels in splenic B cells of Notch2IC//LMP1/CD40//CD19-cre mice in comparison 
to all other genotypes.  
Generally the splenic B cells of Notch2IC//LMP1/CD40//CD19-cre mice display an activated 
phenotype and better survival in culture than Notch2IC-, but not than LMP1/CD40-expressing B 
cells. B cells of Notch2IC//LMP1/CD40//CD19-cre mice display enhanced proliferation in in vitro 
culture surpassing that of splenic B cells expressing either Nocth2IC or LMP1/CD40.  
A small group of mice was left to age in order to observe potential B-cell lymphoma 
development. Indeed it was found that from an age of 13 months onward 
Notch2IC//LMP1/CD40//CD19-cre mice are prone to develop monoclonal B-cell lymphoma and 
strongly suggest further studies with larger cohorts. Aged mice still display an increased number 
of macrophages in their spleens and they maintain the shift towards effector T-cell compartment 
as observed in the young mice. However, they vastly differ from young mice regarding their MZ 
B-cell phenotype since aged Notch2IC//LMP1/CD40-expressing splenic B cells display distinctly 
altered surface marker expression profile. Moreover, old Notch2IC//LMP1/CD40-expressing B 
cells display up-regulation of activation-induced of both B7-proteins and CD5. Furthermore, aged 
Notch2IC//LMP1/CD40//CD19-cre mice develop salivary gland carcinomas, as has also been 
observed for LMP1/CD40//CD19-cre mice. The origin of these carcinomas however could not be 
unambiguously identified within the scope of this work.  
All in all, the data presented fit with the hypothesis that constitutive CD40 signaling can deliver 
survival signal to the B cells that can counteract constitutive Notch-signaling-induced apoptosis 
signals which ultimately results in a profound increase in proliferation rates in the splenic B cells 
of mice that expressing constitutively active Notch2 and constitutively active CD40. 
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6. ZUSAMMENFASSUNG 
Der CD40- und der Notch-Rezeptor-Signalweg sind in verschiedenen Tumoren dereguliert, u.a. im 
Hodgkin-Lymphom. In unserem Labor sind Mäuse mit B-zellspezifischer Expression jeweils einer 
der beiden Rezeptoren, die zudem konstitutiv aktiv sind, generiert und charakterisiert worden; 
LMP1/CD40//CD19-cre und Notch2IC//LMP1/CD40//CD19-cre-Mäuse (Homig-Holzel et al., 2008; 
Hampel et al., 2011). Um die Effekte deregulierter Signale dieser beider Rezeptoren in B-Zellen in 
vivo zu studieren, wurden Mäuse, die konstitutiv aktives Notch2 exprimieren, mit Mäusen, die 
konstitutiv aktives CD40 exprimieren, miteinander verpaart. Hierdurch exprimiert die 
Nachkommengeneration (Notch2IC//LMP1/CD40//CD19-cre-Mäuse) gleichzeitig beide 
Rezeptoren in CD19-abhängiger und damit B-zellspezifischer Form. Alle Mausanalysen sind mit 
CD19-cre, Notch2IC//CD19-cre und LMP1/CD40//CD19-cre Kontrollmäusen gleichen Alters 
durchgeführt worden. 
Die Notch2IC//LMP1/CD40//CD19-cre-Mäuse haben synergistische Effekte sowohl auf die 
Milzgröße, als auch auf das Milzgewicht. Die absoluten Zell- und der B-Zellzahlen in der Milz der 
Notch2IC//LMP1/CD40//CD19-cre-Mäuse waren gegenüber denen der CD19-cre und 
Notch2IC//CD19-cre-Mäusen signifikant erhöht. Jedoch waren die Anzahl der B-Zellen in der Milz 
der Notch2IC//LMP1/CD40//CD19-cre-Mäuse im Vergleich zu den LMP1/CD40//CD19-cre-
Mäusen signifikant geringer. Es wurde daraufhin untersucht, welche anderen Zelltypen für die 
erhöhten absoluten Milzzellzahlen verantwortlich sind. 
Es konnte eine erhöhte Anzahl an akzessorischen Zellen, und zwar myeloider Zellen, 
Makrophagen, Granulozyten und Dendritischer Zellen in Milzen der 
Notch2IC//LMP1/CD40//CD19-cre Mäusen identifiziert werden. Darüber hinaus zeichnen sich 
diese Mäuse durch eine signifikant erhöhte Anzahl an T-Zellen in ihren Milzen verglichen mit den 
Kontrollen aus. Die T-Zellen in den Notch2IC//LMP1/CD40//CD19-cre-Mäusen zeigen eine 
erhöhte Expression T-zellspezifischer Aktivierungsmarker und einen prozentualen Anstieg von 
zentralen Gedächtniszellen sowie Effektor-T-Zellen. Zudem sind regulatorische T-Zellen (Tregs), die 
wichtige Regulatoren in der zellulären Immunantwort repräsentieren, in den Milzen von 
Notch2IC//LMP1/CD40//CD19-cre-Mäusen erhöht. 
Mäuse des Notch2IC//LMP1/CD40//CD19-cre Genotyps weisen einen partiellen Block in der 
frühen B-Zellentwicklung im Knochenmark zwischen dem pre- und unreifen B-Zellstadium auf, 
wahrscheinlich aufgrund abträglicher Auswirkungen, die die frühe Expression beider Transgene 
auf die sich entwickelnde B-Zelle hat. Reife B-Zellen in Notch2IC//LMP1/CD40//CD19-cre Tieren 
zeigen – wie auch Notch2IC//CD19-cre-Mäuse – in der durchflusszytometrischen Analyse eine 
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Expansion der Marginalzonen (MZ) B-Zellen und eine Verminderung der Follikulären (Fo) B-
Zellen. Obwohl sie eindeutig MZ B-Zelloberflächenmarker in der FACS-Analyse aufweisen und B-
Zellen auch in der MZ lokalisierbar sind, saß doch ein unerwartet großer Anteil der B-Zellen in 
Notch2IC//LMP1/CD40//CD19-cre-Mäusen auch im Follikel und die Milzarchitektur wies in der 
Immunhistochemischen-Analyse sehr diffuse B- und T-Zellzonen auf. Distinkte Abweichungen 
hinsichtlich der Expression von Zyto- und Chemokinen in Notch2IC//LMP1/CD40//CD19-cre-
Mäusen (sowohl im Niveau an mRNA in den B-Zellen als solche, als auch im Serum) könnten an 
diesem Effekt beteiligt sein. Im Vergleich zu allen anderen analysierten Mäusen ergab sich in 
Notch2IC//LMP1/CD40//CD19-cre-Mäusen eine Hochregulierung von CXCL9 und CXCL10 im 
Serum und eine Zunahme an CXCR3 und IL13-IL13-Rezeptor α1, IL2-Rezeptor γ, Lymphotoxin β 
und Transforming-Growth-Factor β mRNA der Milz-B-Zellen. 
Allgemein zeigen die Milz-B-Zellen in Notch2IC//LMP1/CD40//CD19-cre-Mäusen einen 
aktivierten Phänotyp und verbessertes Überleben in in-vitro-Kultur verglichen zu Notch2IC-, aber 
nicht zu LMP1/CD40-exprimierenden Milz-B-Zellen. Zudem zeigen die Milz-B-Zellen von 
Notch2IC//LMP1/CD40//CD19-cre-Mäusen eine gesteigerte Proliferation in In-vitro-Kultur, die 
die von B-Zellen übertreffen, die entweder Notch2IC oder LMP1/CD40 exprimieren. 
Eine kleine Gruppe Mäuse wurde zur Analyse in erhöhtem Alter verwahrt, um die potenzielle 
Entstehung von B-Zelllymphomen beobachten zu können. Tatsächlich konnte beobachtet 
werden, dass sie ab einem Alter von 13 Monaten fortschreitend anfällig für die Entstehung von 
monoklonalen B-Zelllymphomen sind, was weitere Studien mit größeren Kohorten empfiehlt. 
Alte Mäuse zeigen immer noch eine erhöhte Anzahl an Makrophagen und eine Verschiebung der 
T-Zell-Population zu den Effektor-T-Zell-Phänotyp in der Milz wie bei jungen Mäusen. Sie 
unterscheiden sich jedoch stark von jungen Mäusen hinsichtlich ihres MZ-B-Zellphänotyps, da 
alte Notch2IC//LMP1/CD40//CD19-cre-Mäuse ein verändertes Oberflächenmarkerprofil 
aufweisen. Darüber hinaus zeigen alte Notch2IC//LMP1/CD40//CD19-cre-Mäuse eine 
Hochregulierung beider aktivierungsinduzierter B7-Proteine und CD5 auf ihren Milz-B-Zellen auf. 
Außerdem entwickeln Notch2IC//LMP1/CD40//CD19-cre-Mäuse Tumore der Speicheldrüse, wie 
es auch bei LMP1/CD40//CD19-cre-Mäusen beobachtet wurde. Der Ursprung dieser Tumore 
konnte im Rahmen dieser Arbeit nicht eindeutig identifiziert werden. 
Insgesamt untermauern die gezeigten Daten die Hypothese, dass ein konstitutives CD40-Signal B-
Zellen ein Überlebenssignal zuführen kann, das dem Notch-Signalweg-induzierten Apoptose-
Signal entgegenwirken kann. Dies resultiert schließlich in einer profunden Zunahme der 
Proliferationsraten in Milz-B-Zellen von Mäusen, die sowohl konstitutiv aktives Notch2 und 
konstitutiv aktives CD40 exprimieren. 
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7. MATERIAL 
Bacteria 
DH5α (Escherchia coli): Genotype: F- endA1 glnV44 thi-1 recA1 relA1 gyrA96 deoR nupG Φ80d 
lacZ ΔM15 Δ(lacZYAargF)U169 hsdR17 (rK- mK+), λ- . 
DNA probes for Southern blotting 
Rosa26-probe: The probe is 550 bp large and was prepared from the pRosa26-5-pBS KS plasmid 
by restriction digest with the enzymes EcoRI und Pac1.  
IgH-probe: The IgH-probe is the sequence between the J4 and Emicro segments of the IgH locus 
and was excised with the enzymes EcoRI and NaeI. It was subsequently cloned into a Bluescript 
Vector from which it can be prepared by digest with the enzymes EcoRI und HindIII (Gao et al., 
2000).  
Enzymes 
Restriction endonucleases were purchased from New England BioLabs and MBI Fermentas. Taq 
DNA polymerase was purchased from Invitrogen Life Technologies. 
B-cell medium 
1 x RPMI 1640  
5 % (v/v) fetal calf serum (FCS; PAA/ 10% (v/v) if used for culture 
1 % (v/v) Penicillin-Streptomycin 
1 % (v/v) non-essential aminoacids 
1 % (v/v) sodiumpyruvate 
1 % (v/v) L-Glutamin 
50 μM β-Mercaptoethanol  
All reagents by Gibco. 
Mouse strains 
All mice were kept on a mixed background (BALB/c x C57BL/6). 
LMP1/CD40flSTOPP (Homig-Holzel et al., 2008) 
The LMP1/CD40fl STOPP It is conditional transgenic for the chimeric LMP1/CD40 gene that has 
been inserted into the murine Rosa26 locus. A STOP cassette flanked by loxP sites is located 
upstream of the LMP1/CD40 gene and prevents its expression. In the presence of Cre, the STOP 
cassette can be excised and LMP1/CD40 is expressed under control of the endogenous Rosa26 
promoter. 
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Notch2IC (Hampel et al., 2011) 
The Notch2ICflSTOPP strain is conditional transgenic for the conditional notch2IC allele. The 
notch2ICflSTOP construct was inserted together with an IRES-hCD2 coding sequence into the 
murine Rosa26 locus. A STOP cassette flanked by loxP sites is located upstream of the notch2IC 
gene and prevents its expression. In the presence of Cre, the STOP cassette can be excised and 
Notch2IC is expressed under control of the constitutively active CAGGS promoter. This leads to 
the expression of the Notch2IC transgene under the transcriptional control of promoter, while 
hCD2 is concomitantly expressed on the surface to the respective Notch2IC-expressing cell. 
CD19-cre (Rickert et al., 1997) 
CD19-cre are a C57BL/6 mouse strain that has the Cre recombinase gene inserted into the CD19 
locus, thereby disrupting the CD19 gene. The expression of the cre gene is regulated by the 
endogenous CD19 promoter. 
Primers for PCR and sequencing reactions 
Primer name Primer sequence (5´ to 3´) Annealing Temp (°C) 
CD19c  AACCAGTCAACACCCTTCC  57 
CD19d CCAGACTAGATACAGACCAG 57 
Cre 7  TCAGCTACACCAGAGACGG  57 
CD40 PCR3 CTG AGA TGC GAC TCT CTT TGC CAT  55 
Ex1Fw1 LMP1 AGG AGC CCT CCT TGT CCT CTA 55 
Notch2IC 25 rev (T) ATCCCGGTCTCCGTATAGTG  59 
Notch2IC 33 fw (T) CCCTTGCCCTCTATGTACCA 59 
Rosa fw1 (60)  CTCTCCCAAAGTCGCTCTG  59 
Rosa rev2 (62) TACTCCGAGGCGGATCACAAGC 59 
Antibodies for immunohistochemistry 
Antigen Source Coupled to Dilution Manufacturer 
Murine CD3 Dog  1:2 By courtesy of E. Kremmer 
Murine IgM Goat   Peroxidase 1:100   Sigma 
Murine MOMA1 Rat    1:100   Biomedicals 
Rat IgG2 Mouse Biotin 1:250 Jackson Laboratories 
Mac1  Rat Biotin 1:100 BD 
Foxp3   Rat Biotin 1:100  eBioscience 
Streptavidin-
conjugated 
 Alkaline Phosphatase 1:400 Sigma 
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8. METHODS 
Mouse breeding 
Mice carrying the notch2ICflSTOP and the LMP1/CD40 allele were crossed to the CD19-cre mouse 
strain to generate mice expressing one or the other or both transgenes. Transgenes were 
expressed upon in Cre-mediated excision of the stop cassette upstream the respective or both 
targeting constructs in the Rosa26 locus. Transgenes are expressed from the pro-B cell stage 
onward with a gradual increase during proceeding B cell differentiation (Rickert et al., 1997). 
Analyses were performed on a mixed background and mice were analyzed at eight to 16 weeks of 
age, unless stated otherwise. Mice that were monitored for the development of lymphomas or 
leukemic disease (>13months) were kept under special observation by designated personnel.  
All mice were bred and maintained in specific pathogen-free conditions. All experiments were 
performed in compliance with the German animal welfare law and have been approved by the 
Institutional Committee on Animal Experimentation and the government of Upper Bavaria. 
Isolation of primary lymphocytes 
Mice were euthanized by CO2 gassing and subsequently dissected. Spleen, thymus, and lymph 
nodes were taken out as whole organs and were maintained in medium until further procedures. 
Cells from the bone marrow were prepared by dissecting tibia bones, cut at neck of the tibia and 
the cavity was flushed with medium. Splenic weight was obtained by placing spleens in sterile 
petri dishes on a microscale. In case small pieces were cut off for histologic preparations (see 
section “Histology”, pp.110-111), the larger piece of spleen was weighed again to be able to 
equate weight with total cell number and finally FACS percentages of particular cell populations 
(see section “Cell number calculations”, p. 108). 
Single cell suspensions from lymph nodes and spleens were obtained by passing the organs 
through a 70 µm cell strainer (Becton Dickinson). Erythrocytes were depleted from single cell 
suspensions from spleen and bone marrow by lysis with a hypotonic buffer (1x RBC lysis buffer; 
eBiosciences) for three minutes or longer for LMP1/CD40//CD19-cre and 
Notch2IC//LMP1/CD40//CD19-cre at RT. All cell suspensions were kept on ice the entire time and 
washing steps with medium or PBS/1% (w/v) BSA were carried out by centrifuging cell 
suspensions for 10 minutes at 300 x g at 4 °C. Cell numbers were determined by Neubauer 
chamber countings. 
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Magnetic Cell Separation (MACS) 
Splenic B cells were isolated from single cells suspensions by depletion of CD43pos non-B cells by 
MACS, using α-CD43 beads and LS columns according to the manufacturer’s specifications 
(Miltenyi Biotec). Thereby, B-cell populations of 85 to 98% purity were obtained as confirmed via 
FACS-analysis.  
Cell number calculations  
Total cell number of any given cell suspension was determined by use of a Neubauer counting 
chamber and a light microscope counting only the light cells (darker cells are probably dead 
having disrupted cell membranes that allows for diffusion of the counting medium into the cell).  
Cell numbers of a cell population can be calculated from the total cell number as determined by 
Neubauer chamber counting and the percentage of the respective population in the organ under 
investigation as determined by FACS.  
In case no small piece was cut off for histologic preparations: 
Total cell no. (as counted)/100 × percentage of respective cell population (as determined by FACS)  
= total no. of respective cell population. 
In case a small piece was cut off for histologic preparations: 
Spleen = x gram,  
i.e. larger piece (as weighed) = x-y1 = y2 = z2 ×10
7 cells 
i.e. smaller piece = x-y2 = y1 = z1 ×10
7 cells 
Hence, Total cell no. (z1 + z2)/100 × percentage of respective cell population (as determined by 
FACS) = total no. of respective cell population. 
 
Surface marker Flow Cytometry (FACS) 
Single cell suspension prepared from BM, LN and SP were surface-stained with a combination of 
FITC-, PE-, PerCP- and APC-conjugated monoclonal antibodies, diluted in MACS buffer (Miltenyi 
Biotec). Antibodies specific for the respective surface antibody employed were purchased from 
BD Biosciences or eBiosciences. Usually 3×104 cells were used for stainings and stained in 
25 microL staining mix for at least 20 min on ice. If indicated cells were additionally labeled with 
TOPRO-3 or propidium iodide (PI) staining (both from Molecular Probes) in order to exclude dead 
cells from analysis. These intercalating fluorescent dyes are able to bind to DNA and thus only 
stain dead cells with damaged cell membranes which allow the dye to diffuse into the nucleus. 
The staining of cells was determined with a four-color FACSCaliburTM flow cytometer (BD 
Biosciences) and results were analyzed using CELLQuest and FlowJo software. 
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Intracellular FACS-analysis 
4×106 cells previously washed in PBS/1 % (w/v) BSA were resuspended in 25 microL surface 
marker staining mix and incubated for at least 20 min on ice. After another washing step, cells 
are resuspended in PBS/4 % paraformaldehyde or Histofix (Carl Roth) and left for 10 min at RT. 
Cells are washed with PBS (then they can be left o/n at 4 °C in PBS), afterwards they are washed 
with intracellular FACS buffer (PBS/1 % (w/v) BSA/1 % (w/v) saponin) and afterwards incubated in 
intracellular FACS buffer for 10 min at RT. Respective staining mixes were prepared in 20 microL 
buffer and incubated for 30 min at RT. Cells were washed twice in 1 mL intracellular FACS buffer 
and cell pellets were resuspended in PBS for FACS measurement. 
Foxp3 staining was performed according to manufactures specifications of the Foxp3 staining kit 
from eBiosciences. 
In vitro culture of primary lymphocytes 
Short term cultivation for stimulation of T-cell responses (Th1/Th2) 
4×107 whole splenic cells/mL were kept in B-cell medium with 10 % (v/v) FCS, supplemented with 
phorbol myristate acetate (PMA; 1:50.000 dilution from 1 mM stock) and calcium ionophore 
ionomycin (Ionomycin; 1:10.000 dilution from 10 mM stock). 
PMA/Ionomycin-treatment provides a polyclonal stimulus activating all cells in a sample 
unspecifically. The cells were incubated at 37 °C for 2 to 2 ½ hrs. Subsequently cells were treated 
with by Brefeldin A (1:500 dilution from 5 mg/ml stock) for no longer than 2 ½ hrs at 37 °C. 
Brefeldin A-treatment is done to ensure that the cytokine under investigation does not diffuse 
from the cell into the medium of the cell suspension. 
Afterwards cells were washed with PBS and in order to stain intracellular cytokines the protocol 
for Intracellular FACS-analysis was followed.  
Proliferation assay (CSFE assay)  
Splenic, MACS-purified B cells were labeled with carboxyfluorescein diacetate succinimidyl ester 
(CFSE, Molecular Probes, final concentration 5 μM) in serum-free B cell medium for 5 min at 
37 °C for 10 min. CFSE is a fluorescent dye that labels intracellular molecules by its succinimidyl 
group. It is passed on to daughter cells during cell division and thereby provides a method to 
measure proliferation of a cell population by the decrease in CFSE-fluorescence of the labeled 
cells.  
B cells were cultured (5×106 cells/ml) in B-cell medium with 10 % (v/v) FCS with or without stimuli 
up to five days in 96-well plates (5×105 cells/well). Stimuli were either IL4 (10 ng/ml; mouse 
recombinant; Sigma) or α-CD40 antibody (2.5 μg/ml; eBioscience) or both. At different time 
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points (day 1, day 3 and day 5), cells were analyzed with a FACSCalibur. The percentage of living 
cells was determined by staining and excluding dead cells by Topro-3.  
Cell cycle analysis (BrdU assay) 
To perform cell cycle analysis B cells were isolated and cultured as described above, at least 5 
wells with 5×105 cells of a 96-well plate were cultivated. Splenic B cells were analyzed on day 0 as 
to determine the immediate ex vivo situation and subsequently on day 1 and day 3 after 
bromdesoxyuridine (BrdU) labeling for four hours. BrdU is a synthetic nucleoside and thymidine 
analogue. If given to cells during their proliferative S-phase BrdU-dye will be incorporated into 
the cell’s DNA and can later be visualized by α-BrdU antibodies. This allows for inference on the 
proliferation rate of the cells. Simultaneous staining of the cells with 7-amino-actinomycin D 
(7AAD; a fluorescent DNA marker) shortly before analysis, permits to determine the full scope of 
the cell cycle of any culture of cells under investigation. In order to ensure functionality of the 
assay LPS (25 μg/ml; E. coli 055:B5; Sigma) was added to B-cell cultures of CD19-cre mice. LPS is a 
potent, polyclonal stimulus, activating the cells and driving them into proliferation. 
BrdU incorporation into the DNA of B cells was analyzed by using the APC BrdU Flow Kit (Becton 
Dickinson) according to manufacturer’s instructions on a LSRII Fortessa (Becton Dickinson).  
Preparation of serum from murine blood 
Blood was collected directly from the heart with a Pasteur pipette. Afterwards, the blood was 
stored on ice for at least four hours and was subsequently centrifuged at 9.000 xg and 4  C for 
10 min. The supernatant was transferred to a new tube and the procedure was repeated once to 
yield pure serum. 
Equal amounts of serum were analyzed for the presence of cyto- and chemokines with the 
Proteome ProfilerTM Array according to manufacturer’s specifications (Mouse Cytokine Array 
Panel A; R&D Sytems) and the obtained data subsequently analyzed with Tina 2.0 software. 
Histology 
 Immunohistochemistry 
Spleens were embedded in O.C.T. Tissue Tek (Sakura) in medium-sized cryomolds (Sakura) and 
placed them on dry ice until completely frozen. Embedded spleens were stored at -20 °C, 
wrapped in aluminum foil and ziplock bags to avoid air contact. 5-8 μm thick sections were cut 
with a cryostat (Leica Microsystems), collected on gelatin-coated microscope slides (Thermo 
Scientific) and air-dried overnight. Sections were subsequently fixed for ten minutes in 100 % 
(v/v) acetone.  
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Slides with sections were then rehydrated with PBS, and incubated for 20 minutes in quenching 
buffer (PBS containing 10 % (v/v) goat serum, 1 % (w/v) BSA) to block endogenous peroxidase. 
Afterwards, sections were incubated for each 15 min in two different blocking buffers, first an 
Avidin, then a Biotin blocking buffer (Avidin-Biotin Blocking Kit; Vector Laboratories) to prevent 
unspecific binding of Avidin- and Biotin-coupled antibodies. Between incubation steps, sections 
were washed for 5 min in PBS. Subsequently, staining was performed by incubating sections with 
different antibodies diluted in PBS/1 % (w/v) BSA for one hour each. Before and after antibody 
stainings, sections were washed with PBS each three times for 5 minutes. Phosphatase-
conjugated antibodies were detected in blue using Blue Alkaline Phosphatase Substrate Kit III 
(Vector laboratories). Peroxidase-conjugated antibodies were detected in red due to a reaction 
with aminoethylcarbazole (AEC) after treatment with Peroxidase Substrate Kit AEC (Vector 
laboratories). Staining reactions were stopped at the latest after 10 min by washing with PBS. All 
incubation steps were performed at 22 °C in a wet chamber. Sections were air-dried and 
subsequently embedded in Kaiser gelatin (Merck) and sealed off with a coverslip. 
For Foxp3 stainings, sections were rehydrated in PBS/1 % (w/v) BSA/1 % (w/v) saponin. Also all 
antibodies were diluted in PBS/1 % (w/v) BSA/1 % (w/v) saponin. 
Stainings were analyzed using a fluorescent microscope (Zeiss). Pictures were obtained with a 
digital camera (AxioCam MRm) and the AxioVision programme. 
 Fluorescent microscopy 
Sections of specimen were prepared, blocked and stained as described for 
immunohistochemistry ultimately using antibodies coupled to flourochromes. Analysis was 
carried out on a confocal microscope (Axiovert 200M, Zeiss) and Pictures were obtained with a 
digital camera (AxioCam MRm) and OpenLab programme and edited using Adobe Photoshop. 
DNA isolation 
 Plasmid isolation from bacteria  
Plasmids were produced and isolated from competent bacteria with the EndoFree Plasmid Maxi 
Kit (Qiagen) according to manufacturer’s instructions. The air-dried pellet was resolved in TE 
buffer and DNA concentration was determined with a photometer (Eppendorf). 
 Isolation of genomic DNA from murine tails and whole splenocyte pellets 
Murine tail clippings, splenic cell pellets or SGTs were incubated shaking at 56 °C o/n in at least 
500 μl lysis buffer (100 mM Tris/HCl pH 8,5 mM EDTA, 0.2 % (w/v) SDS, 200 mM NaCl,) 
supplemented with 100 μg/ml proteinase K (Invitrogen). 1/3 volume of a saturated NaCl (at least 
5 M) were added to precipitate proteins and samples were centrifuged 10 min at 10.000 xg. The 
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supernatant was transferred into a new tube and DNA was precipitated by adding 2x volume 
100 % (v/v) isopropyl alcohol and inverting the sample-containing tube. After another round of 
centrufgation samples were centrifuged and the DNA was washed with 70 % (v/v) ethanol. 
Samples were air-dried, and ultimately dissolved in appropriate volume of TE buffer by shaking at 
37 °C for one hr for genotypings or at least 4 hrs for Southern blots. 
DNA analysis 
Polymerase Chain Reaction (PCR) for genotyping 
The method of PCR was used to analyze DNA of transgenic mice for the configuration of the 
Rosa26 locus (insertion of transgenes) and presence of Cre-recombinase in the CD19-locus in the 
genome. All materials were obtained from Invitrogen. A basic reaction mixture with different 
primers was used: 
 
Master Mix Per reaction (µl) 
H20 19,65 
Taq Puffer (10x) 2,5 
MgCl2 (25 mM) 1 
dNTP (10mM) 0,5 
Primer 1 0,1 
Primer 2 0,1 
Taq Polymerase (5U/µl) 0,15 
DNA 1 
total 25 
Agarose gel electrophoresis of DNA 
Agarose gel electrophoresis was performed to determine PCR reaction results and size-
fractionate restriction-digested DNA molecules, which were either eluted from the gel (Southern 
blot probe) or blotted on a nitrocellulose membrane (Southern blot). Gels were prepared with 1x 
TAE (40 mM Tris/HCl, 20 mM acetic acid, 1 mM EDTA pH 8.5), 5 μg/ml ethidium bromide and 
0.8 % (Southern blot) or 2 % (w/v; genotyping) agarose. 
Electrophoresis was performed in a gel electrophoresis chamber (Peqlab) with 1x TAE buffer at 
90 V for PCR samples or run at 25 V o/n. Results were visualized and documented with a 
geldocumentation system (Vilbert Lourmat). 
DNA fragment for Southern blot probe was excised from agarose gel containing correctly-sized 
fragment with a clean scalpel and the DNA probe was isolated with QIAquick Gel Extraction Kit 
(Qiagen) according to manufacturer’s instructions. 
Restriction digest of DNA for Southern blot 
Restriction digest of plasmid DNA was performed using specific restriction enzymes according to 
manufacturer’s instructions for appropriate conditions and buffers. 
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Genomic DNA from splenic cells and SGTs was digested with EcoRI for both Southern blots. 
Restriction buffer mix (1 mM Spermidin, 1 mM DTT, 100 μg/ml BSA, 50 μg/ml RNase, 1x EcoRI 
buffer, 100 to 150 U of EcoRI enzyme) was added to respective DNA in TE buffer. DNA was 
digested for at least 16 hrs at 37 °C. 
Southern blot (Southern, 1975) 
This method was used for the identification of mono- or oligoclonal B cell lymphomas (whole 
splenic cell preparations) and the deletion of the transgene up-stream the inserted transgene 
(SGTs). After the restriction digest treatment, DNA is electrophoretically separated and 
transferred from the agarose gel to a nitrocellulose membrane. A radioactively-labeled DNA 
probe (Rosa- or IgH-probe) is allowed to hybridize to the denatured DNA on the membrane o/n. 
This allows for the detection of distinct DNA fragments as definite bands on the membrane. 
After digestion as described in the previous section, the respective samples were size-
fractionated on a 0.8 % (w/v) agarose gel along with a standard 1 kb DNA ladder (Invitrogen) at 
25 V o/n. The restriction-digested DNA in the gel was visualized and documented on a UV 
luminescent screen together with a ruler to determine the height of the desired fragment in the 
gel so that the gel could be cut down to a smaller size and only the part containing the fragement 
of interest would be kept. Subsequently, the gel was incubated in 0.25 N HCl for 25 min in order 
to denature the DNA. Afterwards the gel has to be equilibrated for transfer onto the membrane: 
the gel was shortly rinsed in water and incubated in alkaline transfer buffer (0.4 M NaOH, 0.6 M 
NaCl) for 40 min. DNA blotting onto the membrane (ImmobilonTM Ny+ membrane, Millipore) 
was achieved via capillary pressure from transfer buffer flow top to bottom of the set-up. The 
next morning the position of slots of the gel were marked on the membrane. The membrane was 
rinsed shortly in 2x SSC buffer (0.3 M NaCl, 0.03 M NaCitrate, pH 6.5) for neutralization. DNA was 
cross-linked to the membrane by baking it for one hr at 80 °C. In order to limit unspecific binding 
of the respective probe, the membrane was pre-hybridized in pre-heated (65 °C) hybridization 
solution (1 M NaCl, 50 mM Tris, pH 7.5, 10 % (w/v) dextran sulfate, 1 % (w/v) SDS, 250 μg salmon 
sperm DNA/ml) for at least 6 hrs at 65 °C, before incubation with the respective radioactively 
labeled probe. 
The probe was prepared by excision through restrictions digest and 100 ng were labeled by 
Random Prime Labeling Kit (GE Healthcare) according to manufacturer’s instructions with 50 μCi 
32P-dCTP (Hartmann Analytic). The labeled probe was purified using a G50 sephadex column (GE 
Healthcare) according to manufacturer’s instructions. In order to denaturate the probe to enable 
binding to membrane-bound DNA, it was incubated for five minutes at 100 °C and placed for two 
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minutes on ice. The membrane was incubated for at least 16 hrs at 65 °C in the hybridization 
solution, containing pre-hybridization buffer with the respective DNA probe. 
Afterwards, the membrane was rinsed three times or more each for 10 min in pre-heated 
washing buffer (0.2x SSC, 0.5 % (w/v) SDS) at 58 °C to wash off unbound or unspecifically-bound 
probe until radioactivity dropped to 60 to 70 counts. The membrane was placed in transparent 
foil and radioactively-labeled probe was visualized on the membrane by autoradiography with 
radiosensitive films (Biomax MS PE Applied Biosystems 35x43 cm, KODAK), exposed for one day 
or longer at -80 °C in a Biomax cassette. 
RNA analysis 
 RNA preparation 
Total RNA that was isolated by using RNaeasy Mini Kit (Quiagen). In order to use defined and 
equal amounts of total RNA for cDNA synthesis, undiluted 2 μl RNA were applied to a 
spectrophotometer (NanoDrop) and its absorbance at 260 nm was determined to calculate RNA 
concentration. RNA integrity was tested on a Nothern Blot gel (kindly provided by M. Kellner). 
 cDNA synthesis 
RNA can be reversely transcribed into a single-stranded DNA intermediate, i.e. complementary 
DNA (cDNA). Using oligo-dT primers, reverse transcriptase synthesizes a cDNA strand starting at 
the 3´-end of the poly(A)-mRNA. 1 μg total RNA of all samples was simultaneously in the same 
PCR run reversely transcribed with > 10 U of viral AMV Reverse Transcriptase, using 1st Strand 
cDNA Synthesis Kit for RT-PCR [AMV] (Roche Diagnostics) with 0.02 A260 units (0.8 μg) Oligo-
p(dT)15 primers, amount of 10x reaction buffer, 10 mM dNTPs, 25 mM MgCl2 and 50 U RNase 
Inhibitor according to manufacturer’s instructions, adding to a final reaction volume of 25 μl. 
Each RNA preparation was transcribed in quadruplicate. RNA was restored at -80 °C. The resulting 
first strand cDNA was stored at -20 °C and was used as a template for qPCR. 
 Mouse Inflammatory Cytokines & Receptors qRT PCR Array 
The Array used was obtained from SA Biosciences and is based on the principles of quantitative 
real-time PCR (q RT PCR). This method allows studying mRNA expression in a comparative 
manner between different samples (as in this case) genotypes and was carried out using the 
LightCycler system (Roche Diagnostics).  
SYBR green fluorescent dye is included in the reaction and this dye intercalates into the growing 
DNA strands during PCR reaction (unbound dye exhibits very little fluorescence and therefore 
does not have to be taken into account). The process of increase in fluorescence is measured by 
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the LightCycler during each completion of reaction cycle in realtime and the amount of RNA can 
be reversely determined by the amount of bound SYBR green in the sample.  
100 µl of a genotype cDNA was mixed with the reaction mix supplied with array according to 
manufactures instructions. 100 µl of the resulting mix were immidiately added to each of the well 
of the 96-well array with pre-spotted primers for each cytokine and cytokine receptor to be 
analyzed and was centrifuged before placing into the LightCycler instrument. The array was 
always kept on ice during the preparation. 
For each sample the crossing point (CP) was determined. The crossing point describes the cycle in 
which the fluorescence exceeds background signal and the lower the CT, the higher the content 
of the respective amplicon in the respective sample.  
In order to determine the specificity of each DNA product by examining the melting temperature 
of the resulting qRTPCR products, melting curve analysis was performed according to 
manufacturer’s instructions. 
Data analyses were carried out using Excel software (Microsoft). 
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Tab. S.1 Overview over cell numbers of splenic T cell populations of CD19-cre, Notch2IC//CD19-cre, 
LMP1/CD40//CD19-cre and Notch2IC//LMP1/CD40//CD19-cre mice.  
Splenic cells were analyzed by flow cytometry CD62L and CD44 expression on either (A) CD4pos or (B) 
CD8pos lymphocyte-gated T cells. Calculations are based on five independent experiments. 
(A) 
 
(B) 
 
CD4pos 
 
Total cell 
numbers  
(×10
7
) 
naïve T-cells 
(CD62L
hi
 CD44
low
) 
(×10
7
) 
memory T cells 
(CD62L
hi
 CD44
hi
) 
(×10
7
) 
effector T cells 
(CD62L
low
 CD44
hi
) 
(×10
7
) 
CD62L
low
, 
CD44
low
 
(×10
7
) 
CD19-cre 1.2 ±0.2 0.6 ±0.1 0.1 ±0.0 0.3 ±0.1 0.0 ±0.0 
Notch2IC// 
CD19-cre 
1.3 ±0.5 0.6 ±0.2 0.1 ±0.0 0.5 ±0.2 0.1 ±0.0 
LMP1/CD40// 
CD19-cre 
7.7 ±1.9 2.4 ±1.4 0.8 ±0.3 2.1 ±0.7 0.4 ±0.2 
Notch2IC//LMP1/CD40// 
CD19-cre 
8.7± 5.4 1.9 ±1.6 0.4 ±0.4 3.3 ±1.0 1.0 ±0.7 
CD8pos 
 
Total cell 
numbers 
(×10
7
) 
naïve T-cells 
(CD62L
hi
 CD44
low
) 
(×10
7
) 
memory T cells 
(CD62L
hi
 CD44
hi
) 
(×10
7
) 
effector T cells 
(CD62L
low
, CD44
hi
) 
(×10
7
) 
CD62L
low
, 
CD44
low
 
(×10
7
) 
CD19-cre 0.5 ±0.2 0.3 ±0.1 0.1 ±0.0 0.1 ±0.0 0.0 ±0.0 
Notch2IC// 
CD19-cre 
0.8 ±0.2 0.4 ±0.4 0.2 ±0.2 0.2 ±0.2 0.1 ±0.0 
LMP1/CD40// 
CD19-cre 
1.9 ±0.8 0.7 ±0.3 0.2 ±0.1 0.3 ±0.1 0.3 ±0.2 
Notch2IC//LMP1/CD40// 
CD19-cre 
5.7 ±2.5 1.0 ±0.8 0.2 ±0.2 2.0 ±0.9 2.3 ±1.8 
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Fig. S.1 Notch2IC//LMP1/CD40-expressing B cells show an increased proliferation in in vitro culture. 
 Splenocytes were prepared and splenic cell preparations were depleted of CD43pos (i.e. non-B) cells and 
labeled with CFSE. The B cells were subsequently cultivated either with or without stimuli. These stimuli 
included α-CD40 antibody, IL4 as well as both IL4 and α-CD40 antibody. Cells were analyzed by flow 
cytometric analysis on day 1, 3 and 5 of culture. Dead cells were excluded from the analysis by excluding 
Topro-3pos cells. Statistical evaluation of day 5 of percent divided, proliferation and division index for all 
genotypes without stimulus, with IL4-stimulus, with CD40-stimulus and both with IL4- and CD40-stimulus. 
CFSE, Carboxyfluorescein succinimidyl ester. *p < 0.05, ** p < 0.01, *** p < 0.005.  
 
 
